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1. INTRODUCTION AND AIMS 
At the dawn of the 21
st
 century, chemical industry has reached the forefront of the transition to 
more sustainable production. However, progress toward increased sustainability requires 
developments and novel approaches that imply improved performance and value in chemical 
production in association with a reduction of the environmental impact through optimization of 
the use of non-renewable resources, the minimization of waste, safety improvement, etc. 
As a novel sustainable alternative for the conventional batch-based synthetic techniques, the 
concept of continuous-flow (CF) processing has recently emerged in academic and industrial 
research of fine chemicals. CF-based approaches offer significant advantages over classical 
segmented unit methodologies.
1, 2
 For example, the well-regulated flow reactor concept 
provides an increased parameter space for chemical synthesis and enables reactions to be 
performed with an unprecedented level of control due to the greatly enhanced heat and mass 
transfer and improved mixing properties.
3, 4
 This implies higher reaction rates, outstanding 
selectivity, and safer and greener chemistry as compared with mechanically stirred reaction 
vessels.
3
 The screening of CF reaction conditions is a simple and rapid procedure as there is no 
need for the large-scale use of reagents and solvents, and the most important reaction 
parameters (such as, flow rate, pressure, temperature and stoichiometry) can be quickly and 
precisely adjusted.
5
 These advantages and the fundamental differences between batch 
experiments and CF processing offer a plausible opportunity for automation and excellent 
transferability between laboratory-based investigations and industrial-scale production and have 
pushed CF technology to the frontiers of modern sustainable chemistries.
6, 7
 
Our major goal was to exploit the benefits of flow processing for reaction optimization and 
synthesis, and to develop novel sustainable synthetic methodologies with possible usefulness 
for the pharmaceutical industry. We set out to broaden the chemical space and practical 
applicability of transition metal-catalyzed and organocatalytic procedures to obtain 
pharmaceutically relevant intermediates and potentially bioactive compounds in a safe, simple 
and efficient manner. To achieve our goals, we intended to focus on the following areas in CF: 
(i) heterogeneous catalytic deuterations, (ii) Cu(I)-catalyzed azide–alkyne cycloadditions 
(CuAAC) and (iii) organocatalytic asymmetric aldol and conjugate addition reactions. 
Enantiomerically pure compounds are crucially important in pharmaceutical research, and 
the development of enantioselective synthetic methodologies has therefore become one of the 
frontiers of organic chemistry. Organocatalysis has contributed appreciably to the recent 
advances in asymmetric syntheses, as it possesses distinct advantages over organometallic 
2 
 
counterparts, and exhibits inherent potential in the synthesis of chiral building blocks for the 
pharmaceutical industry.
8
 However, long reaction times, difficulties in product isolation and 
selectivity issues often limit the practical applicability of organocatalytic reactions.
9
 
Accordingly, we aimed to develop a novel sustainable methodology which relies on 
immobilized peptidic catalysts in a packed-bed CF reactor and eliminates most of the above 
drawbacks. Utilization of a peptide is highly beneficial, as such a modular catalyst offers an 
unprecedented level of structural diversity, and facilitates the creation of optimized 
organocatalysts.
10
 
CuAAC is a convenient way to obtain 1,2,3-triazoles with various pharmacological 
potentials, such as antibacterial, antiviral or antifungal effects.
11
 The inherent scalability of flow 
processing, the facile opportunity for automation and the safety considerations associated with 
the handling of azides as explosive reactants have recently provoked the development of CF 
CuAAC procedures. However, most CF examples of CuAAC reactions rely on either costly 
apparatus or special catalyst types, thereby hampering their sustainable applications.
12, 13
 We 
therefore planned to develop an easily available and inexpensive CF technique for CuAAC 
reactions, which is at the same time safe and efficient and additionally conveniently adaptable 
for the preparation of potentially bioactive compounds for the drug discovery. 
There are a broad array of pharmacologically interesting molecules among heterocyclic 
structures, and many of them exhibit various biological properties.
14
 Deuteration is widely 
applied in organic chemistry as deuterium-labeled heterocycles are of considerable importance 
in drug discovery.
15
 However, conventional deuteration methodologies suffer from several 
drawbacks.
16
 For this reason, it was our aim to employ a convenient and safe CF technique with 
on-demand electrolytic D2 gas production for the highly selective deuteration of nitrogen-
containing heterocycles which are precursors for a series of bioactive compounds, and we 
proposed to introduce a sustainable alternative for classical batch deuteration approaches. 
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2. LITERATURE SURVEY 
2.1. Flow chemistry – concepts 
The petrochemical industry relies on large-scale continuous chemical processes which 
display high-level efficiency for many years.
17
 In contrast, the synthesis of fine chemicals and 
pharmaceuticals is traditionally performed in well-defined batches both in laboratory practice 
and on an industrial production-scale. In consequence of the widespread existence of the batch 
infrastructure and for historical reasons, smaller-scale manufacturing had to face significant 
challenges to improve the existing conventional methodologies. However, in the past decade the 
limitations of segmented unit operations have become absolutely clear.
18
 The intense need for 
novel sustainable methodologies to enhance efficiency and reduce environmental factors has 
finally opened up new routes in compact-scale chemical engineering, and flow chemistry has 
emerged as a new tool for the synthetic chemistry of fine chemicals.
19, 20
 
There are numerous fundamental differences between classical batch experiments and CF 
reaction technology.
17, 21
 First of all, in standard segmentally operated reaction vessels the 
conversion depends on the reaction time, whereas in a CF apparatus a continuous stream of 
reactant flows through the reactor channels where the transformations take place, and the 
conversion to the products becomes a function of the distance covered in the reactor.
22
 In other 
words, the chemical process becomes space-resolved (Figure 1). The control of the flow of  
 
 
Figure 1. Comparison of batch and CF processes: a time-resolved transformation in a standard reaction vessel 
(a), and a space-resolved chemical process in a flow channel (b). 
fluids in CF reactors is most commonly ensured by means of conventional HPLC pumps 
(hydrodynamic flow), but other approaches, such as electroosmotic or centrifugal flow, are also 
possible.
23
 In a continuous process, the reaction time is assigned as the interval spent by a given 
molecule in the active reactor zone and is referred as the residence time.
3
 The conversion 
correlates with the residence time, and can easily be fine-tuned through adjustment of the flow 
rate. In the traditional batch-based synthetic routine, very fast reactions involving highly 
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reactive species are often difficult or impossible to control without overreaction.
24
 In contrast, 
compact CF reactors offer high-resolution control over the reaction/residence time in the range 
of milliseconds to seconds and introduce an unprecedented level of selectivity.
25-27
 Moreover, 
the precise residence time control prevents the accumulation of hazardous materials, thereby 
leading to safer chemistry.
28, 29
 In CF production, the stoichiometry is easily controllable 
through simple adjustment of the flow ratios of the reactants.
3, 22
 In contrast, batch stoichiometry 
depends on the concentration and the volumetric ratio, and fine-tuning is much more 
complicated. The possibility of facile and rapid reaction parameter screening and the 
elimination of the need for the large-scale use of reactants and solvents make flow chemistry an 
ideal tool for high-throughput process development.
30, 31
 
Heat and mass transfer in modern compact-scale CF devices are greatly enhanced as 
compared with conventional batch procedures.
2
 Mixing in segmentally operated reaction vessels 
is mainly achieved by classical mechanical stirring through turbulence at high Reynolds 
numbers.
4
 However, mass transfer is a key element of many chemical transformations and 
clearly inertial forces often provide insufficient mixing quality (Figure 2a).
1, 32
 In contrast, 
modern flow reactors operate in the range of low Reynolds numbers, where laminar flow 
conditions predominate.
4, 23
 The fluid properties in the capillary-scale ducts of such devices are 
mainly controlled by viscous forces and fluid-surface interactions, and mixing of the separate 
reactant streams occurs by diffusion across fluidic interfaces (Figure 2b).
4
 According to Fick’s 
law, the velocity of diffusion depends on the channel diameter, which clearly suggests that 
 
 
Figure 2. Concentration profiles in a batch (a) and a CF reactor (b) simulated for a neutralization reaction 
between HCl (A) and NaOH (B). Levels of concentration equivalents are given according to the color scale.
32
 
miniaturization of the axial dimensions can dramatically enhance the mass transfer in flow 
reactors.
33
 Moreover, the mixing properties in capillary channels can be further improved by 
using concentric or parallel streams rather than straight lines, and many flow setups include an 
initial mixing zone prior to the inlet of the actual reactor.
2
 In many cases, efficient and rapid 
mass transfer can dramatically reduce the reaction time and improve the reaction rate relative to 
conventional batch experiments.
34
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In the course of a chemical reaction, heat is exchanged via the reactor surface, and the 
surface area-to-volume ratio is therefore a critical factor in efficient reactor design. Compact 
flow devices have specific surface areas several orders of magnitude larger than those of 
conventional batch equipment.
1, 3, 35
 For example, a 10-mL tubular reactor with a channel 
diameter of 1 mm has a surface-to-volume ratio around 50 times higher than that of a standard 
250-mL round-bottomed flask.
36
 Heat transfer in flow reactors is therefore much faster than that 
in conventional batch units, and reactions can be performed with an unprecedented level of 
control over temperature (Figure 3).
3, 4, 32
 For example, in batch processing, removal of the heat  
 
 
Figure 3. Temperature profiles in a batch (a) and a CF reactor (b) simulated for an exothermic model reaction 
(neutralization between HCl (A) and NaOH (B)). Temperature levels are given in Kelvin according to the color 
scale, y is the channel thickness and L is the channel length.
32
 
of highly exothermic reactions can be challenging, whereas the effective heat-exchanging 
properties of CF reactors prevent such reactions from thermal runaway and aid the maintenance 
of isothermal conditions with improved production safety.
2, 37
 Even explosive reactants
38
 or 
highly unstable intermediates can be handled readily.
39
 On the other hand, the superior heat 
absorption abilities in flow channels can greatly reduce the reaction times of endothermic 
transformations. Batch reactors often provide wide temperature profiles, leading to undesired 
byproduct formation (Figure 4).
32
 In contrast, the 
efficient temperature control in flow results in a 
narrow temperature distribution and does not 
permit the formation of hot spots or the 
accumulation of heat in the reaction mixture, and 
undesired side-reactions are suppressed, 
resulting in higher selectivity (Figure 4).
32, 40
 
Thanks to the effective heat and mass transfer, 
an additional advantage is the much better 
reproducibility of CF reactions as compared with 
those in a conventional apparatus.
22
 
Figure 4. Broad temperature profile in a batch 
reactor (blue) leads to the formation of byproduct 
C. but the narrow heat distribution in a flow 
reactor (red) restricts undesired side-reactions.
32
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The application of high pressure in chemical reactions is favorable for many reasons. First of 
all, as indicated by Le Chatelier’s principle, pressurization can result in a rate enhancement in 
numerous transformations. Typical examples are cycloadditions, Diels–Alder reactions, 
condensation reactions, etc. On the other hand, pressure increases the miscibility of liquids and 
the solubility of solids or gases, enhancing synthetic efficiency. High-pressure conditions are 
widely employed in CF reaction technology, as modular backpressure valves ensure simpler 
access to harsh conditions than do conventional high-pressure autoclaves.
5, 41
 The contained 
environment and the ease of pressurizing in modern CF reactors remove the boiling point 
barrier and allow the superheating of solvents in a safe and simple manner, thereby providing 
novel process windows in an increased parameter space for chemical synthesis.
5, 42, 43
 Under 
very high-temperature/pressure conditions, an unprecedented amount of energy can be supplied 
to chemical reactions, which leads to improved kinetics and consequently the dramatic 
shortening of reaction times, even in transformations with very high activation bars.
44, 45
 With 
suitable apparatus, even supercritical (sc) conditions can be achieved for many organic solvents, 
water or CO2.
46
 Elevated temperatures in CF technology are most commonly attained through 
the use of external ovens, and built-in Peltier elements can be used to achieve better control 
over temperature.
47
 Microwave dielectric heating has also been integrated into flow devices, and 
indirect inductive heating techniques were recently introduced.
22
 
Among modern bench-top flow reactors, micro- and mesofluidic approaches can be 
distinguished, depending on the internal channel dimensions, though it is sometimes difficult to 
draw an exact borderline between these classes.
3
 Microfluidic devices (microreactors) are 
mainly self-contained credit card-sized reactors, which consist of a series of miniaturized 
channels with specific layouts to promote the mixing of the reactants (Figure 5a).
46
 The internal 
diameters typically range from 10 to 500 µm, and the surface area per unit volume is commonly 
between 5000 and 50 000 m
2
 m
–3
, which permits the handling of minimal volumes of reactants 
with superior heat and mass transfer properties.
2, 3
 However, the propensity to clogging and 
major pressure drops are common disadvantages which limit their practical applicability.
3
 
Mesoreactors are typically coil-type or tubular devices with larger channel diameters (from 500 
µm to several mm) and lower surface area per volume values (typically between 100 and 10 000 
m
2
 m
–3
), generally designed for higher throughput at the expense of somewhat poorer heat-
transfer capabilities (Figure 5b).
3, 22
 Mesofluidic devices are usually highly modular and can be 
combined with packed beds where solid-supported reagents, catalysts or scavengers can be 
incorporated (Figure 5c).
3, 48
 Instead of filled columns, reactors with functionalized inner walls 
can be utilized.
49
 Even micro channels can be coated through such an approach, but in a 
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Figure 5. CF apparatus: a microreactor chip (a),
50
 a coil-type mesoreactor (b),
51
 and reactor columns (c).
52
 
consequence of issues regarding applicability and ease of use, fixed-bed reactors have become 
more popular. For heterogeneous catalytic transformations, monolithic flow reactors are also 
applicable, where the catalyst is employed in the form of a structured material, obtained most 
commonly by copolymerization.
48
 It follows from the nature of these materials that pressure 
drops along the reactor are avoided; however, their application is still very limited. The use of 
immobilized materials offers distinct advantages over conventional homogeneous approaches, 
and this has therefore recently become one of the main driving forces behind the rapid advance 
of flow processing. Heterogenized reagents and catalysts allow more sustainable chemical 
synthesis, as such materials can be reused several times, and in many cases regeneration is also 
possible.
53
 Moreover, immobilization reduces the need for time-consuming work-up and 
purification steps, thereby greatly simplifying the product isolation.
54
 The incorporation of 
hazardous reagents and catalysts into fixed beds ensures excellent ease of use and improved 
safety because of the lack of direct contact. The local catalyst concentration in filled column 
reactors is very high, which means that reaction rates can be greatly enhanced. Through the use 
of immobilized catalysts, reagents and scavengers, multistep consecutive reactions can be 
adapted into CF synthetic sequences, permitting rapid access to target molecules without the 
isolation of any intermediates.
55, 56
 A combination of supported materials and the recently 
introduced in-line analytics
57
 offers the opportunity of a high level of automation in high-
throughput CF synthesis.
7, 58
 
Another beneficial feature of CF reaction technology is the inherent scalability.
18, 22
 This 
means that the volume is given as a function of the operation time and flow rate, whereas in 
conventional segmented units the output depends on the batch size.
3
 Increasing the dimensions 
of a classical reaction vessel after a level makes the process unfeasible, as stirring, heating or 
cooling become increasingly more difficult, and a further issue arises when noxious materials 
are to be handled on larger scales. However, even an on-chip microfluidic device can safely 
produce gram or even kilogram quantities without alteration of the reactor engineering when 
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continuously operated for hours or even a whole day.
3, 5
 Alternatively, scale-up can be further 
facilitated through the parallel operation of multiple identical reactors (numbering-up concept) 
or simple extension of the reactor dimensions (length and/or inner diameter).
4, 35
 However, if the 
reactor size is increased above a certain level, reoptimization of the most important reaction 
parameters may be necessary.
6
 
Modern flow technologies satisfy many of the requirements of environmentally benign 
production (minimal reagent consumption, prevention of waste generation, energy efficiency, 
atom economy, catalyst reusability, inherently safer chemistry, etc.),
59
 thereby contributing 
considerably to the concept of green and sustainable chemical synthesis.
60
 The beneficial 
features of continuous processing and the rapid developments in this field have motivated the 
pharmaceutical industry to explore flow chemistry as a novel innovative synthetic alternative 
from laboratory-based investigations to the subsequent production-scales.
61
 
2.2. Applications of flow chemistry
*
 
2.2.1. Heterogeneous catalytic hydrogenations and deuterations 
Heterogeneous catalytic hydrogenations are among the most widely investigated 
transformations in the flow chemistry field, as concerns either academic or industrial 
applications.
59, 61, 62
 In traditional batch-based methodologies, such triphasic catalytic reactions 
pose a challenge (particularly on a relatively large scale) because of the hazardous and highly 
explosive nature of the gaseous reactant. Extreme precautions and costly special apparatus, 
including high-pressure-resistant autoclaves, are therefore required to maintain sufficient 
operational safety. The direct handling of flammable and pyrophoric catalyst types is another 
potential contingency, and the exothermic character of these reactions makes efficient heat 
removal a further issue to consider. Moreover, gas–liquid–solid reaction systems often suffer 
from long reaction times in conventional batch-based technologies, in consequence of the small 
interfacial areas between the different phases and the inadequate mixing.
63
 Heterogeneous 
catalytic hydrogenations can furnish significant benefits through the advantageous features of 
flow processing, and gas–liquid–solid reactions can be carried out with shorter reaction times, 
improved reaction rates and selectivities, enhanced safety and operational simplicity.
1, 62, 64
 
There are several approaches for heterogeneous catalytic hydrogenations in flow. One of the 
first examples of gas–liquid–solid reactions in a microstructured device was provided by Yeong 
et al.,
65
 who developed a falling-film microreactor for the highly exothermic reduction of 
                                                 
*
Due to the restrictions of the Doctoral School of Pharmaceutical Sciences regarding the length of dissertations, 
only the most relevant applications are discussed in this section. 
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nitrobenzene to aniline. The Pd catalyst was deposited onto microstructured plates on which the 
thin film (<100 µm) of the reactants was moving under the force of gravity, with a flow of H2 
gas above the liquid film. This reactor set-up facilitated very close interactions between the 
reacting phases, resulting in very high reaction rates. Fixed-bed or micropacked reactors are 
also widely applied in heterogeneous catalytic hydrogenations, as illustrated by the publications 
of a number of groups.
62
 For example, Yoswathananont et al. carried out the continuous 
hydrogenation of 4-cyanobenzaldehyde in a tube reactor packed with Pd/C.
66
 As an intriguing 
example of gas–liquid–solid reactions, Kobayashi et al. utilized a glass microchannel reactor 
with a Pd catalyst immobilized on the channel walls.
67, 68
 An effective interaction was achieved 
between the three phases due to the large interfacial areas and the narrow channel diameter. As 
an improvement, high-pressure conditions were utilized and scCO2 was used as solvent, which 
resulted in dramatically short reaction times (<1 s).
69
 A wide variety of transformations were 
carried out, such as alkene/alkyne reductions and deprotections, with excellent yields. 
The above-described approaches rely on extraneous H2 gas sources, which involve potential 
hazards. The recently introduced H-Cube
®
 (ThalesNano Inc) high-pressure flow hydrogenation 
mesoreactor eliminates the difficulties in gas handling, greatly improving the operational safety, 
as H2 gas is generated in situ by the electrolytic decomposition of water. The hydrogenation 
catalyst is packed into cartridge-like columns, thereby eliminating potentially dangerous direct 
catalyst handling. Due to its beneficial features, the H-Cube
®
 has gained serious interest over 
the past years. A wide array of gas–liquid–solid reactions have been fulfilled, such as carbon-
carbon double and triple bond hydrogenations. For example, Lou et al. utilized an H-Cube
®
 
reactor for the selective reduction of carbon-carbon double bonds during the synthesis of highly 
functionalized tetrahydropyrimidones (Scheme 1a).
70
 Nitro, nitrile, carbonyl, oxime and imine 
reductions and deprotections have also been carried out. For example, Ekholm et al. reported 
the deprotection of benzyl- and/or benzylidene-protected carbohydrates in an H-Cube
®
 system 
within short reaction times, obtaining excellent yields (Scheme 1b).
71
 
 
 
Scheme 1. Selected examples of hydrogenation reactions in the H-Cube
®
 flow reactor. 
Deuteration is widely applied in chemical research, e.g. in tracer studies to follow reaction 
paths,
72
 or as a tool to investigate pharmacokinetics.
15
 Moreover, deuterium-labeled compounds 
are widely used in structural analysis, e.g. as internal standards in mass spectrometry,
73
 and in 
NMR spectroscopy for the promotion of signal assignments and structure elucidations.
74
 The 
10 
 
batch synthesis of deuterated compounds suffers from several drawbacks and, in general, lacks 
sustainability. On the one hand, this is due to the potentially dangerous gas handling, just as in 
the case of hydrogenations. Another point is that conventional methods for the production of D2 
gas, such as the fractional distillation of liquid hydrogen, pyrolysis of UD3, and reactions of 
D2O with Na, Fe, or Mg, are far from perfect;
16
 and as an alternative route, catalytic H–D 
exchange reactions between H2 and D2O do not supply adequately pure D2 gas.
75, 76
 By 
changing the hydrogen source to deuterated water in an H-Cube
®
 reactor, Mándity et al. 
presented the first approach for CF deuteration reactions (Scheme 2a).
77
 The simple, efficient, 
selective and safe technique eliminated most of the drawbacks of the conventional deuteration 
procedures and offered high yields, excellent deuterium incorporation ratios and short reaction 
times for an array of substrates, including β-amino acid derivatives. Most recently, 
Chandrasekhar et al. utilized the above-described methodology in the selective partial reduction 
of alkynes, resulting in dideuterated olefins in high yields (Scheme 2b).
78
 
 
 
Scheme 2. Examples of deuteration reactions in the H-Cube
®
 flow reactor. 
 
2.2.2. Copper-catalyzed azide–alkyne cycloadditions 
The 1,3-diploar cycloaddition of organic azides with alkynes as dipolarophiles is the most direct 
way to obtain useful 1,2,3-triazoles.
79
 The classical Huisgen reaction utilizes only thermal 
induction and gives an approximately 1:1 mixture of 1,4- and 1,5-disubstituted 1,2,3-triazoles.
80
 
Due to the high activation energy barrier, these cycloadditions are often very slow, even at 
elevated temperatures. As a pioneering improvement, Tornøe et al. and Rostovtsev et al. 
discovered independently that the application of Cu(I) catalysis leads regioselectively to the 
formation of the 1,4-disubstituted isomer under mild reaction conditions within shorter reaction 
times (Scheme 3).
81, 82
 The selective formation of the 1,5-disubstituted 1,2,3-triazole isomer was 
achieved through catalysis with Ru(II) complexes, but the catalytic activity and regioselectivity 
proved to be sensitive functions of the ligand environment.
83
 Thanks to its outstanding 
efficiency and selectivity, CuAAC has become the definition of the “click chemistry” concept.84 
 
 
Scheme 3. 1,3-Dipolar azide–alkyne cycloadditions. 
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In the past decade, the applications of CuAAC have conquered many areas of modern 
chemistry. In the field of bioconjugation, the CuAAC reaction has emerged as a versatile tool 
for the labeling of biomolecules with various functionalities.
85
 As the 1,2,3-triazole moiety is an 
excellent mimetic of the amide bond, CuAAC is increasingly found in peptidomimetic 
chemistry, e.g. for the ligation of peptide fragments, for peptide cyclizations, or for backbone 
modifications.
86
 The field of polymer and materials sciences has also greatly exploited the 
CuAAC reaction,
87
 and it holds great promise for surface modifications,
88
 for supramolecular 
chemistry
89
 and for radiolabeling studies.
90
 In consequence of their potential biological 
properties, 1,2,3-triazole-containing compounds have recently become feasible targets for drug 
discovery.
91
 A large number of 1,2,3-triazole-contining compounds exhibit various biological 
activities, e.g. antiviral, antibacterial, antifungal and anticancer effects (Figure 6).
92
 The 1,2,3-
triazole moiety is frequently used as a pharmacophore for the modification of known 
pharmaceutics and to potentiate their biological effects. For example, 1,2,3-triazole analogs of 
the well-known antiviral cyclic amino acid derivatives oseltamivir and zanamivir have recently 
been reported (Figure 6).
93, 94
 The 1,2,3-triazole skeleton is a constituent part of many modified 
nucleosides or carbanucleosides with various activities. For instance, the 1,2,3-triazole analog 
of the bioactive carbanucleoside neplanocin A exhibits notable antiviral effect (Figure 6).
95
 
 
 
Figure 6. Some examples of 1,2,3-triazoles with various biological activities. 
The synthesis of 1,2,3-triazoles via CuAAC comprises an extraordinarily robust and 
straightforward transformation, which can be performed under a wide array of reaction 
conditions.
11
 For such reactions, the safety aspects associated with the handling of explosive 
azides and the inherent scalability of CF processing are particularly appealing, thereby reviving 
CF CuAAC approaches. Smith et al. utilized a combination of immobilized catalysts and 
scavenger resins in a modular flow reactor (Scheme 4).
96
 CuI was immobilized in a complex 
form on a dimethylaminomethyl-grafted polystyrene (PS) support.
97
 The copper catalyst was 
expected to leach from the resin due to the weak coordinative forces, and a subsequent in-line 
scavenging step was therefore necessary, a thiourea-based metal resin being used to remove the 
copper contamination from the solution phase. The azide was required in excess to drive the 
reaction to completion. To obtain the corresponding 1,2,3-triazole products in pure form, the 
12 
 
unreacted azide was removed in-line over a phosphine resin, the azide being captured onto the 
solid phase via a Staudinger reaction. Triazole products were obtained in short process times, in 
high yields (up to 93%) and without the need for further purification steps, and gram-scale 
production was also successfully implemented. Baxendale et al. later extended the procedure to 
a reaction sequence with the in situ generation of the alkyne from an aldehyde and the 
Bestmann–Ohira reagent as the initial step.98 
 
 
Scheme 4. CuAAC in CF with solid-supported CuI catalyst and scavenger resins. 
Bogdan and Sach introduced an experimentally more convenient approach for azide–alkyne 
cycloadditions by developing an on-demand flow reactor made of Cu.
99
 The surface of the Cu is 
covered with non-self-protecting layers of different copper oxides, and the use of Cu tubing 
ensures catalytically active Cu(I) species without the need for any additional copper catalyst. 
Furthermore, the reactive organic azides were generated in situ from NaN3 and the 
corresponding alkyl halides, utilizing one-pot click methodology. Heating was necessary to 
obtain sufficient reactivity through the CuAAC. 1,4-Disubstituted 1,2,3-triazole isomers were 
obtained regioselectively in a highly efficient manner, and scale-up experiments were also 
performed with fewer safety issues than in the corresponding batch process. The scope of the 
methodology was further extended to the expedient synthesis of drug-like macrocycles based on 
1,4-disubstituted and 1,4,5-trisubstituted 1,2,3-triazoles obtained via intramolecular click 
reactions (Scheme 5).
100, 101
 Tu et al. later demonstrated that ultrasound promotion can 
practically eliminate the need for harsh reaction conditions, and 1,2,3-triazoles can be obtained 
at lower temperatures with Cu flow reactor technology.
102
 
 
 
Scheme 5. Synthesis of 1,4-disubstituted (a) and 1,4,5-trisubstituted (b) 1,2,3-triazole-containing macrocycles with 
Cu flow reactor technology. 
 
Ceylan et al. employed an inductively heated flow reactor solution for CuAAC reactions.
103
 
A glass column was filled with Cu wiring, which was heated directly and instantly with 
electromagnetic induction (Scheme 6). With this setup, very high temperatures could be 
generated inside the Cu, which led to the formation of active Cu(I) species on the surface of the 
metal without further catalytic source. This extent of reactivity was not attainable with 
conventionally heated Cu. In order to keep the solvent in the liquid phase even at high 
13 
 
temperatures, a backpressure regulator was introduced into the flow line, and the system was 
equipped with a metal scavenger cartridge so as to remove copper contamination from the 
solution phase in-line. Similarly as in the work of Bogdan and Sach,
99
 one-pot click 
methodology was utilized through the in situ generation of organic azides, thereby greatly 
enhancing operational safety. The proposed methodology was successfully applied for the 
effective synthesis of a small library of vinyl triazoles.
104
 
 
 
Scheme 6. CuAAC with an inductively heated CF reactor filled with Cu wiring. (DMF=N,N-dimethylformamide.) 
As a heterogeneous Cu(I) source, copper-in-charcoal (Cu/C) was utilized in a dedicated 
high-pressure/high-temperature flow reactor by Fuchs et al. for the CuAAC reaction between 
benzyl azide and phenylacetylene.
12
 They established that the catalysis through the CF reaction 
proceeded in the homogeneous phase, due to the leaching of catalytically active copper species. 
The Cu/C system was originally introduced for azide–alkyne cycloadditions by Lipshutz and 
Taft as an inexpensive self-stable catalyst, with different types of copper oxides, including 
Cu2O, present within the charcoal matrix.
105
 
Although the most popular sources of Cu(I) in CF studies are mainly heterogeneous 
approaches, Varas et al. recently reported an efficient approach for CF CuAAC reactions by 
using a homogeneous copper-complex ([Cu(phen)(PPh3)2]NO3) as catalyst.
13
 They succeeded in 
utilizing very low catalyst loadings and short reaction times at elevated temperatures. Copper 
contamination was efficiently removed via an in-line extraction process, with aqueous 
ethylenediaminetetraacetic acid (EDTA) as a homogeneous copper-scavenging system. 
2.2.3. Asymmetric organocatalysis 
Organocatalysis uses metal-free low-molecular-weight organic molecules as chiral catalysts 
for the stereoselective synthesis of valuable compounds. Beneficial features, such as high 
stability, availability, non-toxicity, and low cost, make the use of organocatalysts extremely 
attractive as compared with organometallic counterparts. In the 1970s, two industrial research 
groups independently discovered that the naturally occurring L-proline efficiently catalyzed the 
enantioselective intramolecular aldol reaction of cyclic triketones (Hajos–Parrish–Eder–Sauer–
Wiechert reaction, Scheme 7).
106, 107
 However, the potential behind this finding remained 
undiscovered for almost three decades. The revival of this chemistry is closely related with the 
discovery of the proline-catalyzed direct asymmetric intermolecular aldol reaction by List  
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Scheme 7. Enantioselective intramolecular aldol reactions with L-proline as organocatalyst by Eder, Sauer and 
Wiechert.
106
 (Hajos and Parrish investigated the same reactions under slightly modified conditions.
107) 
et al.
108
 Since then, L-proline has become a powerful organocatalyst for numerous asymmetric 
transformations involving enamine intermediates,
9, 109
 including Mannich reactions,
110
 Michael 
additions,
111
 α-amination reactions,112 α-aminoxylations,113 and Diels–Alder reactions.114 In 
such transformations, the function of the amine residue of proline is to activate the carbonyl 
compound by formation of an enamine for reaction with an electrophile, whereas, the 
carboxylic acid moiety coordinates the stereochemical outcome through hydrogen bonding 
(Scheme 8).
115, 116
 In the golden age of asymmetric catalysis, a wide array of new proline-
derived organocatalysts were designed that offered improved catalytic activity and selectivity, 
and increased substrate scope.
9
 In general, proline modifications mean the substitution of the 
carbon atoms of the pyrrolidine ring,
117
 or the replacement of the carboxylic group with various 
functions, such as amide,
118
 tetrazole
119
 or siloxy groups.
120
 Moreover, apart from proline-
derived techniques, alternative efficient organocatalytic approaches have also come to light, 
such as 1,1’-bi-2-naphthol (binol)-, cinchona alkaloid- or thiourea-based catalysts.8, 121 
 
 
Scheme 8. Proline-catalyzed aldol (a) and Mannich reactions (b) with transition-state models. 
However, the limitation of the above-mentioned techniques (particularly of proline-based 
catalysis) is that small, rigid organocatalysts offer only restricted structural and functional 
diversity, which limits the opportunities of creating optimized catalysts. In contrast, the 
utilization of synthetic peptides, as on-demand organocatalysts, eliminates these drawbacks in 
consequence of their highly modular nature, readily designable structure and inherent 
chirality.
10
 The earliest examples of peptide-catalyzed asymmetric transformations are an 
enantioselective cyanohydrin synthesis by Oku and Inoue with a cyclic dipeptide, cyclo(L-Phe-
L-His) (Phe=phenylalanine, His=histidine),
122
 and the epoxidation of electron-deficient olefins 
with poly-α-aminoacids by Julia et al.123 It was later shown by several research groups that N-
terminal prolyl-peptides are interesting candidates for reactions proceeding via enamine 
intermediates.
124-126
 However, these approaches usually meant only modest procedural 
enhancements as compared with proline catalysis. Tripeptides with the general formula  
15 
 
H-Pro-Pro-Xaa-NH2 (Pro=proline), where Xaa is an amino acid with acidic side-chain, were 
recently employed as effective organocatalysts for the asymmetric aldol and Michael 
reactions.
127
 These structures can be regarded as proline mimetics, as they contain secondary 
amine and carboxylic acid moieties in a specific orientation due to the turn-conformation of the 
peptide.
128
 These functional groups play similar roles as in conventional proline-mediated 
transformations.
128, 129
 The peptide H-Pro-Pro-Asp-NH2 (Asp=aspartic acid) was found to be an 
efficient catalyst for direct aldol reactions,
130
 and the closely related peptides H-D-Pro-Pro-Asp-
NH2 and H-D-Pro-Pro-Glu-NH2 (Glu=glutamic acid) proved to be excellent catalysts for 
conjugate additions between aldehydes and nitroolefins.
131, 132
 There are many further examples 
of synthetic peptide-mediated asymmetric transformations, including Morita–Baylis–Hillman 
reactions, Stetter reactions, Friedel–Crafts alkylations, asymmetric acylations, etc.,10 but their 
discussion is beyond the scope of this dissertation. 
Through the past decade, it was repeatedly demonstrated that flow chemistry is highly 
beneficial for organocatalytic purposes in terms of productivity, easy automation or facile scale-
up; and the development of reliable immobilization techniques for chiral catalysts significantly 
contributed to this revelation.
133-135
 The first (and somewhat forgotten) example of a CF 
organocatalytic procedure was demonstrated by Cappi et al. in 1998.
136
 In an improvement of 
the classical Julia–Colonna asymmetric epoxidation of α,β-unsaturated ketones, they 
immobilized poly-L-Leu (Leu=leucine) on cross-linked aminomethyl-PS resin, which was 
packed into a glass column together with H2O2 as oxidant. A solution of chalcone and a base (to 
promote the formation of the reactive peroxy anion) was passed through the packed bed by 
means of the force of gravity. The resulting chiral chalcone epoxide was obtained as an 
important synthetic intermediate within a short residence time with excellent conversion (97%) 
and an enantiomeric excess (ee) of 98%. Subsequently, Tsogoeva et al. utilized soluble 
polymer-bound oligo-L-Leu compounds in a continuously operated chemzyme membrane 
reactor for the asymmetric epoxidation of chalcone, where a nanofiltration membrane retained 
the polymer-enlarged catalyst, while the resulting epoxide and unconverted chalcone could 
freely pass through.
137
 Kee and Gavriilidis recently designed a dedicated microflow system for 
homogeneous poly-L-Leu-catalyzed chalcone epoxidation, in which gram-scale production was 
attainable.
138
 With a well-regulated reactor concept, this study implied potential industrial uses. 
As another pioneering example, Hafez et al. revealed that a combination of multiple 
“reaction columns” packed with solid-phase reagents, catalysts and scavengers is a powerful 
tool for the stereoselective multistep synthesis of complex compounds.
139
 They applied a Wang-
resin-supported quinine derivative (1) as chiral organocatalyst in the reactions of imino esters 
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with ketenes, leading to highly enantioenriched β-lactams. The three-step reaction sequence was 
carried out as a single process in sequentially linked fillable glass columns with gravity-driven 
flow-through (Scheme 9). To avoid direct handling of reactive intermediates, the ketene was 
generated in situ from the corresponding acid chloride and a polymer-supported base, and then 
reacted with an imino ester in the presence of immobilized organocatalyst 1. The excess 
reactants and byproducts were removed in-line on an immobilized nucleophilic scavenger, 
thereby greatly simplifying further work-up and purification procedures. The resulting chiral β-
lactams were obtained in good yields (53–65%), high diastereoselectivites (up to a 
diastereomeric ratio (dr) of 14:1) and excellent enantioselectivites (up to an ee of 94%). 
Another beneficial feature is that the system proved to be highly robust, as no decrease in 
activity or selectivity was observed after 60 reaction cycles when the same batch of resins was 
utilized. Bernstein et al. later extended the scope of this concept to the CF stereoselective α-
chlorination of acid chlorides with the same immobilized organocatalyst.
140
 Besides being the 
source of stereoselective induction, the cinchona alkaloid-derived catalyst also served as a 
dehydrohalogenation reagent. Chiral α-chloroester products were generated in good yields (40–
61%) and excellent enantioselectivities (up to an ee of 94%). Later, the diasteroselective total 
synthesis of a metalloproteinase inhibitor was successfully fulfilled by utilizing this column-
based flow technique, with the α-chlorination reaction as a key step.141 
 
 
Scheme 9. CF asymmetric synthesis of β-lactams with an immobilized quinine derivative as organocatalyst. 
In 2009, Odedra and Seeberger reported the first example of an organocatalytic asymmetric 
aldol reaction in CF, this being the first successful application of a proline-derived catalyst in a 
flow system.
142
 Homogeneous 5-[(2S)-pyrrolidin-2-yl]-1H-tetrazole (2) was utilized as chiral 
organocatalyst in a glass microreactor.
119
 The solution of the reactants and the catalyst 2 were 
injected into the heated reactor zone separately through two inlets. Aldol reactions between 
acetone and various aromatic aldehydes were investigated (Scheme 10a). After thorough 
optimization of the reaction conditions, it was found that the reaction times could be shortened 
dramatically under reduced catalyst loading and at higher temperature (60 °C), while the yield 
and stereoselectivity remained commensurable with the conventional batch results. The scope 
of the method was further extended to the Mannich reaction between p-methoxyphenyl (PMP)-
17 
 
protected α-iminoglyoxylate and cyclohexanone, yielding the corresponding β-amino ketone 
product in excellent ee and dr (Scheme 10b). As an intriguing extension of the homogeneous 
catalytic concept, Fritzsche et al. designed a microfluidic organocatalytic system for the 
enantioselective vinylogous Mannich reaction with fully integrated on-chip analysis .
143
 The CF 
device was successfully utilized to screen a number of binol-based chiral phosphoric acid 
catalysts, with a very good correlation with the results of the corresponding batch experiments. 
 
 
Scheme 10. CF asymmetric aldol (a) and Mannich reactions (b) with a homogeneous proline-derived 
organocatalyst in a microreactor. 
As a significant improvement, in 2009 Alza et al. took advantage of heterogeneous 
supporting and reported for the first time the successful utilization of an immobilized proline-
based organocatalyst for highly selective Mannich reactions in CF.
144
 To avoid alteration of the 
catalytically active functions of proline, 4-hydroxyproline was converted to an O-propargyl 
derivative, and then connected to an azido-functionalized PS resin by means of a click strategy, 
leading to immobilized catalyst 3 (Scheme 11a).
145
 In fact, the resulting 1,2,3-triazole moiety 
not only served as a linker between the proline unit and the polymeric backbone, but also 
contributed to the formation of a highly selective catalytic system. The reactions between 
various aldehydes and a preformed imine were studied by pumping the solution of the reactants 
through a glass column containing catalyst 3 (Scheme 11b). Synthetically useful Mannich 
products were obtained in almost diastereo- and enantiomerically pure form (with ee values of 
>99% and dr values of >97:3). Another beneficial feature of this sustainable process is that it 
proved promisingly rapid, with a residence time on the catalyst bed as low as 6 min. In contrast 
with the previously mentioned homogeneous approaches,
142, 143
 the use of the insoluble 
polymer-bound catalyst eliminated the need for any further work-up or purification steps, which 
was highly favorable, as Mannich adducts are rather labile substances. Ayats et al. later utilized 
the same strategy for CF enantioselective aldol reactions between various aromatic aldehydes 
and cyclohexanone, with PS-supported 4-(1-triazolyl)proline as organocatalyst (4, Figure 7a).
146
 
β-Hydroxyketone products were obtained with excellent enantio- and diastereoselectivities (ee 
values of 95–98% and dr values of 96:4–97:4) in gram-amounts with short residence times. 
Furthermore, the flow process allowed a 6-fold reduction in the effective catalyst loading as 
compared with the subsequent batch reaction utilizing the same immobilized catalyst. 
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Scheme 11. Synthesis of PS-supported organocatalyst 3 (a), and asymmetric Mannich reactions in CF with 3 (b). 
(Boc=tert-butoxycarbonyl.) 
Massi et al. recently employed SiO2-immobilized organocatalysts in miniaturized HPLC 
columns for asymmetric aldol reactions. At the beginning of their studies, they utilized SiO2-
supported proline, but this system had serious limitations as the immobilized catalyst 
deactivated through irreversible decarboxylation, even at room temperature (RT).
147
 Later, they 
reported the use of a SiO2-supported prolin-derived tetrazole catalyst (5, Figure 7b), which was 
not prone to the above-mentioned deactivation pathway, thereby permitting a more stable 
catalytic system for aldol reactions.
148
 With the improved catalyst, they achieved high 
conversions (58–>95%) and enantioselectivities (ee values of 68–95%) in the reactions of 
various aromatic aldehydes and cyclohexanone at various temperatures and in various solvents. 
However, only modest diastereoselectivities (dr values of 1:1–3:1) could be reached with any of 
the reaction conditions. As an interesting example of a heterogeneously catalyzed aldol reaction 
in a flow reactor, Demuynck et al. applied a non-covalently immobilized chiral primary amino 
acid-derived diamine as organocatalyst (6, Figure 7c).
149
 A sulfonated fluoropolymer, nafion
®
 
NR50, served as solid support, and the chiral diamine was anchored through acid−base 
interactions. In this approach, the solid acid not only served as catalyst support, but also 
governed the activity and selectivity of the chiral catalyst. The system was benchmarked with 
the aldol reaction between 2-butanone and 4-(trifluoromethyl)benzaldehyde, resulting in the 
corresponding β-hydroxyketone with ee values up to 97% and dr of 3:1. 
 
 
Figure 7. Immobilized organocatalysts for asymmetric aldol reactions utilized in various CF systems: PS-
supported 4-(1-triazolyl)proline catalyst (a), SiO2-supported prolin-derived tetrazole catalyst (b), and a non-
covalently immobilized chiral primary amino acid-derived diamine catalyst (c). 
The first example of a CF Michael reaction was provided by Bonfils et al. in 2006, with PS-
supported cinchonidine as organocatalyst (7).
150
 They investigated the reaction between methyl 
1-oxo-2-indanecarboxylate and methyl vinyl ketone. The solutions of the reactants were passed 
through an incubated fluid bed by means of peristaltic pumps. Under optimized reaction 
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conditions, the corresponding chiral Michael product was obtained within a residence time of 
6 h in a yield of 97% and an ee of 51% (Scheme 12). Later, Alza et al. investigated an 
enantioselective domino Michael−Knoevenagel reaction in CF operation.151 A diarylprolinol 
silyl ether was employed as chiral organocatalyst (8), immobilized via a click strategy onto a PS 
support, and filled into a glass column (Scheme 13). The reaction between 3-(4-
methoxyphenyl)acrolein and dimethyl 3-oxoglutarate was investigated. It was found that 
1 equivalent of benzoic acid additive was necessary for effective transformation. The 
immobilized organocatalyst proved to be remarkably robust: after 72 h of continuous use, no 
significant deterioration of its performance was observed. After a simple NaBH4 reduction, 
8.7 g of a synthetically useful highly functionalized cyclohexane derivative was obtained 
(equivalent to a yield of 62%), with an ee of 97%. 
 
 
Scheme 12. CF asymmetric Michael reaction in a fluid bed reactor filled with PS-supported cinchonidine. 
 
 
Scheme 13. Enantioselective domino Michael−Knoevenagel reaction in CF operation with a PS-immobilized 
diarylprolinol silyl ether as organocatalyst. 
For the stereoselective formation of C−N bonds via the α-amination of aldehydes, Massi et 
al. furnished the first CF example with SiO2-immobilized proline as organocatalyst.
147
 
However, besides high conversions, they attained only modest enantioselectivities (up to an ee 
of 58%), even at 0 °C. Fan et al. later reported a more sustainable approach for asymmetric α-
amination reactions in flow.
152
 They employed a PS-supported diphenylprolinol silyl ether 
catalyst (9) similar to that used for Michael reactions.
151, 153
 It was found that a high excess of 
aldehyde was needed to prevent rapid catalyst deactivation, and 0.1 equivalent of AcOH as 
acidic additive was necessary to accelerate the transformation. The reaction between propanal 
and dibenzyl azodicarboxylate (DBAD) was studied (Scheme 14a). The swollen heterogeneous 
catalyst was packed into a glass catalyst bed, which was filled initially with a mixture of the 
aldehyde and AcOH to promote enamine formation. The circulation of the DBAD solution was 
subsequently started by another pump. The system was kept in operation continuously for 8 h, 
with full conversion in the first 6 h. After reduction of the resulting aldehyde, a synthetically 
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useful α-hydrazino alcohol product was obtained on the gram-scale with an ee of 88%. 
Cambeiro et al. utilized a similar concept for the organocatalytic asymmetric α-aminoxylation 
of aldehydes.
154
 PS-immobilized organocatalyst 3 was employed, just as in an earlier study of 
CF Mannich reactions.
144
 Reactions between various aliphatic aldehydes and nitrosobenzene 
were studied at 0 °C (Scheme 14b). Because of the intrinsic instability of the resulting α-
aminoxy aldehydes, the products of the CF reactions were reduced in situ to the corresponding 
alcohols, which were obtained with high productivities and excellent ee values (up to 96%) in 
short reaction times. However, it must be noted that a slow decrease in conversion was observed 
during continuous operation for hours, which is due to possible catalyst deactivation. Opalka et 
al. reported a different strategy for the same reaction, relying on continuous proline catalysis via 
leaching of solid proline.
155
 By pumping a solution of aldehyde and a thiourea additive through 
a column filled with solid L-proline, the leaching of the catalyst occurred into the homogeneous 
phase, thereby giving rise to homogeneous catalytic α-aminoxylation between the aldehyde and 
nitrosobenzene, which were introduced separately. After the reduction of the α-aminoxy 
aldehyde products, the corresponding alcohols were obtained in high yields and ee values. 
 
 
Scheme 14. Asymmetric α-amination (a) and α-aminoxylation (b) of aldehydes in CF with PS-supported 
organocatalysts. 
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3. EXPERIMENTAL SECTION 
3.1. CF methodology 
CF experiments were carried out in an H-Cube
®
 mesoreactor system containing a stainless steel 
cartridge as catalyst bed with internal dimensions of 30×4 mm or 70×4 mm.156 The filled 
cartridge was embedded in a heating unit controlled by a Peltier system, up to a maximum of 
100 °C. This also included a coiled stainless steel reaction line (with an internal diameter of 500 
µm) for preheating of the liquid phase before entering the catalyst bed. A backpressure regulator 
ensured constant pressures up to a maximum of 100 bar, and the CF of the reaction medium was 
provided by a conventional HPLC pump (Knauer WellChrom K-120).
157
 For heterogeneous 
hydrogenations, the H-Cube
® 
system contains a gas-generation unit consisting of a reservoir for 
deionized water and a built-in electrolysis cell for the generation of H2. The in situ generated 
gas is combined via a gas–liquid mixer with the solution of the substrate, and the mixture is then 
transported to the catalyst bed, where the triphasic reaction takes place.
47
 CF deuterations were 
carried out by changing the hydrogen source to D2O.
77
 In the case of CF organocatalysis and CF 
CuAAC reactions, the gas generation unit was turned off (i.e. the H-Cube
®
 system was 
switched to ‘no H2’ mode). A brief outline of the CF system is shown in Figure 8. 
 
 
Figure 8. Experimental setup for the CF reactions. 
To determine the residence time on the filled catalyst bed, a solution of a dye was pumped 
through the cartridge. The time that elapsed between the first contact of the dye with the catalyst 
bed and the moment when the colored solution appeared at the column output was measured. 
For the CF reactions, the starting materials were dissolved by sonication, and then pumped 
through the flow reactor. Most important reaction parameters (such as temperature, pressure, 
flow rate and substrate concentration) were systematically fine-tuned to determine optimal 
conditions. The crude products were checked by thin-layer chromatography and, if necessary, 
column chromatographic purification was carried out. The products of the CF reactions were 
characterized by means of NMR spectroscopy (
1
H, 
13
C, 
13
C HMBC
158
 and 
13
C HSQC
159
), MS 
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and elemental analysis. In cases of chiral compounds, ee was assigned with chiral NP-HPLC, 
and dr was determined from the 
1
H NMR spectra of the crude material. The deuterium content 
of the deuterated compounds (i.e. the deuterium incorporation ratio over incidental hydrogen 
addition) was determined from the relative intensity of 
1
H NMR indicator signals and by MS 
analysis. In CF CuAAC reactions, the copper contamination of the resulting materials was 
determined by means of inductively coupled plasma mass spectrometry (ICP-MS). 
3.2. Synthesis and modification of the immobilized peptidic catalysts 
The peptidic catalysts were prepared manually by means of solid-phase peptide synthesis 
(SPPS),
160
 utilizing 9H-fluoren-9-ylmethoxycarbonyl (Fmoc)/tBu chemistry.
161
 Amino-
functionalized non-trifluoroacetic acid (TFA)-labile resins were utilized as solid-supports for 
the SPPS: polyethylene glycol (PEG)–PS copolymer without any linker (TentaGel, Figure 
9a),
162
 and PS resin with a 4-methylbenzhydrylamine linker (PS-MBHA, Figure 9b).
163
 With 
respect to the different swelling properties of the applied resins,
164
 DMF was used as solvent in 
the case of TentaGel, and DMF/CH2Cl2 1:1 was employed for couplings with PS-MBHA. 
Before any synthetic steps, the resin was swollen thoroughly for 1 h in the appropriate solvent.  
 
 
Figure 9. Solid supports utilized for immobilization of peptidic catalysts: TentaGel (a), PS-MBHA (b). 
A further treatment with 5% N,N-diisopropylethylamine (DIEA) solution was carried out in the 
case of PS-MBHA to liberate the amino function from the HCl salt form. 3 equivalents of the 
Fmoc-protected amino acid and 3 equivalents of 1-[bis-(dimethylamino)methyliumyl]-1H-
1,2,3-triazolo[4,5-b]pyridine-3-oxide (HATU)
165
 were dissolved, and 6 equivalents of DIEA 
was added. The solution of the activated amino acid was then poured onto the swollen resin, 
and the couplings were fulfilled by agitation for 3 h. After that, the incorporation of the amino 
acid was monitored by means of the ninhydrin or isatin test.
166, 167
 Fmoc deprotection was 
performed in a solution of 2% 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 2% piperidine 
with agitation for 2×15 min, and the peptide chain was then elongated with repetition of the 
coupling and deprotection steps (Scheme 15). After each step, the resin was washed 3 times 
with CH2Cl2, once with MeOH and 3 times with CH2Cl2. Finally, the carboxyl side-chain was 
deprotected without cleavage of the peptide from the solid support by means of agitation 
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Scheme 15. An example of the solid-phase synthesis of immobilized peptidic catalysts. 
for 3 h in a mixture of TFA and H2O (9:1 v/v). After filtration and washing with the same 
solvents as described previously, the resin-bound peptide was kept at RT for 6 h to dry. The 
immobilized catalysts were obtained in TFA salt form after the SPPS. 
Acetylation of the N-terminus of the immobilized peptide was performed in CF while being 
loaded into a catalyst cartridge. A mixture of 10% Ac2O and 2% pyridine in CHCl3 was 
circulated for 60 min under the following conditions: 0.3 mL min
–1
, atmospheric pressure and 
RT. After that, the resin was washed with CHCl3 for 30 min at a flow rate of 1 mL min
–1
. 
TentaGel-bound catalysts were characterized by suspension-phase 
13
C NMR measurements. 
The structure of MBHA-immobilized peptides was verified by means of MS and RP-HPLC 
investigations after cleaving from the resin in a mixture of thioanisole, 1,2-ethanedithiol (EDT), 
TFA and trifluoromethanesulfonic acid (TFMSA) (2:1:20:2 v/v/v/v) for 0.5 h at –10 °C and 
then at RT for 1.5 h. Next, the peptide was precipitated with cold Et2O, collected by filtration 
and dissolved in TFA. The volume of TFA was reduced to 1 mL by evaporation, and the 
peptide was precipitated again with Et2O. After filtration, the peptide was dissolved in 10% 
AcOH and lyophilized. 
3.3. Analytical investigations 
NMR measurements were carried out on Bruker Avance DRX 400 or 500 spectrometers in 
CDCl3 as solvent, using tetramethylsilane as internal standard.
168
 
1
H NMR spectra were 
recorded at 400.1 or 500.1 MHz, 
13
C NMR at 100.6 or 125.0 MHz, respectively. MS analyses 
were performed with an Agilent 1100 LC/MSD trap.
169
 Microanalysis was carried out on a 
Perkin–Elmer 2400 elemental analyzer.170 An analytical HPLC was used with a diode array 
detector from JASCO.
171
 Chiral columns were purchased from Daicel (Chiralcel
®
 OD-H, 
Chiralpak
®
 IA, Chiralpak
®
 AS),
172
 RP-HPLC investigations were performed on a Phenomenex 
Luna 5μ C18 100A column (250×4.60 mm).173 The exact conditions for the HPLC analyses can 
be found in the original papers.
II, IV
 ICP-MS investigations were performed on an Agilent 
7700x-type instrument equipped with a collision cell, using He as collision gas.
174
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4. RESULTS AND DISCUSSION 
4.1. CF deuteration of nitrogen-containing heterocycles
I
 
Biologically active compounds are often derived from heterocyclic structures. For example, 
quinoline, isoquinoline, quinoxaline, and their saturated analogs are commonly used as building 
blocks in pharmaceutical chemistry.
14
 Derivatives of such nitrogen-containing heterocycles 
exhibit various pharmacological properties, such as antimalarial,
175
 antitumor,
176
 antibacterial
177
 
or antidepressant effects,
178
 and this structural class has therefore received special attention in 
the field of drug discovery. Incorporation of deuterium-labeled heterocycles into drugs or drug-
like molecules is an ultimate goal for the preparation of tools to investigate pharmacokinetics,
15
 
but as pointed out in section 2.2.1, conventional methodologies for deuterium labeling suffer 
from several drawbacks.
16
 For this reason, we developed a sustainable CF method for the highly 
selective deuteration of nitrogen-containing heterocycles. 
4.1.1. CF method development 
On the basis of earlier results,
77
 D2 was generated in situ by means of electrolytic decomposition 
of D2O in an H-Cube
®
 reactor (Figure 8).
47
 This approach is highly favorable, as the purity of 
the D2 gas produced can be as high as 99.99%,
179
 and the consumption of D2O is very low, 
which implies much higher deuterium efficiency than in earlier methods.
75, 76
 Approximately 
150 mg of a heterogeneous hydrogenation catalyst was incorporated into the catalyst cartridge 
with internal dimensions of 30×4 mm. To prevent D–H exchange and maximize deuterium 
incorporation, EtOAc was employed as aprotic solvent. For an optimization study, deuteration 
of substituted 3,4-dihydroisoquinoline derivative 10 was selected as a model reaction. 20 mL 
aliquots of 10 (in 1 mg mL
–1
 solution) were pumped through the CF reactor, maintaining a flow 
rate of 1 mL min
–1
, and further reaction conditions were systematically fine-tuned (Table 1). 
Initially, 5% Pd/BaSO4 was chosen as heterogeneous catalyst over Pd/C, as it is known from the 
literature that various protic contaminations in the activated charcoal matrix can easily bias the 
deuterium incorporation ratio.
180
 At RT and atmospheric pressure, no conversion was obtained 
(Table 1, entry 1). As pressurizing apparently increases the solubility of gases, it is 
straightforward that higher pressures mean higher reaction rates. Accordingly, at 40 bar a 
conversion of 50% was achieved (Table 1, entry 3), but further elevation to 80 bar did not prove 
beneficial, as the conversion remained steady at 50% (Table 1, entries 4 and 5). To improve the 
reaction rates, we tried raising the temperature from RT and simultaneously, increasing the 
residence time on the catalyst bed by the recirculation of the substrate solution. However, after 
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three consecutive circulations at 90 °C and 50 bar, the conversion was still below optimal 
(Table 1, entry 7). Thus, as a more active catalyst, 5% Pt/Al2O3 was chosen. At 30 °C and 50 
bar, almost quantitative conversion was obtained in a single run (Table 1, entry 8). Moreover, 
the reduction was highly selective, as the benzene ring remained intact, whereas the heterocycle 
was successfully deuterated, leading to 10d with an excellent deuterium incorporation ratio of 
97% (Table 2, entry 1). It must be noted that the N–D bond could not be detected in the NMR 
spectra, as it instantly changed to N–H due to moisture while being exposed to air. 
 
Table 1. Optimization of the reaction conditions in the CF deuteration of 10. 
 
Entry Catalyst p (bar) T (°C) Runsa Conv. (%)b 
1 5% Pd/BaSO4 1 RT 1 0 
2 5% Pd/BaSO4 20 RT 1 0 
3 5% Pd/BaSO4 40 RT 1 50 
4 5% Pd/BaSO4 60 RT 1 50 
5 5% Pd/BaSO4 80 RT 1 50 
6 5% Pd/BaSO4 50 70 2 60 
7 5% Pd/BaSO4 50 90 3 80 
8 5% Pt/Al2O3 50 30 1 99 
aNumber of circulations through the CF reactor. bDetermined by 1H NMR spectroscopic analysis 
of the crude material. 
 
4.1.2. Investigation of the scope and applicability of the CF methodology 
Deuteration of various nitrogen-containing heterocycles was carried out to generalize the CF 
methodology. It was found that deuteration of partially unsaturated heterocycles was successful 
under the previously optimized reaction conditions. In the cases of 11-13, the corresponding 
deuterated products (11d-13d) were obtained with excellent conversions (>96%) and deuterium 
contents (>95%) within a single run (Table 2, entries 2-4). Deuterium incorporation was 
selective into the carbon-nitrogen double bond as the aromatic ring remained saturated in all 
cases. It is noteworthy that 13 (drotaverine), a spasmolytic drug, was selectively deuterated on 
the endo position of the double bond. Deuteration of fully aromatic nitrogen-containing 
heterocycles was also attempted. As was expected, saturation of the heteroaromatic systems 
required stronger conditions as compared with the 3,4-dihydroisoquinoline derivatives 10-13. In 
the case of quinoxaline (14), utilization of the previous conditions (5% Pt/Al2O3, 30 °C, 50 bar) 
allowed a conversion of 92% (Table 2, entry 5). However, increasing the temperature to 50 °C 
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resulted in almost quantitative conversion and selective deuterium introduction into the 
heterocycle with an excellent deuterium content of 95% (Table 2, entry 6). Due to its more 
stable heteroaromatic system, the efficient deuteration of quinoline (15) required more stringent 
conditions. At 30 °C and 50 bar with 5% Pt/Al2O3 as catalyst, a conversion of only 80% could 
be obtained (Table 2, entry 7). To improve the reaction rate, the temperature was raised to 70 °C 
and the solution of 15 was circulated consecutively through the flow reactor three times. The 
incorporation of deuterium into the nitrogen-containing ring was selective even under these 
conditions. Finally, a deuterium content of 97% and a conversion of 98% could be achieved 
(Table 2, entry 8). Deuteration of pyrazine was also attempted, but presumably the aromatic 
ring underwent fragmentation into volatile compounds, and thus no deuterated product could be 
isolated. Deuterated products 10d-15d were obtained in a sufficiently pure form, and were 
analyzed after evaporation without further work-up steps. 
 
Table 2. CF deuteration of selected nitrogen-containing heterocycles.
a
 
Entry Starting material Product T (°C) Runsb Conv. (%)c D (%)d 
1 
  
30 1 99 97 
2 
  
30 1 99 95 
3 
  
30 1 97 96 
4 
  
30 1 96 98 
5 
  
30 1 92 n.d. 
6 50 1 99 95 
7 
 
 
30 1 80 n.d. 
8 70 3 98 97 
aConditions: c=1 mg mL–1 in EtOAc, 5% Pt/Al2O3, 50 bar, flow rate 1 mL min
–1. bNumber of circulations through the CF 
reactor. cDetermined by 1H NMR spectroscopic analysis of the crude material. dDeuterium content, which represents the 
deuterium incorporation ratio over incidental hydrogen addition. 
In terms of productivity and selectivity, the above-described CF methodology is highly 
competitive with the batch results from the literature.
181, 182
 Moreover, it means a sustainable 
alternative for the conventional approaches, as it is safe, simple, rapid and cost efficient, whilst 
it allows pharmaceutically relevant deuterated products without ponderous purification steps. 
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4.2. Copper-catalyzed azide–alkyne cycloadditions in CFV,VI 
4.2.1. CF method development 
As detailed in the Literature survey (section 2.2.2), there are already a number of CF approaches 
for CuAAC reactions.
12, 13, 96, 99, 102, 103
 However, most examples rely on either costly apparatus 
or special catalyst types, which limit their sustainable applications. Therefore, we recognized 
that there would be a huge demand for an easily available, inexpensive CF technique 
for CuAAC reactions which is at the same time efficient and safe. We envisioned that Cu 
powder can act as the simplest source for catalytically active Cu(I) species, as Cu undergoes 
constant oxidation when exposed to air, and non-self-protecting layers of different oxides, 
including Cu2O, are formed on its surface and, similarly to cases when heated Cu wiring is 
employed,
99-101
 this can promote CuAAC.
183
 In this context, Cu powder can be referred as a 
readily available ‘supported’ Cu(I) catalyst, and accordingly, when oxide layers are removed 
from the surface, the catalytic activity decreases appreciably.
12
 
For the CF reactions, 900 mg of Cu powder (with an average particle size of 200 µm) was 
charged into a catalyst cartridge with internal dimensions of 70×4 mm. The 1,3-dipolar 
cycloaddition between benzyl azide and phenylacetylene was chosen as a test reaction for an 
elaborate optimization study (Scheme 16). CH2Cl2 was selected as solvent, in which the azide 
was applied in a concentration of 0.085 M, this proving to be the highest possible concentration 
which prevented the precipitation of the resulting triazole and a blockage in the channels of the 
reactor. As small-scale test experiments, 2.5 mL aliquots of a reaction mixture containing 
1 equivalent of benzyl azide and 1.5 equivalents of phenylacetylene were pumped through the 
system in each run, and conversion was determined after each step. 
 
 
Scheme 16. 1,3-Dipolar cycloaddition between benzyl azide and phenylacetylene as a test reaction for 
optimization of the CF reaction conditions. 
As the starting point of the optimization study, the test reaction was carried out at 
atmospheric pressure, RT, and a flow rate of 0.5 mL min
–1
, resulting in a conversion of only 
20%. To improve the reaction rate of the CF CuAAC, we first employed high-pressure 
conditions, as elevated pressures can expectedly promote triazole formation in accordance with 
Le Chatelier’s principle. On investigation of the pressure dependence (at RT, and maintaining a 
flow rate of 0.5 mL min
–1
), it was found that a pressure of at least 80 bar should be employed to 
obtain any higher conversion (Figure 10). At 100 bar, a conversion of 34% was achieved, and 
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further elevation would probably have resulted in even higher conversions, but 100 bar was 
taken as an optimal value as further pressurizing could not be reached with the H-Cube
®
 
system.
47
 Elevation of the pressure allowed the use of temperatures well above the boiling point 
of CH2Cl2. Thus, as a next step, high-temperature conditions were examined. While the pressure 
and flow rate were maintained at 100 bar and 0.5 mL min
–1
, the temperature was increased 
gradually from RT to 100 °C. Figure 11 shows that the conversion started to increase steeply at 
40 °C; at 50 °C, it exceeded 90%, and finally at 100 °C quantitative conversion was achieved. 
Besides physical chemistry, heating is most likely to enhance the rates of the CuAAC reaction 
by increasing the solubility of Cu2O from the surface of the zerovalent Cu matrix. 
 
 
Figure 10. Pressure dependence of the test CF CuAAC reaction (Scheme 16). Conditions: RT, flow rate 0.5 
mL min
–1
, no additives. 
 
 
Figure 11. Temperature dependence of the test CF CuAAC reaction (Scheme 16). Conditions: 100 bar, flow rate 
0.5 mL min
–1
, no additives. 
Under the previously optimized reaction conditions (100 bar, 100 °C), the residence time on 
the catalyst bed was also fine-tuned. As quantitative conversion was obtained at 0.5 mL min
–1
, it 
was unnecessary to employ even lower flow rates; we rather then tried increasing the flow rate 
to achieve the shortest possible process time. However, it was found that the reaction is very 
sensitive to the reduction of the residence time, as the conversion decreased dramatically with 
enhancement of the flow rate (Figure 12). For example, at 1 mL min
–1
, the conversion was only 
31%. Thus, 0.5 mL min
–1
 was regarded as an optimal flow rate, which involved a residence 
time on the catalyst bed as low as 1.5 min, and a process time of only 5 min to pump the 2.5 mL 
aliquot of the reaction mixture through the reactor. 
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Figure 12. Fine-tuning of the flow rate in the test CF CuAAC reaction (Scheme 16). ▲: 100 bar, 100 °C, no 
additives. ♦: 100 bar, RT, 0.04 equivalents of DIEA + 0.04 equivalents of AcOH. 
At 100 bar, 100 °C and a flow rate of 0.5 mL min–1, quantitative conversion was obtained, 
and due to flow processing the risks that are associated with the handling of azides were 
successfully lowered as compared with conventional batch approaches,
2, 11
 but we envisioned 
that it would be highly beneficial to avoid harsh reaction conditions completely, with the CF 
CuAAC procedure at maximum operational safety. Accordingly, we next attempted to improve 
the rates of the test reaction in the presence of additives, without the use of high temperature. 
Amines, as basic additives, are known to boost the reactivity of the CuAAC considerably,
11
 in 
particular by coordinating to catalytically active Cu(I) species and promoting their liberation 
from the Cu matrix, thereby assisting the formation of a distinct Cu–alkyne complex (Scheme 
17).
82, 184, 185
 Additionally, it was recently shown that catalytic amounts of certain acids can 
further accelerate the formation of the triazole product through promotion of the conversion of 
C–Cu bond-containing intermediates by protonation.186-188 Furthermore, utilization of acidic 
additives is beneficial as it prevents the formation of unwanted byproducts, such as 
diacetylenes, bis-triazoles, etc.
185
 In contrast, byproduct formation is catalyzed by base. The 
joint application of a basic and an acidic additive is therefore highly advantageous: this buffer 
system improves reactivity in CuAAC, even at RT, but without the formation of byproducts.
185
 
 
 
Scheme 17. Catalytic cycle of the base–acid jointly promoted CuAAC reaction.
185
 
As basic and acidic additives, DIEA and AcOH were selected, relying on literature data.
185
 
To investigate the effects of additives, pressure and flow rate was set to 100 bar and 0.5 
mL min
–1
, respectively, and heating was avoided (i.e. RT was utilized). Under these conditions, 
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a conversion of 34% could be achieved without any additives (Table 3, entry 1). Addition of 0.1 
equivalent of AcOH improved the conversion to 56% (Table 3, entry 2), and when 0.1 
equivalent of DIEA was employed instead, the conversion rose further to 96% (Table 3, entry 
3). The best result was obtained with the joint use of DIEA and AcOH (each in 0.1 equivalent) 
as additives, allowing the test reaction to proceed quantitatively (Table 3, entry 4). The effects 
of the amounts of DIEA and AcOH were then scanned on the reaction efficiency. As shown in 
Table 3, 0.04 equivalents of each additive was sufficient to maintain quantitative conversion 
(entry 6), but reducing the equivalents further gave poorer results (entries 7 and 8). When the 
flow rate was increased from 0.5 mL min
–1
 at 100 bar and RT with the joint use of both 
additives (each in 0.04 equivalents), it was found that the drop in the conversion was not as 
steep as under the high-pressure/high-temperature conditions (Figure 12). This implies that the 
joint use of DIEA and AcOH relieves the harsh reaction conditions without heating in CF.  
 
Table 3. Effect of the DIEA/AcOH ratio on the CF reaction between benzyl azide and phenylacetylene with 
Cu powder (Scheme 16).
a
 
Entry 
DIEA 
(equivalent) 
AcOH 
(equivalent) 
Conv. (%)
a
 Entry 
DIEA 
(equivalent) 
AcOH 
(equivalent) 
Conv. (%)
a
 
1 0 0 34 5 0.08 0.08 quant. 
2 0 0.1 56 6 0.04 0.04 quant. 
3 0.1 0 96 7 0.02 0.02 63 
4 0.1 0.1 quant. 8 0.01 0.01 40 
aConditions: 1 equivalent of azide (cazide=0.085 M in CH2Cl2), 1.5 equivalents of alkyne, 100 bar, RT, flow rate 0.5 
mL min–1. bDetermined by 1H NMR analysis of the crude material. 
As a result of the method development, we determined two distinct parameter sets as optimal 
conditions: i) 100 bar, 100 °C, flow rate of 0.5 mL min–1, without any additives as conditions 
CF A, and ii) 100 bar, RT, flow rate of 0.5 mL min
–1
, with DIEA and AcOH (each in 0.04 
equivalents) as conditions CF B. Both of them afforded quantitative conversion in the test 
CuAAC reaction between benzyl azide and phenylacetylene, and selectively gave the 1,4-
disubstituted 1,2,3-triazole isomer (16) as the product. Moreover, the introduced CF 
methodologies are safe, simple, and rapid; while, due to the easily available Cu(I) source and 
cheap additives, they are cost-efficient, enabling sustainable production. 
4.2.2. Model reactions 
A wide array of model reactions were next carried out under both conditions CF A and B to 
obtain a clear comparison between the performances of the two approaches. At first, the azide 
scope was examined, employing phenylacetylene as dipolarophile. As can be seen in Table 4, 
excellent results were achieved with either aliphatic or aromatic azides. In the case of aromatic 
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azides, it was found that either electron-withdrawing (entries 2-7) or electron-donating 
substituents (entries 8-10) are nicely tolerated, and yields were not distorted significantly upon 
varying the position of the substituents on the phenyl ring. α-Azido ketones are known to be 
poor reaction partners in CuAAC reactions, but their 1,3-diploar cycloaddition to different 
alkynes results in a wide variety of pharmaceutically important compounds.
189
 To benchmark 
our CF methodologies, the reaction of 2-azidoacetophenone with phenylacetylene as 
dipolarophile was also attempted, and both conditions CF A and B afforded triazole 28 in 
outstanding yields (entry 13). 
Reactions of a series of alkynes with benzyl azide were also carried out to further broaden 
the applicability of the methodologies. It was found that, besides phenylacetylene, non-aromatic 
alkynes, such as pent-1-yne and ethyl propiolate, are nicely tolerated (Table 4, entries 16 and 
17). Diethyl acetylenedicarboxylate, as a non-terminal alkyne, was also successfully reacted, 
thereby resulting in 1,4,5-trisubstituted 1,2,3-triazole 33 in high yields (Table 4, entry 18), 
which is itself a potent antitubercular agent.
190
 Ferrocene–triazole conjugates are widely applied 
in medicinal chemistry for the labeling and detection of various systems, e.g. in immunoassays, 
as biosensing probes and in host–guest chemistry,191 and the incorporation of ferrocene into 
amino acids or peptides is an efficient tool for secondary structure determinations.
192
 Thus, the 
CuAAC reaction of benzyl azide with ethynyl ferrocene was also attempted, and the 
corresponding ferrocene–triazole conjugate (34) was obtained in excellent yields under both CF 
conditions (Table 4, entry 19). 
 
Table 4. Azide–alkyne cycloadditions with Cu powder under optimized conditions in CF. 
Entry 
Azide
a
 
(1 equivalent) 
Alkyne 
(1.5 equivalents) 
Product 
Yield (%)
b
 
CF A
c
 CF B
d
 
1 
  
 
99 99 
2 
  
 
98 99 
3 
  
 
99 99 
4 
   
99 99 
5 
  
 
93 99 
      
32 
 
Table 4. (Continued) 
Entry 
Azide
a
 
(1 equivalent) 
Alkyne 
(1.5 equivalents) 
Product 
Yield (%)
b
 
CF A
c
 CF B
d
 
6 
   
99 99 
7 
  
 
94 99 
8 
  
 
83 99 
9 
   
72 94 
10 
  
 
99 99 
11 
   
94 99 
12 
   
77 98 
13 
   
96 99 
14 
   
99 99 
15 
   
99 99 
16 
 
 
 
94 91 
17 
  
 
99 99 
18 
  
 
84 82 
19 
 
 
 
99 99 
acazide=0.085 M. 
bYield of isolated product. cConditions CF A: CH2Cl2 as solvent, 100 bar, 100 °C, flow rate 
0.5 mL min–1, without any additives. dConditions CF B: CH2Cl2 as solvent, 100 bar, RT, flow rate 0.5 
mL min–1, with 0.04 equivalents of DIEA + 0.04 equivalents of AcOH. 
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As can be seen in Table 4, though the application of conditions CF B (i.e. the use of 
additives at RT) resulted in slightly higher yields in some of the model reactions (entries 5, 7-9 
and 11-13), significant differences between the efficacies of the two approaches could not be 
recognized. In the cases of terminal alkynes, the corresponding 1,4-disubstituted 1,2,3-triazole 
isomers were formed regioselectively. No work-up or purification step was necessary when the 
conversion was quantitative and any excess alkyne could be volatilized on evaporation 
(phenylacetylene, pent-1-yne and ethyl propiolate). 
4.2.3. Synthesis of 1,2,3-triazole-modified alicyclic β-amino acid derivatives 
As a consequence of their pharmacological potential, alicyclic β-amino acids have captured 
great attention in the past twenty years.
193
 One of the most appealing representative of such 
compounds is cispentacin ((1R,2S)-ACPC, ACPC=2-aminocyclopentanecarboxylic acid), a 
naturally occurring antifungal antibiotic (Figure 13).
194
 Its synthetic 4-methylene derivative 
(icofungipen) also exhibits strong antifungal properties,
195
 and there are many bioactive 
compounds amongst highly functionalized cyclohexane-structured β-amino acid derivatives as 
well, such as oryzoxymycin and tilidine, both exhibiting antiviral properties (Figure 13).
196
 
Furthermore, alicyclic β-amino acids are important intermediates for synthetic chemistry,197 and 
they are widely employed as building blocks of foldamers and peptidic structures.
198
 
 
 
Figure 13. Bioactive alicyclic β-amino acids. 
The literature findings discussed in section 2.2.2 reveal that the 1,2,3-triazole moiety can be 
regarded as a pharmacophore, as it is frequently used for the modification of known bioactive 
products, such as certain cyclic amino acid derivatives (Figure 6).
93, 94
 In consequence of these 
properties, we aimed to employ the newly developed CF CuAAC procedures for the 1,2,3-
triazole modification of some alicyclic β-amino acid derivatives, and thereby the sustainable 
synthesis of a library of potentially bioactive compounds. 
To prepare 1,2,3-triazole-modified β-amino acids, azido-substituted cispentacin derivatives 
35 and 36 (as racemic compounds) were used initially as reaction partners of phenylacetylene 
and ethynyl ferrocene.
199
 Besides both CF conditions (A and B), the CuAAC reactions were 
carried out by employing conventional batch techniques as well to obtain a clear comparison. In 
the presence of CuI in MeCN under reflux for 12 h, batch reactions of 35 and 36 with 
phenylacetylene afforded the corresponding 1,2,3-triazole-substituted cispentacin derivatives 37 
34 
 
and 38 in only moderate yields (69% and 73%, respectively; Table 5, entries 1 and 2). 
Conditions CF A afforded triazoles 37 and 38 in yields comparable with those of the batch 
reactions (62% and 42%, respectively; Table 5, entries 1 and 2); but with method CF B, both 37 
and 38 could be isolated in an excellent yield of 99% (Table 5, entries 1 and 2). Conjugates of 
the azido-functionalized cispentacin derivatives 35 and 36 with ethynyl ferrocene were prepared 
in flow with outstanding results: both conditions CF A and B afforded ferrocenyl triazoles 39 
and 40 with yields as high as 99% (Table 5, entries 3 and 4). In contrast, in batch, in the 
presence of CuI under reflux in MeCN, no transformation could be detected at all; and upon 
changing the catalyst to CuSO4/ascorbic acid, the reaction furnished triazoles 39 and 40 in only 
moderate yields (51% and 69%, respectively; Table 5, entries 3 and 4) within 14 h. 
 
Table 5 Synthesis of 1,2,3-triazole-substituted cispentacin derivatives with CF CuAAC methods and with 
conventional batch procedures. 
Entry 
Azide
a
 
(1 equivalent) 
Alkyne 
(1.5 equivalents) 
Product 
Yield (%)
b
 
CF A
c
 CF B
d
 batch 
1 
 
 
 
62 99 69
e
 
2 
 
 
 
42 99 73
e
 
3 
 
 
 
99 99 51
f
 
3 
 
 
 
99 99 69
f
 
acazide=0.085 M, racemic compounds. 
bYield of isolated product. cConditions CF A: CH2Cl2 as solvent, 100 bar, 100 °C, 
flow rate 0.5 mL min–1, without any additives. dConditions CF B: CH2Cl2 as solvent, 100 bar, RT, flow rate 0.5 mL min
–1, 
with 0.04 equivalents of DIEA + 0.04 equivalents of AcOH. eTo a solution of azido ester 35 or 36 (1 equivalent) in 
MeCN, CuI (1 equivalent) and alkyne (1.1 equivalents) were added and the mixture was stirred under reflux for 12 h. fTo 
a solution of azido ester 35 or 36 (1 equivalent) in EtOH/H2O=12:1, CuSO4 (1 equivalent), ascorbic acid (1 equivalent) 
and alkyne (1.1 equivalents) were added and the mixture was stirred at RT for 14 h. 
Next, azido-substituted β-aminocyclohexanecarboxylates 41-44 were employed as reaction 
partners of three different alkynes (phenylacetylene, diethyl acetylenedicarboxylate and ethynyl 
ferrocene) to obtain 1,2,3-triazole-modified target compounds.
200
 (41-44 were used as racemic 
compounds.) In reactions with phenylacetylene, method CF A afforded triazoles 45-48 in only 
moderate yields (Table 6, entries 1-4). Under conditions CF B, 45 and 46 were isolated in 
excellent yields (96% and 97%, respectively; Table 6, entries 1 and 2), but triazoles 47 and 48 
could not be obtained with satisfactory results (yields were 76% and 89%, respectively; Table 6, 
 
35 
 
Table 6. CF synthesis of 1,2,3-triazole-modified β-aminocyclohexanecarboxylic acid derivatives. 
Entry 
Azide
a
 
(1 equivalent) 
Alkyne 
(1.5 equivalents) 
Product 
Yield (%)
b
 
CF A
c
 CF B
d
 
1 
 
 
 
61 96 
2 
   
47 97 
3 
 
 
 
33 
76 
(98)
e
 
4 
   
53 
89 
(98)
e
 
5 
 
 
 
98 97 
6 
 
 
 
97 98 
7 
 
 
 
97 96 
8 
 
 
 
97 98 
9 
  
 
95 97 
10 
   
91 98 
11 
  
 
96 93 
12 
  
 
75 97 
acazide=0.085 M, racemic compounds. 
bYield of isolated product. cConditions CF A: CH2Cl2 as solvent, 100 bar, 100 °C, 
flow rate 0.5 mL min–1, without any additives. dConditions CF B: CH2Cl2 as solvent, 100 bar, RT, flow rate 0.5 mL min
–1, 
with 0.04 equivalents of DIEA + 0.04 equivalents of AcOH. eAchieved under the following conditions: CH2Cl2 as solvent, 
100 bar, 100 °C, flow rate 0.5 mL min–1, with 0.04 equivalents of DIEA + 0.04 equivalents of AcOH. 
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entries 3 and 4). Thus, CF reactions of azides 43 and 44 with phenylacetylene were repeated 
under high-pressure/high-temperature conditions (100 °C, 100 bar) with the simultaneous use of 
DIEA and AcOH (each in 0.04 equivalents), resulting in triazoles 47 and 48 in yields of 98% 
eventually (Table 6, entries 3 and 4). Upon the application of diethyl acetylenedicarboxylate as 
dipolarophile, trisubstituted 1,2,3-triazole dicarboxylates (49-52) were obtained in yields of 
>96% under either of the CF conditions (Table 6, entries 5-8). CuAAC reactions with ethynyl 
ferrocene gave the corresponding ferrocene–triazole conjugates in excellent results under both 
CF conditions in the cases of 53-55 (Table 6, entries 9-11). Triazole 56 was obtained in a yield 
of 75% by method CF A, but CF B resulted in an excellent yield of 97% (Table 6, entry 12). 
It can be recognized that the yields of the triazole products formed with phenylacetylene 
were usually lower than in the reactions with diethyl acetylenedicarboxylate and ethynyl 
ferrocene, and the differences were significant only in the case of conditions CF A (see Table 5, 
entries 1 and 2 vs. entries 3 and 4; and Table 6, entries 1-4 vs. 5-12). To understand these 
findings, it must be considered that the carboxylate groups of diethyl acetylenedicarboxylate 
and the aromatic system of the ferrocenyl group can act as ligands and coordinate Cu(I) 
effectively from its matrix.
201
 Due to this substrate effect, the concentration of the catalytically 
active Cu(I) and therefore the reactivity is increased as compared with phenylacetylene. In the 
case of conditions CF B, the use of DIEA masks the effect of the alkynes. 
1,2,3-Triazole-modified β-amino acid derivatives obtained in reactions with terminal alkynes 
were selectively formed as 1,4-disubstituted regioisomers. It should be emphasized that 
epimerization of the triazole products was not detected in the NMR spectra of the crude 
materials, even under basic conditions, which is due the very short residence time (1.5 min). 
Some leaching of copper from the catalyst bed was expected, and thus the trace amounts of 
copper were determined in the triazole products obtained with both CF methodologies. The 
analytical data in Table 7 show that the copper contents in the samples obtained under high-
pressure/high-temperature conditions without any additives (CF A) were lower than those when 
DIEA and AcOH were jointly applied (CF B). After column chromatographic purification, the 
copper impurities were reduced significantly (entries 1 and 2 vs. 3-16). Copper contents 
detected in our systems were nicely comparable with the literature CF or batch results.
12, 202
 
4.2.4. Scale-up studies 
As pointed out in the Literature survey (section 2.1), scale-up in CF processing is 
straightforward, as volume is a function of time and of flow rate rather than the batch size.
3
 
Thus, gram-scale syntheses could be performed in a simple, safe and efficient manner. 
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Table 7. Contents of copper impurities in the 1,2,3-triazole products obtained in CF. 
Entry Product 
Copper content  
(µg g–1)a Entry Product 
Copper content  
(µg g–1)a 
CF A
b
 CF B
c
 CF A
b
 CF B
c
 
1 37 14.8(±0.8)
d
 70.1(±1.4)d 9 49 5.2(±0.4)
e
 7.9(±0.4)
e
 
2 38 12.1(±0.7)
d
 66.2(±1.5)d 10 50 5.1(±0.3)
e
 7.5(±0.6
 )e
 
3 39 4.4(±0.3)
e
 7.1(±0.6)e 11 51 4.8(±0.6)
e
 7.7(±0.7)
e
 
4 40 5.2(±0.5)
e
 7.3(±0.7)e 12 52 5.3(±0.3)
e
 8.2(±0.6)
e
 
5 45 4.6(±0.5)
e
 8.4(±0.6)e 13 53 6.1(±0.5)
e
 8.6(±0.5)
e
 
6 46 4.2(±0.3)
e
 7.7(±0.6)
e
 14 54 4.8(±0.4)
e
 7.7(±0.8)
e
 
7 47 3.9(±0.5)
e
 8.0(±0.4)
e
 15 55 5.4(±0.3)
e
 9.1(±0.4)
e
 
8 48 4.7(±0.6)
e
 8.2(±0.7)
e
 16 56 4.9(±0.6)
e
 7.8(±0.7)
e
 
aDetermined by ICP-MS. bConditions CF A: CH2Cl2 as solvent, 100 bar, 100 °C, flow rate 0.5 mL min
–1, without any 
additives. cConditions CF B: CH2Cl2 as solvent, 100 bar, RT, flow rate 0.5 mL min
–1, with 0.04 equivalents of DIEA + 
0.04 equivalents of AcOH. dWithout column chromatographic purification. eAfter column chromatographic purification. 
For the scale-up studies, a reaction mixture containing 1 equivalent of the azide 
(cazide=0.085 M) and 1.5 equivalents of the alkyne (and 0.04 equivalents of both additives in the 
case of conditions CF B) in CH2Cl2 was continuously pumped through the system under either 
conditions CF A or B. During a discrete experiment, the same portion of Cu powder was 
employed in the catalyst cartridge. First, the CuAAC between benzyl azide and phenylacetylene 
was scaled up (Scheme 16), utilizing both conditions CF A and B. In each case, 75 mL of the 
reaction mixture was pumped through in 150 min. After both experiments, 1.5 g of triazole 16 
could be isolated respectively (3 g altogether, which is equivalent to a yield of 99%), without 
the need for any further work-up but evaporation. Gram-scale synthesis of triazole 52 was then 
performed under conditions CF B. 50 mL of the reaction mixture containing azide 44 and 
diethyl acetylenedicarboxylate was pumped through the CF reactor in 100 min. After 
purification, 2.06 g of triazole 52 was obtained, which is equivalent to a yield of 96%. 
4.3. CF organocatalysis with solid-supported peptidic catalysts
II-IV 
Organocatalytic aldol reactions and conjugate additions between aldehydes and nitroalkenes are 
among the most powerful ways for the formation of asymmetric C–C bonds.8 The resulting 
chiral β-hydroxy carbonyl compounds and γ-nitroaldehydes are valuable intermediates for 
various syntheses in pharmaceutical chemistry.
203, 204
 Thus, we developed the first CF 
organocatalytic technique for the stereoselective 1,4-addition of aldehydes to nitroolefins, and 
then extended the scope of the methodology for asymmetric aldol reactions. 
As chiral organocatalysts, N-terminal prolyl-peptides bearing an acidic side-chain at the C-
terminus were applied immobilized onto swellable polymer supports. Employing a peptide was 
highly beneficial, as such modular organocatalysts offered higher structural diversity than small 
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proline-like counterparts.
10
 Moreover, the synthesis and immobilization of the catalyst could 
easily be combined in SPPS without the need for further synthetic steps. With the use of non-
TFA-labile resins as support for the peptide synthesis, the deprotection of the carboxyl side-
chain could be fulfilled without cleavage of the peptide after the coupling steps. This provided a 
highly sustainable methodology, as the heterogeneous support of the SPPS served also as 
catalyst carrier. The experimental setup was simple, time- and cost-efficient, as it eliminated the 
need for the peptide work-up and purification steps, and there was no product loss. 
4.3.1. CF organocatalytic conjugate additions 
4.3.1.1. CF method development 
For optimization of the CF reaction conditions, the 1,4-addition of propanal to E-β-nitrostyrene 
(BNS) was chosen as test reaction (Scheme 18). Initially, the peptide H-D-Pro-Pro-Asp-NH-
resin was employed, immobilized on PS-MBHA resin with a loading of 0.64 mmol g
–1
 (catalyst 
58).
131
 For the CF reactions, 150 mg of the heterogeneous catalyst was incorporated into a 
stainless steel cartridge with internal dimensions of 70×4 mm. To provide accessibility of the 
immobilized catalyst molecules, the matrix of the supporting polymer should be swollen. Thus, 
CHCl3/iPrOH=9:1 was chosen as an optimal solvent system. This medium ensured appropriate 
swelling properties for the immobilized catalyst and, at the same time, sufficient solubility of 
the reactants.
164
 In each run, 5 mL aliquots of a reaction mixture were pumped through the CF 
reactor, and the most important reaction parameters were systematically fine-tuned. 
 
 
Scheme 18. Organocatalytic asymmetric 1,4-addition of propanal to BNS as a CF test reaction. 
At a flow rate of 0.5 mL min
–1
, a rapid screen indicated that a BNS concentration of 8 mg 
mL
–1
 was favorable at RT and atmospheric pressure, while propanal was applied in 15 
equivalents as an initial high excess (Table 8). Utilization of a very high excess of the aldehyde 
may help the reaction to reach completion, but also makes the procedure less economical. With 
this in mind, 5 equivalents of propanal was chosen as optimal value. 
 
Table 8. Fine-tuning of the BNS concentration in the test reaction (Scheme 18) in CF.
a
 
Entry cBNS (mg mL
–1
) Yield (%)
b
 Entry cBNS (mg mL
–1
) Yield (%)
b
 
1 1 0 3 8 54 
2 4 35 4 16 45 
aConditions: 1 equivalent of BNS and 15 equivalents of propanal in CHCl3/iPrOH=9:1, 1 bar, RT, flow 
rate 0.5 mL min–1, catalyst 58. bYield of isolated product. 
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Next, the flow rate was fine-tuned at 60 bar and RT to obtain an optimized residence time on 
the catalyst bed. At 0.01 mL min
–1
, a yield of 99% was achieved, but a very long residence time 
made the process unfeasible. Upon enhancement of the flow rate, the yield decreased almost 
linearly (Figure 14a). For example, at 0.5 mL min
–1
, a yield of only 50% could be achieved. As 
a compromise between throughput and process time, 0.1 mL min
–1
 was set as the optimal flow 
rate, which involved a residence time on the catalyst bed as low as 7 min, and a process time of 
50 min to pump the 5 mL aliquot of the reaction mixture through the system. Particularly  
 
 
Figure 14. Optimization of the flow rate in the test CF reaction (Scheme 18). Conditions: 1 equivalent of BNS 
(c=8 mg mL
–1
) and 5 equivalents of propanal in CHCl3/iPrOH=9:1, 60 bar, RT, catalyst 58. The 
enantioselectivity was not dependent on the flow rate: ee was found to be 92–93% in all cases. 
important is that the adjustment of the flow rate influenced not only the productivity, but also 
the diastereoselectivity. It was found that, the higher the flow rate, the better the dr (Figure 
14b). For example, at 0.1 mL min
–1
, 57 could be obtained with a syn:anti ratio of 11:1, but at 
0.01 mL min
–1
 dr dropped to 8:1. We hypothesized that the N-terminal secondary amine residue 
of the peptidic catalyst may catalyze enolization of the γ-nitroaldehyde, and thus the catalyst 
itself is responsible for the configurational instability of the product.
205
 To understand the 
observed decrease in diastereoselectivity, the isolated γ-nitroaldehyde 57 (8 mg mL–1 solution in 
CHCl3/iPrOH=9:1) was recirculated through the bed of catalyst 58 under the following 
conditions: flow rate of 0.1 mL min
–1
, 60 bar, RT. It was found that the syn:anti ratio decreased 
from 11:1 to 4:1 (Scheme 19). However, when the recirculation of 57 was carried out after the 
acetylation of the secondary amine of the D-Pro residue of catalyst 58, no epimerization was 
detected. This verifies that the decrease in dr is induced by the catalyst and consequently, the 
shorter the residence time, the higher the diastereoselectivity. The enantioselectivity was not 
dependent on the flow rate; ee was 92–93% in all cases. 
 
 
Scheme 19. The N-terminal secondary amine of the peptidic catalyst epimerizes the γ-nitroaldehyde product. 
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The pressure dependence of the CF reaction was then investigated at RT and a flow rate of 
0.1 mL min
–1
. It was observed that enhancement of the pressure from atmospheric to 60 bar 
improved the reaction rate, but further elevation proved not to be beneficial (Figure 15a). The 
diastereoselectivity showed a slight dependence on the pressure. For example, at 1 bar a syn:anti 
ratio of 9:1 was detected, but increasing the pressure to an optimal 60 bar resulted in a dr of 
11:1 (Figure 15b). The enantioselectivity did not change upon pressurizing; ee was constant at 
around 92–93% in all cases. To improve productivity further, we tried elevating the temperature 
(at 60 bar and a flow rate of 0.1 mL min
–1
). It was found that heating gave rise to higher yields 
(Figure 16a), but also dramatically reduced the diastereo- and enantioselectivity (Figure 16b). 
For example, at 90 °C a yield of 99% was achieved, but the syn:anti ratio was only 1.5:1 and ee 
was only 77%. Consequently, RT was regarded as optimal temperature. 
 
 
Figure 15. Pressure dependence of the test CF reaction (Scheme 18). Conditions: 1 equivalent of BNS 
(c=8 mg mL
–1
) and 5 equivalents of propanal in CHCl3/iPrOH=9:1, RT, flow rate 0.1 mL min
–1
, catalyst 58. The 
enantioselectivity was not dependent on the pressure: ee was found to be 92–93% in all cases. 
 
 
Figure 16. Temperature dependence of the test CF reaction (Scheme 18). Conditions: 1 equivalent of BNS 
(c=8 mg mL
–1
) and 5 equivalents of propanal in CHCl3/iPrOH=9:1, 60 bar, flow rate 0.1 mL min
–1
, catalyst 58. 
On the right side, ee values are presented in red. 
The supported peptidic catalyst was obtained in a TFA salt form after the SPPS, and the 
effect of a basic additive was next examined to promote the liberation of the N-terminal 
secondary amine and maybe facilitate catalysis.
129
 On the basis of literature data, N-
methylmorpholine (NMM) was chosen as base,
131
 and the effects of different amounts of NMM 
were then investigated under the previously optimized CF reaction conditions. It emerged that 
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the diastereoselectivity decreased dramatically upon addition of the base, whereas the yield and 
enantioselectivity remained intact (Table 9). These results suggested that NMM causes 
epimerization of the γ-nitroaldehyde product, and thus it proved best to avoid basic additives 
and leave the peptide in the TFA salt form. 
 
Table 9. Investigation of the effect of NMM as an additive on the 1,4-addition of propanal to BNS (Scheme 
18) under the previously optimized CF reaction parameters.
a
 
Entry 
NMM 
(equivalent) 
Yield 
(%)
b
 
syn:anti
c
 
eesyn 
(%)
d
 
Entry 
NMM 
(equivalent) 
Yield 
(%)
b
 
syn:anti
c
 
eesyn 
(%)
d
 
1 0 91 11:1 93 3 0.02 90 7:1 91 
2 0.01 92 9:1 92 4 0.04 91 6:1 92 
aConditions: 1 equivalent (c=8 mg mL–1) and 5 equivalents of propanal in CHCl3/iPrOH=9:1, 60 bar, RT, flow rate 0.1 
mL min–1, catalyst 58. bYield of isolated product. cDetermined by 1H NMR analysis of the crude material. dDetermined by 
chiral-phase HPLC analysis. 
As a final step of the optimization study, the peptidic catalyst was also fine-tuned. First, the 
effect of the exchange of the C-terminal amino acid from aspartic acid to the homologous 
glutamic acid (bearing an additional methylene group on the acidic side-chain) was 
examined.
132
 H-D-Pro-Pro-Glu-NH-resin was synthetized on PS-MBHA with a loading of 0.64 
mmol g
–1
 (59). In the 1,4-addition of propanal to BNS under the previously optimized reaction 
conditions, catalyst 59 furnished comparable diastereo- and enantioselectivities to 58, but lower 
yield (Table 10, entries 1 and 2). Next, the influence of the resin loading was investigated. Thus, 
H-D-Pro-Pro-Asp-NH-resin and H-D-Pro-Pro-Glu-NH-resin were immobilized on PS-MBHA 
with a loading of 0.32 mmol g
–1
 (catalysts 60 and 61). The lower loadings resulted in lower 
yields, but ee and dr were not affected (Table 10, entries 3 and 4). TentaGel resin with a loading 
of 0.29 mmol g
–1
 was also tested as solid support for the former peptide sequences (catalysts 62 
and 63). Despite the poorer swelling properties of TentaGel in CHCl3,
164
 the results were 
comparable with the cases when catalysts 60 and 61 were employed (Table 10, entries 5 and 6). 
We next explored the effects of the peptide conformation-directing role of the bioinspired 
substitution of the central proline unit with β-amino acids.206 Thus, novel tripeptide catalysts 
containing various ACPC isomers were synthetized on PS-MBHA resin (with a loading of 0.64 
mmol g
–1
). Only the application of (1R,2R)-ACPC (64) gave comparable results with the 
catalysts containing the central proline unit (Table 10, entry 7). Insertion of (1S,2S)- (65), 
(1S,2R)- (66) or (1R,2S)-ACPC(=cispentacin) (67) into the sequence gave notably lower yields, 
but in some cases, higher dr (Table 10, entries 8 and 10). These results suggest that exchange of 
the central proline residue distorts the peptide conformation significantly in the cases of 
catalysts 65, 66 and 67. In the case of (1R,2R)-ACPC (catalyst 64), however, the peptide 
conformation remains similar to that of the parent catalyst, which allows efficient catalysis. The 
structures of the utilized catalysts are shown in Figure 17. 
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Table 10. Fine-tuning of the immobilized peptidic catalyst in the 1,4-addition of propanal to BNS (Scheme 
18) under the previously optimized reaction conditions in CF.
a
 
Entry Peptide sequence Resin 
Loading 
(mmol g–1)b 
# 
Yield 
(%)
c
 
syn: 
anti
c
 
eesyn 
(%)
d
 
1 H-D-Pro-Pro-Asp-NH-resin PS-MBHA 0.64 58 91 11:1 93 
2 H-D-Pro-Pro-Glu-NH-resin PS-MBHA 0.64 59 79 12:1 91 
3 H-D-Pro-Pro-Asp-NH-resin PS-MBHA 0.32 60 78 11:1 92 
4 H-D-Pro-Pro-Glu-NH-resin PS-MBHA 0.32 61 69 11:1 91 
5 H-D-Pro-Pro-Asp-NH-resin TentaGel 0.29 62 81 11:1 92 
6 H-D-Pro-Pro-Glu-NH-resin TentaGel 0.29 63 73 12:1 91 
7 H-D-Pro-(1R,2R)-ACPC-Asp-NH-resin PS-MBHA 0.64 64 83 10:1 90 
8 H-D-Pro-(1S,2S)-ACPC-Asp-NH-resin PS-MBHA 0.64 65 41 15:1 93 
9 H-D-Pro-(1S,2R)-ACPC-Asp-NH-resin PS-MBHA 0.64 66 70 9:1 70 
10 H-D-Pro-(1R,2S)-ACPC-Asp-NH-resin PS-MBHA 0.64 67 35 19:1 89 
aConditions: 1 equivalent (c=8 mg mL–1) of BNS and 5 equivalents of propanal in CHCl3/iPrOH=9:1, 60 bar, RT, flow 
rate 0.1 mL min–1. bLoading of the resin. cYield of isolated product. cDetermined by 1H NMR analysis of the crude 
material. dDetermined by chiral-phase HPLC analysis. 
Thus, the best results were given with catalyst 58. Under the overall optimized reaction 
conditions (cBNS=8 mg mL
–1
, 5 equivalents of propanal, flow rate 0.1 mL min
–1
, 60 bar, RT), γ-
nitroaldehyde 57 was obtained in a yield of 91%, with a syn:anti ratio of 11:1, and an ee of 
93%. These results compare well with those of the literature batch procedure utilizing the same 
catalyst in the homogeneous phase.
131
 However, the batch reaction required a reaction time of 
24 h, whereas the flow process proved much more rapid with a short residence time on the 
catalyst bed, and the ease of product isolation further enhanced sustainability of the CF method. 
 
 
Figure 17. Structures of the immobilized peptidic catalysts. H-D-Pro-Pro-Asp-NH-resin (a), H-D-Pro-Pro-Glu-
NH-resin (b), H-D-Pro-(1R,2R)-ACPC-Asp-NH-resin (c), H-D-Pro-(1S,2S)-ACPC-Asp-NH-resin (d), H-D-Pro-
(1S,2R)-ACPC-Asp-NH-resin (e), H-D-Pro-(1R,2S)-ACPC-Asp-NH-resin (f). 
4.3.1.2. Testing of the catalyst reusability 
Catalyst reusability was investigated by repetition of the test reaction between BNS and 
propanal under the previously optimized reaction conditions, the same portion of catalyst 58 
being recycled. In each run, a 5 mL aliquot of the reaction mixture was pumped through the 
system in 50 min. It was found that the yield decreased slowly through the consecutive reaction 
cycles, but ee remained constant around at 93% (Table 11). Interestingly, a slight increase in the 
43 
 
diastereoselectivity could be observed. The decrease in the yield and the enhancement of dr 
may equally be explained in terms of some kind of irreversible blocking of the N-terminal 
secondary amine of the catalyst. The turnover number (TON) of the immobilized catalyst in the 
CF process was 46, which could be calculated from the data in Table 11. 
 
Table 11. Investigation of the reusability of catalyst 58 in the 1,4-addition of propanal to BNS (Scheme 18) 
under the previously optimized CF reaction conditions.
a, b
 
Cycle Yield (%)
c
 syn:anti
d
 eesyn (%)
e
 Cycle Yield (%)
c
 syn:anti
d
 eesyn (%)
e
 
1. 91 11:1 93 6. 76 15:1 93 
2. 86 12:1 93 7. 74 15:1 93 
3. 84 12:1 94 8. 72 16:1 93 
4. 83 12:1 93 9. 67 15:1 94 
5. 82 13:1 93 10. 66 15:1 94 
aIn each run, 5 mL of the reaction mixture was pumped through the system in 50 min. bConditions: 1 equivalent (c=8 
mg mL–1) of BNS and 5 equivalents of propanal in CHCl3/iPrOH=9:1, 60 bar, RT, flow rate 0.1 mL min
–1.cYield of 
isolated product. dDetermined by 1H NMR analysis of the crude material. eDetermined by chiral-phase HPLC analysis. 
4.3.1.3. Investigation of the scope and applicability of the CF method 
A number of conjugate additions between various aldehydes and BNS were studied under the 
previously optimized reaction conditions with catalyst 58 to explore the applicability of the CF 
process. As can be seen in Table 12 (entries 1-5), excellent results were obtained with linear 
aldehydes, affording the corresponding γ-nitroaldehyde products in good yields (60–91%), high 
diastereoselectivites (up to a dr of 36:1) and excellent enantioselectivities (up to an ee of 93%). 
A branched aldehyde bearing a substituent in the β-position was also tested as Michael donor, 
but a significantly lower yield resulted (entry 6). In the case of α-branched aldehydes, no 
conversion was observed due to steric hindrance of the formyl group. 
 
Table 12. Investigation of the scope and applicability of the optimized CF organocatalytic procedure.
a
 
 
Entry R Yield (%)
b
 syn:anti
c
 eesyn (%)
d
 
1 Me 91 11:1 93 
2 Et 60 22:1 91 
3 nPr 68 15:1 91 
4 nBu 87 14:1 91 
5 Bn 65 36:1 92 
6 iPr 22 20:1 91 
aA 5 mL aliquot of the reaction mixture was pumped through in 50 min. bYield of isolated product. cDetermined 
by 1H NMR analysis of the crude material. dDetermined by chiral-phase HPLC analysis. 
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4.3.2. CF organocatalytic aldol reactions 
4.3.2.1. CF method development 
To extend the scope of the CF organocatalytic procedure to asymmetric aldol reactions, 
reoptimization of the reaction conditions was necessary. The aldol addition between p-
nitrobenzaldehyde (pNBA) and acetone resulting in β-hydroxyketone 68 was set out as a test 
reaction (Scheme 20). Acetone was employed not only as reactant, but also as solvent. 0.1 
equivalent of imidazole was used as a base to prevent the formation of any elimination side-
product. According to the literature, the most effective peptidic catalyst for aldol reactions is H-
Pro-Pro-Asp-NH2.
130
 We therefore chose this catalyst sequence for an initial optimization study. 
H-Pro-Pro-Asp-NH-resin was synthetized on TentaGel (with a loading of 0.27 mmol g
–1
, 
catalyst 69), as it swells better in polar solvents than PS-MBHA.
164
 For the CF experiments, 300 
mg of the solid-supported peptide was filled into a catalyst cartridge with internal dimensions of 
70×4 mm. In each run, 5 mL of the reaction mixture was pumped through the system in 50 min. 
 
 
Scheme 20. Organocatalytic asymmetric aldol reaction between pNBA and acetone as a CF test reaction. 
The aldehyde concentration was rapidly fine-tuned at a flow rate of 0.5 mL min
–1
, RT and 
atmospheric pressure. It was found that the lower the aldehyde concentration, the higher the 
conversion (Table 13), and 4 mg mL
–1
 was assigned as the optimal value. Under these 
conditions, a conversion of 71% could be achieved, but it was observed that increasing the 
pressure improves the reaction rates further. Similarly to the earlier results with CF conjugate 
additions, it was found that pressurizing improved conversions up to an optimal 60 bar, but 
further elevation to 100 bar was not beneficial, as the conversion remained steady at around 
80% (Figure 18). It was noted that ee was not dependent on pressurizing: it was 79–81% in all 
cases. On investigation of the temperature dependence (at a flow rate of 0.5 mL min
–1
 and 60 
bar), it emerged that heating enhanced the reaction rates, but also dramatically decreased the  
 
Table 13. Fine-tuning of the pNBA concentration in the test reaction (Scheme 20) in CF.
a
 
Entry cpNBA (mg mL
–1
) Conversion (%)
b
 Entry cpNBA (mg mL
–1
) Conversion (%)
b
 
1 0.25 83 5 4 71 
2 0.5 81 6 8 67 
3 1 77 7 16 61 
4 2 73    
aConditions: 1 equivalent of pNBA and 0.1 equivalent of imidazole in acetone, 1 bar, RT, flow rate 0.5 mL min–1, 
catalyst 69. bDetermined by 1H NMR spectroscopic analysis of the crude material. 
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enantioselectivity. For example, at 80 °C, nearly quantitative conversion was achieved, but ee 
dropped to 50% (Figure 19). Thus, RT was assigned as optimal temperature. To improve 
conversion at RT and 60 bar, the residence time on the catalyst bed was extended. Thus, the 
flow rate was decreased systematically from 0.5 mL min
–1
. 0.1 mL min
–1
 was found optimal, 
resulting in quantitative conversion within a residence time on the catalyst bed as low as 6 min 
(Figure 20). It is worth mentioning that, even at a flow rate of 1 mL min
–1
, the conversion was 
still nearly 60%. The enantioselectivity did not change in the investigation of the flow rate 
dependence: ee was 79–81% in all cases. 
 
 
Figure 18. Pressure dependence of the test aldol reaction (Scheme 20) in CF. Conditions: 1 equivalent of pNBA 
and 0.1 equivalent of imidazole in acetone, RT, flow rate 0.5 mL min
–1
, catalyst 69. The enantioselectivity was 
not dependent on the pressure: ee was found to be 79–81% in all cases. 
 
 
Figure 19. Temperature dependence of the test aldol reaction (Scheme 20) in CF. Conditions: 1 equivalent of 
pNBA and 0.1 equivalent of imidazole in acetone, 60 bar, flow rate 0.5 mL min
–1
, catalyst 69. 
 
 
Figure 20. Fine-tuning of the flow rate in the test aldol reaction (Scheme 20) in CF. Conditions: 1 equivalent of 
pNBA and 0.1 equivalent of imidazole in acetone, 60 bar, RT, catalyst 69. The enantioselectivity was not 
dependent on the flow rate: ee was found to be 79–81% in all cases. 
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As a solid support for the H-Pro-Pro-Asp-NH-resin peptide sequence, PS-MBHA with a 
loading of 0.64 mmol g
–1
 (catalyst 70) was also tested under the previously optimized reaction 
conditions. However, due to its poorer swelling properties in acetone, lower conversion and ee 
were obtained than with catalyst 69 (Table 14, entries 1 and 3). We were interested in the 
activities of the conjugate addition catalysts 62 and 58 in aldol reactions too. It was found that 
neither of the D-proline N-terminal catalysts gave comparable results to 69 or 70. The 
conversion and ee were dramatically decreased, and it must be noted that the absolute 
configuration of the β-hydroxyketone product 68 inverted to R (Table 14, entries 4 and 5). 
 
 
Table 14. Fine-tuning of the immobilized peptidic catalyst in the aldol reaction between pNBA and acetone 
(Scheme 20) under the previously optimized reaction conditions in CF.
a
 
Entry Peptide sequence Resin 
Loading 
(mmol g–1)b 
# 
Conv. 
(%)
c
 
Yield 
(%)
d
 
ee (%)
e
 
1 H-Pro-Pro-Asp-NH-resin TentaGel 0.27 69 quant. >99 80 
2
f
 H-Pro-Pro-Asp-NH-resin TentaGel 0.27 69 90 89 85 
3 H-Pro-Pro-Asp-NH-resin PS-MBHA 0.64 70 71 68 62 
4 H-D-Pro-Pro-Asp-NH-resin TentaGel 0.27 62 29 27 –26g 
5 H-D-Pro-Pro-Asp-NH-resin PS-MBHA 0.64 58 19 16 –18g 
aConditions: 1 equivalent of pNBA and 0.1 equivalent of imidazole in acetone, 60 bar, RT, flow rate 0.1 mL min–1 
bLoading of the resin. cDetermined by 1H NMR analysis of the crude material. dYield of isolated product. eDetermined by 
chiral-phase HPLC analysis. fCarried out at 4 °C. gThe absolute configuration of the β-hydroxyketone inverted to R. 
Under the overall optimized reaction conditions (cpNBA=4 mg mL
–1
, flow rate 0.1 mL min
–1
, 
60 bar, RT) with catalyst 69, the test aldol reaction afforded β-hydroxyketone 68 in a yield of 
>99% with an ee of 80% (Table 14, entry 1). No work-up or purification step was necessary: 68 
could be isolated in a pure form after evaporation. When the reaction was carried out at 4 °C 
instead of RT, ee increased to 85%, whereas the yield remained at around 90% (Table 14, entry 
2). It should be noted that, under the optimal reaction conditions, no self-aldol or H2O-
eliminated side-product was detected. These results are nicely comparable with those of the 
literature batch procedure. However, when the same solid-supported catalyst was employed for 
the same aldol reaction in a simple flask, a reaction time of 6 h was needed for completion,
207
 
whereas the flow process relies on short residence times on the catalyst bed, and thus, 
prominently short process times. 
4.3.2.2. Testing of the catalyst reusability 
Reusability of catalyst 69 was evaluated through the repetition of the aldol reaction between 
pNBA and acetone under the previously optimized reaction conditions. In each cycle, a 5 mL 
aliquot of the reaction mixture was pumped through the reactor in 50 min, and the same portion 
of catalyst was reused for the whole study. No decrease in activity or selectivity was observed 
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after 20 consecutive runs. The conversion was still quantitative and ee was at around 80%, just 
as in the first run (Table 15). This mean that, after nearly 17 h of persistent use in flow, the 
immobilized catalyst was still as active as initially. The described CF methodology is therefore 
extremely robust. To determine the TON of the immobilized catalyst for the flow procedure, the 
experiment was run further after the 20
th
 cycle. The solution of the starting materials was 
continuously pumped through the catalyst bed, but after 80 h of continuous use the immobilized 
catalyst was still not totally deactivated. TON was calculated to be 710, which is an 
extraordinarily high value. 
 
Table 15. Testing of the reusability of catalyst 69 in the aldol reaction between pNBA and acetone (Scheme 
20) under the previously optimized CF reaction conditions.
a, b
 
Cycle Conv. (%)
c
 Yield (%)
d
 ee (%)
e
 Cycle Conv. (%)
c
 Yield (%)
d
 ee (%)
e
 
1–5 98–quant. 97–>99 79–80 11–15 quant. >99 79–80 
6–10 quant. 97–>99 78–81 16–20 99–quant. 98–>99 79–80 
aIn each run, 5 mL of the reaction mixture was pumped through the system in 50 min. bConditions: 1 equivalent of pNBA 
and 0.1 equivalent of imidazole in acetone, 60 bar, RT, flow rate 0.1 mL min–1. cDetermined by 1H NMR analysis of the 
crude material. dYield of isolated product. eDetermined by chiral-phase HPLC analysis. 
Due to the extremely reusable peptidic catalyst, the straightforward technique of catalyst 
synthesis/immobilization, the ease of product isolation and the short process times, the CF 
approach emerged as highly sustainable methodology. 
4.3.2.3. Investigation of the scope and applicability of the CF method 
To extend the applicability of the described procedure, a wide array of aromatic aldehydes were 
tested in aldol reactions with acetone under the previously optimized conditions with catalyst 
69. As can be seen in Table 16, aldehydes with an electron-withdrawing group on the aromatic 
ring performed as excellent reaction partners. The corresponding β-hydroxyketone products 
were obtained in excellent yields (68–>99%) and high enantioselectivities (up to an ee of 80%, 
entries 1-8). It was observed that the reactivity increased with the electron-withdrawing 
capability of the substituting residue and it was also dependent on the position of the electron-
withdrawing group. In the event of quantitative conversion, no work-up or purification was 
necessary after evaporation. Lower yields (27–59%), but still good enantioselectivities (up to an 
ee of 76%), were obtained with aldehydes bearing an electron-donating substituent on the 
aromatic ring or no substituent at all (entries 9-12). Productivities were determined as a 
benchmark of the flow reactions, and the results compared well with CF references from the 
literature.
146, 147
 Self-aldol product formation was not observed in the above experiments; but, in 
some cases, H2O elimination occurred from the corresponding β-hydroxyketone. 
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Table 16. Investigation of the scope and applicability of the optimized CF organocatalytic procedure.
a
 
 
Entry Ar Productivity
b
 Conv. (%)
c
 Yield (%)
d
 ee (%)
e
 
1 p-NO2C6H4 1.96 quant. >99 80 
2 o-NO2C6H4 1.96 quant. >99 79 
3 p-NCC6H4 2.26 quant. >99 74 
4 o-ClC6H4 2.11 quant. >99 79 
5 m-ClC6H4 1.50 78 71 (5)
f
 76 
6 p-ClC6H4 1.48 80 70 (7)
f
 78 
7 p-BrC6H4 1.09 76 68 (6)
f
 80 
8 p-FC6H4 2.05 quant. 86 (13)
f
 79 
9 o-MeOC6H4 0.81 39 37 76 
10 C6H5 1.65 76 59 (13)
f
 70 
11 2-naphthyl 0.57 37 30 (5)
f
 75 
12 1-naphthyl 0.51 35 27 (4)
f
 71 
aA 5 mL aliquot of the reaction mixture was pumped through the reactor in 50 min. bIn mmol of pure isolated product 
(mmolresin
–1 h–1). cDetermined by 1H NMR analysis of the crude material. dYield of isolated product. eDetermined by 
chiral-phase HPLC analysis. f Yield of the corresponding dehydration product. 
4.3.3. Exploring the role of pressure in the CF reactions 
It was observed through the CF method development that pressurizing improved the rates of 
both organocatalytic reactions (Figures 15 and 18). The question can arise whether the 
conversion is dependent on the catalyst activity itself (kinetic regime) or is limited by the 
transport phenomena of the reactants in the matrix of the catalyst carrier (diffusion regime). In 
the case of the kinetic regime, the rate of the catalytic reaction is proportional to the catalyst 
loading in the packed bed. To probe the diffusion dependence, the Koros–Nowak test was 
performed.
208, 209
 Thus, the loading in the catalyst bed was halved, and the test reactions 
(Schemes 18 and 20) were repeated. It was found for both CF organocatalytic systems that the 
decrease in conversion (and in yield) was not proportional to the loading decrease. For 1,4-
addition, see Table 10, entries 1 vs. 3. For aldol reaction, the diagnostic test was performed 
under the following conditions: 60 bar, RT, flow rate of 0.5 mL min
–1
 with catalyst 69, and the 
conversion decreased from 81 to 52%. This means that, under the present conditions, the CF 
reactions are diffusion-controlled, and the role of pressure is to aid the diffusion of the reactants 
into the swollen polymer matrix. It can be concluded that pressurizing is definitely beneficial 
when swellable resins are to be used as heterogeneous catalyst support. 
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5. SUMMARY 
Novel, sustainable heterogeneous catalytic methodologies were developed for the CF synthesis 
of pharmaceutically relevant intermediates and potentially bioactive compounds. 
For the CF deuteration of nitrogen-containing heterocycles, on-demand electrolytic D2 
production was applied, which afforded much higher deuterium efficiency and improved safety 
as compared with the conventional batch techniques. 
EtOAc was chosen as aprotic solvent to prevent D–H exchange and to maximize deuterium 
incorporation. 5% Pd/BaSO4 proved insufficiently active even at high temperatures, and 5% 
Pt/Al2O3 was therefore chosen as optimal heterogeneous catalyst. It was observed that the 
utilization of pressures as high as 50 bar was necessary to obtain high reaction rates. 
Besides heterocyclic model compounds and substituted derivatives, a spasmolytic drug, 
drotaverine, was also deuterated. The deuterium-labeled products were obtained in excellent 
conversions (96–99%) and deuterium contents (95–98%). It was found that deuterium 
incorporation was highly selective, as the benzene ring remained intact in all cases. 
The described CF deuteration procedure lacks most of the drawbacks of the classical batch 
techniques, while it is convenient, time- and cost-efficient and safe. 
A simple, inexpensive and rapid CF technique was developed for 1,3-dipolar cycloaddition 
reactions between organic azides and acetylenes, which eliminated the need for costly special 
apparatus and applied Cu powder as a readily available Cu(I) source. 
Initially, the merits of flow processing were exploited by increasing the reaction rates with 
high-pressure/high-temperature conditions. Subsequently, it was demonstrated that the harsh 
reaction conditions can be relieved through the joint use of DIEA and AcOH as basic and acidic 
additives, the CF CuAAC thereby being accomplished with maximum operational safety at RT. 
The applicability of the CF methodology was found extremely wide, for different azides and 
alkynes. Excellent yields (72–99%) were obtained with either aliphatic or aromatic starting 
materials. In some of the cases, the joint use of basic and acidic additives (each in 0.04 
equivalents) at RT resulted in higher yields than at 100 bar and 100 °C. 
The scope of the CF CuAAC process was extended to the preparation of 1,2,3-triazole-
substituted alicyclic β-amino acid derivatives, as novel potentially bioactive compounds. 
Phenylacetylene, diethyl acetylenedicarboxylate and ethynyl ferrocene were reacted as 
dipolarophiles. Yields were as high as 99% in some of the cases, and the copper impurities 
detected in our systems compared well with CF or batch results from the literature. No 
epimerization of the triazole products were observed even upon applying basic conditions. 
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Large-scale synthesis was implemented simply and safely as a function of process time. 3 g 
of triazole 16 was isolated in 3 h, and 2.06 g of triazole 52 was prepared in 100 min. 
In all reactions with terminal alkynes, the 1,4-disubstituted regioisomers were formed 
selectively due to the efficient Cu(I) catalysis. 
We introduced the first CF organocatalytic methodology for asymmetric 1,4-addition of 
aldehydes to nitroolefins, and extended the scope of the sustainable procedure to aldol reactions. 
Solid supported peptidic catalysts containing a proline unit at the N-terminus and an acidic 
side-chain at the C-terminus were applied. The catalysts were readily synthetized and 
immobilized in the same step by SPPS without the cleavage of the peptide from the resin. 
For both organocatalytic transformations, appropriate test reactions were chosen and the 
most important reaction conditions were thoroughly fine-tuned. In the case of conjugate 
additions, it was observed that the diastereoselectivity decreased continuously when the flow 
rate was reduced. It was verified that the catalyst itself epimerized the product. 
Pressurizing improved reaction rates in both transformations up to an optimal value of 
60 bar. It was established that the CF reactions are diffusion-controlled and the role of pressure 
is to promote the transport of the reactants into the matrix of the catalyst carrier. 
It was found that heating also enhanced the reaction rates, but it proved best to employ RT, 
as higher temperatures dramatically lowered stereoselectivities. 
The effect of a basic additive was examined to improve the catalytic activity in cases of 1,4-
additions. However, the best result was obtained without the base, as it epimerized the product. 
It emerged that for 1,4-additions the catalyst H-D-Pro-Pro-Asp-NH-resin on PS-MBHA was 
the most favorable, and exchange of the central proline unit gave satisfactory results only if the 
substituting amino acid did not generate significant distortion in the conformation of the 
peptide. For aldol reactions, H-Pro-Pro-Asp-NH-resin on TentaGel performed best. 
In aldol reactions, the reusability of the peptidic catalyst was extremely high, as it did not 
lose any of its activity or selectivity during 17 h of continuous use in the flow reactor. In cases 
of conjugate additions, the heterogenous catalyst was reusable, but its activity decreased slowly 
in the course of the consecutive reaction cycles. 
With the CF method, chiral γ-nitroaldehydes were obtained in yields up to 91% with high 
diastereoselectivites (up to a dr of 36:1) and excellent enantioselectivites (up to an ee of 93%). 
β-Hydroxyketones, as aldol adducts, were furnished with excellent yields (up to 91%) and high 
enantioselectivities (up to an ee of 85%). The CF results were nicely comparable with those of 
the literature batch procedures. The batch reactions required hours of reaction time, whereas the 
CF procedures were rather rapid, with residence times on the catalyst bed as short as 7 or 6 min. 
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Abstract A simple and efficient flow-based technique is
reported for the catalytic deuteration of several model nitro-
gen-containing heterocyclic compounds which are impor-
tant building blocks of pharmacologically active materials.
A continuous flow reactor was used in combination with on-
demand pressure-controlled electrolytic D2 production. The
D2 source was D2O, the consumption of which was very low.
The experimental set-up allows the fine-tuning of pressure,
temperature, and flow rate so as to determine the optimal
conditions for the deuteration reactions. The described pro-
cedure lacks most of the drawbacks of the conventional batch
deuteration techniques, and additionally is highly selective
and reproducible.
Keywords Deuteration · Flow chemistry · Heterogeneous
catalysis · Nitrogen-containing heterocycles · Reduction
Introduction
The replacement of one or more atom by one of its iso-
topes has proven to be unique in its efficacy [1]. In organic
chemistry, deuteration has frequently been used, especially
in tracer studies, to follow reaction paths [2], and in kinetic
studies to determine the effects of the isotope on reaction
rates [3]. Furthermore, the stability of this nuclide and its
nuclear properties have contributed to the development of
its use in structural analysis. For instance, deuterated com-
pounds are widely used in NMR spectroscopy to facilitate
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signal assignment and structure determination [4, 5], and
they are general internal standards in mass spectrometry
(MS) [6].
Conventional batch techniques for the synthesis of deu-
terated compounds utilize D2 gas as deuterium source [7].
The general methods of producing D2 gas suffer from sev-
eral drawbacks on a laboratory scale, such as difficulties
in gas handling, high costs, etc. Other methods have been
employed to overcome these difficulties, such as catalytic
H–D exchange reactions. However, these methods are far
from being perfect. They do not produce adequately pure
D2, and they also require high pressure, the use of a spe-
cial catalyst or an excess amount of a strong base or acid
[8, 9].
Flow chemistry approaches have recently emerged as
a new productive organic synthetic methodology [10]. As
pointed out below they offer many useful advantages over
conventional batch techniques. For example, mixing in con-
tinuous flow (CF) is much more efficient than conventional
mechanical stirring: it can be achieved rapidly, which leads
to shorter reaction times [11]. Moreover, CF reactors are able
to tolerate high pressure, and thus the reaction temperature
can be far above the solvent’s boiling point, which is another
gain from the aspect of reaction time. Multistep reactions
can be arranged in a continuous sequence, which is especially
beneficial if intermediate compounds are unstable, since they
will exist only momentarily and in very small quantities. Fur-
thermore, reactions which involve gaseous reagents can be
safely handled, whereas in batch a complicated high-pressure
autoclave is necessary. Multiphase liquid reactions can be
performed well with high reproducibility over a range of
conditions, because CF systems allow the use of fixed-bed
catalysts. In such reactors, residence times can be easily fine-
tuned with the flow rate, and consequently all compounds can
be sufficiently exposed to the catalyst [12].
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606 Mol Divers (2011) 15:605–611
Among flow chemistry techniques, the best-characterized
and most widely used reaction is heterogeneous hydroge-
nation, although flow-based deuterium labeling is currently
gaining in interest as it is time- and cost-efficient and far more
convenient than the conventional batch deuteration [13].
Nitrogen-containing heterocycles such as quinoline, iso-
quinoline, quinoxaline, and their saturated derivatives are
commonly used building blocks in pharmaceutical chemis-
try [14]. They are of high importance among both naturally
occurring and synthetic pharmacologically active com-
pounds. Quinoline, isoquinolines, and their tetrahydro
derivatives are present in the structures of many biologically
interesting materials. This family of heterocycles has been
used as HIV protease inhibitors [15], antimalarial drugs [16],
antitumor agents [17], antidepressants [18], and drugs for
the treatment of asthma [19] and they have potential as anti-
bacterial agents [20]. Examples of pharmaceutically inter-
esting quinoxalines include broadly active antitumor agents
[21], antitrypanosomal drugs [22], an angiotensin II recep-
tor antagonist [23] and an adenosine receptor antagonist [24].
As the above examples clearly show, substituted heterocyclic
compounds can offer a high degree of structural diversity and
have proven to be broadly useful therapeutic agents. Because
of their potential biological effects and wide-ranging syn-
thetic applicability, the preparation and transformations of
these compounds have recently acquired considerable sig-
nificance in heterocyclic chemistry [25]. Moreover, consid-
erable interest has recently been demonstrated in this type of
compounds for the synthesis of huge combinatorial libraries,
which offers an opportunity for the rapid synthesis of drug-
like molecules [14].
Although the demand for isotopically labeled compounds
is continuously growing, and the search for rapid, convenient,
catalytic procedures leading to enhanced isotope incorpora-
tion is a hot topic [26], the CF synthesis of deuterated prod-
ucts has rarely been applied. However, conventional batch
techniques for the synthesis of highly deuterated heterocyclic
compounds are quite popular, in spite of their several draw-
backs. For instance, the transfer deuteration of unsaturated
heteroaromatic compounds has been developed in recent
years, where deuterated ammonium formate has been used as
in situ deuterium source and mild catalytic conditions have
been applied [27]. Additionally, several new substitutional
H–D exchange methods have been reported [28, 29]. All of
these techniques provide moderate yields and quite good
deuterium contents and they are constantly being improved;
however, most of them are highly time- and cost-demanding
and require special apparatus. In this situation, flow-based
techniques can be of advantage in the field of isotopically
labeled heterocyclic synthesis. For this reason, we propose
here a convenient flow-based route for the highly selective
deuteration of certain nitrogen-containing heterocycles and
some of their substituted derivatives (Fig. 1).
Fig. 1 Compounds to be deuterated
Experimental
CF methodology
Deuteration reactions were performed in a flow system
(H-Cube, ThalesNano) combined with a built-in electro-
lytic cell [12]. The D2 gas necessary for the reactions was
generated in situ by the electrolytic decomposition of D2O,
no other external gas source being needed. In contrast with
the earlier methods, the purity of the D2 gas produced can
be as high as 99.9%, and the D2O consumption is rather low.
The flow of substrate is combined with D2 gas, and the mix-
ture is then transported to the catalyst bed, where the reac-
tion takes place. The appropriate heterogeneous catalyst is
contained in a cartridge-like stainless steel tube, as in con-
ventional HPLC columns, which eliminates potentially dan-
gerous direct catalyst handling and ensures excellent ease
of use. The process of flowing a deuterium/substrate mix-
ture through the catalyst bed vastly increases the interaction
between the three phases (solid catalyst, liquid substrate, deu-
terium gas). This interaction is important due to the limited
solubility of deuterium in solvent. The catalyst cartridge,
with a linear dimension of 3 cm and internal diameter of
123
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Fig. 2 Experimental scheme for CF deuteration
4 mm, encompasses approximately 150 mg of catalyst, which
is reusable after thorough washing with solvent until deacti-
vation. The comparatively small amounts of excess gas are
continually exhausted by the system, eliminating the need
for many of the special precautions normally required for
the handling of dangerous and flammable gases. The system
can be pressurized and heated. The heater unit is a Peltier
heating system which consists of a stainless steel reaction
line coil contained within a stainless steel block in which
the catalyst holder cartridge is placed as well. The appli-
cation of pressure not only helps to shift reaction equilib-
ria, but also means that a far greater proportion of gas will
be in solution during the reaction than in a conventional
autoclave. So as to prevent D–H exchange and maximize
deuterium incorporation, an aprotic solvent was used. Reac-
tion conditions such as catalyst type, pressure, temperature,
and flow rate were systematically adjusted in order to deter-
mine the optimal conditions for the deuteration reactions. A
schematic outline of the CF deuteration reactor is presented
in Fig. 2.
General procedure of the synthesis and analysis
of the deuterated compounds
20 mg of substrate 1–6 was dissolved, respectively, in 20 mL
ethyl acetate with 10 min sonication. After that, the deu-
teration reactions were carried out under the previously
optimized conditions with the CF reactor (the optimization
procedure is outlined in Table 1, for the optimal conditions
see Tables 2 and 3). Before further analytical investigations
TLC analyses were performed routinely, CHCl3:MeOH=9:1
was used as eluent. Reagents and catalysts were pur-
chased from Sigma-Aldrich and were used without further
purification.
After evaporation of the solvent and drying of the samples,
the crude deuterated products were characterized by MS,
1H-NMR spectroscopy, and 13C-HSQC and 13C-HMBC
experiments. The deuterium content (which represents the
deuterium incorporation rate over incidental hydrogen addi-
tion) was determined from the relative intensity of the
1H-NMR indicator signals and by MS analysis.
1H-NMR and 13C-NMR spectra were recorded on a
Bruker Avance DRX 400 spectrometer, in CDCl3 as applied
solvent, with TMS as internal standard, at 400.1 and
100.6 MHz, respectively. MS analysis was carried out with
an Agilent 1100 LC/MSD trap.
Characterization data of the deuterated products
1-Deutero-6,7-dimethoxy-1-methyl-1,2,3,
4-tetrahydroisoquinoline (1d)
1H-NMR (400.1 MHz, CDCl3)δH : 1.47 (3H, s, CH3), 2.63–
2.72, 2.76–2.87 (1H, m, CH), 2.98–3.07, 3.24–3.32 (1H, m,
CH–N), 3.88 (6H, s, 2CH3-O), 6.60, 6.66 (1H, s, H–Ar).
13C-NMR (100.6 MHz, CDCl3)δC : 22.6 (CH3), 29.7 (CH2),
42.0 (CH2–N), 51.0 (CD–N), 56.2 (2CH3–O), 109.2, 111.8
(CH–Ar),126.3, 131.8 (C–Ar), 147.3 (O–C–Ar). MS m/z:
209.3 (M+1) + .
Table 1 Optimization of
reaction conditions for the
deuteration of compound 1 at
1 mg/mL, with a flow rate of
1 mL/ min, in ethyl acetate as
solvent
a Number of discrete
circulations via the CF reactor
Entry Catalyst p/atm T/◦C Runsa Conv./%
1 5% Pd/BaSO4 1 RT 1 0
2 5% Pd/BaSO4 20 RT 1 0
3 5% Pd/BaSO4 40 RT 1 50
4 5% Pd/BaSO4 60 RT 1 50
5 5% Pd/BaSO4 80 RT 1 50
6 5% Pd/BaSO4 50 70 2 60
7 5% Pd/BaSO4 50 90 3 80
8 5% Pt/Al2O3 50 30 1 99
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Table 2 Deuteration of selected isoquinolines containing an unsaturated hetero ring
Entry Starting material Product Optimal conditions Conv./% Db/%
1
N
MeO
MeO
Me1
NH
Me D
MeO
MeO
1d
5% Pt/Al2O3, 50 atm, 30 ◦C, 1 runa 99 97
2
N
Me2
NH
Me D2d
5% Pt/Al2O3, 50 atm, 30 ◦C, 1 runa 99 95
3
N
3
NH
D3d
5% Pt/Al2O3, 50 atm, 30 ◦C, 1 runa 97 96
4
N
EtO
EtO
OEt
OEt
4
NH
EtO
EtO
OEt
D
OEt
4d
5% Pt/Al2O3, 50 atm, 30 ◦C, 1 runa 96 98
a Number of discrete circulations via the CF reactor
b Deuterium contents (represent the deuterium incorporation rate over incidental hydrogen addition)
Table 3 Deuteration of selected compounds containing a heteroaromatic ring
Entry Starting material Product Optimal conditions Conv./% Db/%
5
N
5
N
H
D
D
D
5d
5% Pt/Al2O3, 50 atm, 70 ◦C, 3 runsa 98 97
6
N
N
6
N
H
H
N D
D
6d
5% Pt/Al2O3, 50 atm, 50 ◦C, 1 runa 99 95
a Number of discrete circulations via the CF reactor
b Deuterium contents (represent the deuterium incorporation rate over incidental hydrogen addition)
1-Deutero-1-methyl-1,2,3,4-tetrahydroisoquinoline (2d)
1H-NMR (400.1 MHz, CDCl3)δH : 1.49 (3H, s, CH3), 2.73–
2.82, 2.86–2.96 (1H, m, CH), 3.02–3.11, 3.26–3.35 (1H, m,
CH–N), 7.09–7.23 (4H, m, 4H–Ar). 13C-NMR (100.6 MHz,
CDCl3)δC : 22.3 (CH3), 29.7 (CH2), 41.4 (CH2–N), 50.7
(CD–N), 125.7, 128.9 (2CH–Ar),134.7, 139.6 (C–Ar). MS
m/z: 149.2 (M+1)+.
1-Deutero-1,2,3,4-tetrahydroisoquinoline (3d)
1H-NMR (400.1 MHz, CDCl3)δH : 2.84 (2H, t, J =
6.0 Hz, CH2), 3.18 (2H, t, J = 6.0 Hz, CH2–N), 4.01–4.06
(1H, m, CHD–N), 7.01–7.18 (4H, m, 4H–Ar). 13C-NMR
(100.6 MHz, CDCl3)δC : 28.8 (CH2), 43.9 (CH2–N), 47.2
(CHD–N), 125.7, 126.1, 127.1, 129.1 (CH–Ar), 134.4 (2C–
Ar). MS m/z: 135.2 (M+1)+.
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1-Deutero-1-(3,4-diethoxybenzyl)-6,7-diethoxy-1,2,3,4-
tetrahydroisoquinoline (4d)
1H-NMR (400.1 MHz, CDCl3)δH : 1.41–1.50 (12H, m,
4CH3), 2.63–2.76 (2H, m, CH2–N), 2.84–2.98, 3.11–3.26
(2H, m, CH2), 4.03–4.15 (8H, m, 2CH2–O), 6.63, 6.72 (1H,
s, H–Ar), 6.76–6.80 (2H, m, 2H–Ar), 6.86 (H, m, H–Ar).
13C-NMR (100.6 MHz, CDCl3)δC : 14.5 (4CH3), 29.1, 40.7
(CH2), 42.0 (CH2–N), 56.2 (CD–N), 64.6 (4CH2–O), 111.2,
113.1, 113.7, 114.7, 121.5 (CH–Ar),127.6, 129.9, 131.2
(C–Ar), 146.5, 147.0, 147.9, 148.3 (O–C–Ar). MS m/z:
401.7 (M+1)+.
2,3,4-Trideutero-1,2,3,4-tetrahydroquinoline (5d)
1H-NMR (400.1 MHz, CDCl3)δH : 1.90–2.00 (1H, m, CHD),
2.74–2.82 (1H, m, CHD), 3.28–3.36 (1H, m, CHD–N), 6.50
(1H, d, J = 7.7 Hz, H–Ar), 6.64 (1H, t, J = 7.7 Hz, H–
Ar), 6.94–7.03 (2H, m, 2H–Ar). 13C NMR (100.6 MHz,
CDCl3)δC : 22.3, 27.1 (CHD), 42.3 (CHD–N), 114.7, 117.6,
127.0, 130.5 (CH–Ar), 121.8 (C–Ar), 144.7 (N–C–Ar). MS
m/z: 137.2 (M+1)+.
2,3-Dideutero-1,2,3,4-tetrahydroquinoxaline (6d)
1H-NMR (400.1 MHz, CDCl3)δH : 3.40–3.47 (2H, m,
2CHD), 6.50–6.56 (2H, m, 2H–Ar), 6.59–6.65 (2H, m, 2H–
Ar). 13C-NMR (100.6 MHz, CDCl3)δC : 41.1 (2CHD–N),
115.3, 118.9 (2CH–Ar), 133.6 (2N–C–Ar). MS m/z: 137.2
(M+1)+.
Results and discussion
The present starting compounds (Fig. 1) can be divided into
two main groups: 1, 2, 3 and 4 are partially unsaturated,
whereas 5 and 6 contain a fully aromatic hetero ring con-
densed to a benzene ring. It may be expected that the reduc-
tion of the C=N bond of the unsaturated starting materials
requires milder conditions than those in the case of the fully
aromatic hetero rings.
Substrate 1 was chosen as subject for optimization of the
reaction conditions (Fig. 3), initially with 5% Pd/BaSO4 as
catalyst because activated charcoal as carrier is not suitable:
it can contain various protic contaminants which can easily
lead to H–D scrambling [30, 31]. In an attempt to maximize
deuterium incorporation, ethyl acetate was used as aprotic
solvent. At room temperature and atmospheric pressure, no
conversion was achieved. At 40 atm, the conversion reached
50%, but further pressurizing was completely ineffective, as
in the range 40–80 atm at room temperature the conversion
remained at 50%. We next tried increasing the temperature
while moderate pressure was applied, so as to keep the deute-
rium dissolved. When this proved to be insufficient, we tried
circulating the reaction mixture repeatedly. After three circu-
lations at 90 ◦C, the methyl signals of the methoxy groups in
the 1H-NMR spectrum indicated that the conversion was still
below optimal. At this point, we changed to the more active
5% Pt catalyst on A12O3 carrier. This led to almost complete
conversion at 30 ◦C in point of the deuteration of the het-
ero ring, whereas the protons of the benzene ring remained
intact, as it is indicated in the 1H and 13C-NMR spectra by the
presence of the aromatic protons (at 6.60 and 6.66 ppm) and
aromatic carbons (at the region of 109.2–147.3 ppm). This
result is highly competitive as compared with the literature
batch methods mentioned above [27, 28]. Throughout the
whole optimization procedure, the concentration and flow
rate were maintained constant at 1 mg/mL and 1 mL/ min,
respectively. The fine tuning of the reaction conditions is
outlined in Table 1.
On the basis of the promising results obtained with 1, the
partially unsaturated 2, 3, and 4 were also subjected to deu-
teration in the CF system, with ethyl acetate as solvent and
5% Pt/A12O3 as catalyst. Under the previously optimized
reaction conditions, almost full conversion and more than
95% deuterium content could be achieved in all three cases
(Table 2). Moreover, the deuterium incorporation is proved
to be highly selective in each case, since the benzene ring
remained unsaturated as it is indicated by the aromatic signals
of the NMR spectra. Drotaverine (4), a spasmolytic drug, has
two structural isomers specified by the endo and exo position
of the non-aromatic double bond. The presence of the multi-
plet signal of the two protons of the bridging carbon atom in
the 1H NMR spectra at 3.11–3.26 ppm gave evidence of the
selective deuterium incorporation at the C-1 (endo) position,
though the N–D bond is not evident as it instantly changes to
Fig. 3 Deuteration of
compound 1 (the N–D bond
instantly changes to N–H while
being exposed to air)
123
610 Mol Divers (2011) 15:605–611
N–H from H2O vapor while being exposed to air (Table 2).
Consequently, we can conclude that with CF under optimal
conditions substitution did not influence the deuterium incor-
poration at the non-aromatic hetero rings.
As expected, the saturation of the aromatic hetero rings
required more stringent conditions. It was pointless to
attempt their deuteration with a Pd catalyst, so we tried the
previously optimized conditions with 5% Pt/A12O3 as cat-
alyst. Because of the considerable electronegativity of the
nitrogen atoms, the symmetry of the electron distribution
and the aromatic stability of the hetero ring are lower as com-
pared with the non-heterocyclic rings, and consequently the
reactivity is higher. Quinoline (5) contains only one nitro-
gen atom, whereas quinoxaline (6) contains two nitrogens
in the 1,4-positions. Accordingly, it is not at all surpris-
ing that selective saturation of the hetero ring of quinoline
requires a higher temperature and repeated runs, whereas for
quinoxaline milder conditions and a single circulation were
sufficient. As may be seen in Table 3, almost full conver-
sion and an outstanding deuterium incorporation ratio were
achieved in both cases. Moreover, the reactions proved to
be highly selective, as the NMR spectra clearly indicate that
the aromatic rings remained intact, whereas the hetero rings
became saturated as the signals of their hydrogen and car-
bon atoms can be found in the aliphatic region, at 1.90–
3.47 ppm and 22.3–42.3 ppm, respectively. Selective deuter-
ation of pyrazine was also attempted, but proved unsuccess-
ful. It is probable that the aromatic ring underwent fragmen-
tation into volatile compounds, irrespective of the catalyst
type.
To summarize, we have developed a simple flow-based
method for the deuterium labeling of model unsaturated het-
erocyclic compounds, which are precursors of a series of
pharmacologically active materials. As expected, the satu-
ration of the heteroaromatic rings required more stringent
conditions than for the C=N bonds; nevertheless, we suc-
ceeded in finding optimal conditions for the highly selective
deuteration of all six starting materials. Our set of model com-
pounds contained several substituted derivatives and a drug
molecule. It emerged that under the optimal conditions, sub-
stitution did not influence the deuterium incorporation and
conversion appreciably; consequently, this technique appears
to offer the opportunity to arrange a large number of related
compounds rapidly into huge combinatorial libraries. We
should emphasize that the proposed CF-based method lacks
most of the drawbacks of the conventional batch deutera-
tion techniques, while additionally it is convenient, cost- and
time-efficient and safe, besides being highly selective and
reproducible.
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Highly Efficient 1,4-Addition of Aldehydes to Nitroolefins: Organocatalysis
in Continuous Flow by Solid-Supported Peptidic Catalysts
Sndor B. tvçs, Istvn M. Mndity, and Ferenc Flçp*[a]
Continuous flow (CF) approaches have recently gained in sig-
nificance among synthetic techniques, in consequence of the
massive number of advantages they offer over conventional
batch procedures, for example, the efficient mixing of sub-
strates, faster heat and mass transfer, and shorter reaction
times.[1] Modern flow technologies eliminate the need for the
large-scale use of reagents and solvents, and the most impor-
tant reaction parameters (such as flow rate, temperature, and
pressure) can be fine-tuned and monitored quickly and pre-
cisely. This implies time- and cost-efficient reaction condition
screening, facilitating the generation of large libraries of drug-
like molecules and easy scale-up.[2] Heterogenizing homoge-
neous catalysts on a solid support is a trend towards the in-
crease of the efficiency of synthetic techniques. By incorporat-
ing immobilized catalysts, the scope of chemical processes in-
volving flow can be further broadened.[3]
A variety of CC bond-forming reactions have been ach-
ieved through asymmetric organocatalysis in recent years.[4]
Proline (Pro) has been described as a catalyst for reactions in-
volving enamines, in general with moderate yield or enantiose-
lectivity.[5] Small rigid organocatalsyts offer only a limited
number of sites for structural and functional diversity ; in con-
trast, peptides have a modular nature which allows the crea-
tion of optimized catalysts.[6] In recent years, a large number of
peptidic catalysts have been designed,[7] and it has been
shown that N-terminal prolyl-peptides efficiently catalyze reac-
tions proceeding via enamine intermediates.[8] Wennemers
et al. introduced tripeptide-containing proline and carboxylic
acid moieties (proline mimetics) as organocatalysts for the 1,4-
addition of aldehydes to nitroolefins,[9] leading to g-nitroalde-
hydes, which are valuable intermediates for the synthesis of
various compounds.[10] These peptides provide higher catalytic
activity and stereoselectivity than proline itself, under mild
conditions and at low catalyst loadings.[11]
We present here the first CF approach for the selective
asymmetric synthesis of g-nitroaldehydes, utilizing solid-sup-
ported peptidic catalysts, readily synthesized and immobilized
in one single step. The simple and efficient technique permit-
ted catalyst reusability, facile scale up, and ease of product iso-
lation. Reaction condition optimization led to dramatically
shortened reaction times, high yields and stereoselectivities
comparable with those in the batch process.[9c] The peptidic
catalysts were synthesized by using Fmoc/tBu protocols on
solid supports with different swelling properties: polyethylene
glycol–polystyrene copolymers (TentaGel) without any linker
and polystyrene resins with 4-methylbenzhydrylamine (MBHA).
These experimental set-ups allowed catalyst synthesis and im-
mobilization in a single step; for example, after the coupling
steps, the side-chain protecting groups were removed by the
use of trifluoroacetic (TFA) acid without cleavage of the pep-
tide. This eliminated the need for further peptide work-up and
purification steps and made the whole procedure highly
simple and efficient. The heterogenized catalyst was incorpo-
rated into a cartridge-like stainless steel tube. The reactions
were performed in an H-Cube system in the ‘no H2’ mode; the
cartridge was placed in a stainless steel block, which contained
a Peltier heating system. Constant pressure was ensured by
using a back pressure valve, and the CF of the reaction
medium was provided by using an HPLC pump. A schematic
outline of the packed bed reactor is presented in Scheme 1.[12]
For an initial reaction condition optimization study, the pep-
tide H-d-Pro-Pro-Asp-NH-resin (1a, Asp=aspartic acid) was
used as catalyst in the test reaction of the 1,4-addition of
propanal to E-b-nitrostyrene (BNS). The catalyst was immobi-
lized on MBHA resin with a loading of 0.64 mmolg1. The sol-
vent system used (CHCl3/iPrOH=9:1) was chosen on the basis
of literature data, this medium ensuring appropriate swelling
properties for the immobilized catalysts.[9c] A rapid screen indi-
cated that 8 mgmL1 of BNS was suitable at room temperature
and atmospheric pressure, while the aldehyde was applied in
an initial high excess (Table S1 in the Supporting Information).
In further parameter screening, the aim was to make the pro-
cedure efficient while maintaining high yield and selectivity.
Adjustment of the flow rate means fine-tuning of the residence
time on the catalyst bed; the longer the residence time, the
Scheme 1. Experimental set-up for the CF organocatalysis.
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higher the yield. With a flow rate as low as 0.01 mLmin1, a
quantitative yield was achieved, but more than 8 h was re-
quired to pump 5 mL of the starting material through the
system. In contrast, when a flow rate of 0.5 mLmin1 was used,
10 min was sufficient for a single run, but the yield dropped to
50%. As a compromise between reaction time and through-
put, the flow rate was set to 0.1 mLmin1 to achieve a yield
>90% (Figure 1 and Table S2 in the Supporting Information).
The fine-tuning of the flow rate influenced not only
the yield, but also the diastereoselectivity: the lower
the flow rate, the lower the diastereomeric ratio (dr).
To explain this phenomenon, a short epimerization
study was performed. When the resulting g-nitroal-
dehyde was recirculated on the bed of catalyst 1a at
0.1 mLmin1, the syn/anti ratio decreased from 11:1
to 4:1, whereas when the recirculation of g-nitroalde-
hyde was repeated after the acetylation of the sec-
ondary amine of the d-Pro residue of catalyst 1a, no
epimerization occurred. This suggested that the cata-
lyst itself can affect the epimerization of the product,
and consequently, the longer the residence time, the
lower the diastereoselectivity. Application of a high
excess of the aldehyde may push the reaction equi-
librium to completion, resulting in higher yields, but
also makes the procedure less economical. With this
in mind, 5 equivalents of propanal were chosen as
optimum (Table S2 in the Supporting Information).
Next, we examined the pressure dependence of the
flow process. Increasing the pressure from atmos-
pheric to 60 bar (1 bar=105 Pa) led to higher yields;
further elevation proved to be not beneficial (Figure 2 and
Table S3 in the Supporting Information). This phenomenon
raises the question of whether the conversion is dependent on
the catalyst activity itself or is influenced by the transport phe-
nomena of the reactants in the polymer. To investigate the dif-
fusion dependence, we performed the Koros–Nowak test.[13]
The loading of the MBHA resin was halved by acetylation, and
the same reaction was performed with catalyst 1b. The de-
crease in the yield was not proportional to the decrease in
loading (Table 1, entries 1 and 2). Consequently, the reaction is
under diffusion control, and pressure is necessary to virtually
raise the active surface of the catalyst. Increase of the tempera-
ture provided higher yields, but also dramatically lowered the
selectivity. For example, at 90 8C a quantitative yield was ob-
tained, but with 77% ee and a syn/anti ratio of 1.5:1 (Table S3
in the Supporting Information).
The effects of different additives have been investigated pre-
viously.[11b] The role of N-methylmorpholine (NMM) in the reac-
Figure 1. Fine-tuning of the flow rate in the conjugate addition of propanal
to BNS.
Figure 2. Pressure dependence of the conjugate addition of propanal to
BNS.
Table 1. Fine-tuning of the peptidic catalyst for the conjugate addition of propanal to
BNS under optimum flow conditions.
Entry Immobilized catalyst Yield[a]
[%]
syn/anti[b] ee(syn)[c]
[%]
1 H-d-Pro-Pro-Asp-NH-resin[d] (1a) 91 11:1 93
2 H-d-Pro-Pro-Asp-NH-resin[e] (1b) 78 11:1 92
3 H-d-Pro-Pro-Glu-NH-resin[d] (2a) 79 12:1 91
4 H-d-Pro-Pro-Glu-NH-resin[e] (2b) 69 11:1 91
5 H-d-Pro-(1R,2R)-ACPC-Asp-NH-resin[d] (3) 83 10:1 90
6 H-d-Pro-(1S,2S)-ACPC-Asp-NH-resin[d] (4) 41 15:1 93
7 H-d-Pro-(1S,2R)-ACPC-Asp-NH-resin[d] (5) 70 9:1 70
8 H-d-Pro-(1R,2S)-ACPC-Asp-NH-resin[d] (6) 35 19:1 89
9 H-d-Pro-Pro-Asp-NH-resin[f] (7) 81 11:1 92
10 H-d-Pro-Pro-Glu-NH-resin[f] (8) 73 12:1 91
[a] Yield of isolated product. [b] Determined by performing 1H NMR spectroscopic
analysis of the crude material. [c] Determined by performing chiral-phase HPLC analy-
sis. [d] Resin: MBHA with a loading of 0.64 mmolg1. [e] Resin: MBHA with a loading
of 0.32 mmolg1. [f] Resin: TentaGel with a loading of 0.29 mmolg1.
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tion mixture was tested by utilizing catalyst 1a under opti-
mum flow conditions. The higher the NMM amount added, the
lower the diastereoselectivity observed because of possible
epimerization, whereas the yield and enantioselectivity re-
mained intact (Table S4 in the Supporting Information). This
raises the question of whether NMM itself epimerized the
product. Therefore, we incubated the product in an NMM-con-
taining solvent and investigated the syn/anti ratio before and
after this procedure. The diastereoselectivity decreased dra-
matically. Thus, it proved best to not use NMM at all and to
leave the peptides in the TFA salt form, in which they are pres-
ent after the solid-phase peptide synthesis (SPPS).
To achieve optimum conditions, we also fine-tuned the pep-
tide catalyst. We first tested the effect of the exchange of the
C-terminal amino acid from aspartic acid to the homologous
glutamic acid (Glu).[9b] H-d-Pro-Pro-Glu-NH-resin was synthe-
sized on the MBHA support with two different loadings (0.64
and 0.32 mmolg1, 2a and 2b). These furnished comparable
selectivities to catalyst 1a, but lower yields (Table 1, entries 3
and 4). Wennemers et al. recently applied the same solid-sup-
ported catalyst with Glu as C-terminal utilizing a standard
batch technique. They achieved quantitative yields and high
selectivities, but very long reaction times were needed.[9a] The
effect of the peptide conformation-directing role of the bioin-
spired substitution of the central proline unit with b-amino
acids was also investigated.[14] Insertion of (1R,2R)-2-aminocy-
clopentane-carboxylic acid (ACPC) (3) led to comparable results
with catalyst 1a, whereas application of (1S,2S)- (4), (1S,2R)- (5),
or (1R,2S)-ACPC (6) resulted in significantly lower yields
(Table 1, entries 5–8). This suggests that exchange of the pro-
line linker gives satisfying results, if the substituting residue
does not induce significant distortion in the conformation of
the peptide. H-d-Pro-Pro-Asp-NH-resin and H-d-Pro-Pro-Glu-
NH-resin were also synthesized on TentaGel (with a loading of
0.29 mmolg1, 7 and 8). The different swelling properties and
the lower loading of the resin gave rise to lower yields, where-
as the selectivity of the reaction remained comparable to that
obtained with MBHA (Table 1, entries 9 and 10).
Catalyst reusability was verified by repetition of the test re-
action under optimum flow conditions by using catalyst 1a. In
each run, 50 mg of crude product was collected in 50 min.
During the first five consecutive reactions, the yield remained
>80%, and after the 10th run it was still nearly 70%. Notably,
the enantioselectivities remained practically constant, whereas
the diastereoselectivities increased slightly (Table S5 in the
Supporting Information). The increase in the syn/anti ratio can
be explained by blocking of the secondary amine moiety of
the d-Pro motif of the catalyst, which leads to epimerization of
the product.
Under the optimum conditions for catalyst 1a, the corre-
sponding g-nitroaldehyde product of the test reaction was ob-
tained in a yield of 91%, a syn/anti ratio of 11:1, and 93% ee.
These results compare well with those of the batch procedure,
in which the same catalyst was applied in the homogeneous
phase.[9c] However, it should be noted that the batch reaction
required 24 h, whereas at the optimum flow rate of
0.1 mLmin1, the residence time on the catalyst bed with the
CF method was only 7 min, which can be regarded as the reac-
tion time. This considerable decrease in reaction time is attrib-
utable to the beneficial features of the technique: the use of
CF, the high local catalyst concentration in the catalyst bed,
and the high pressure.[1]
To investigate the scope and applicability of the described
method, a number of conjugate addition reactions between
various aldehydes and BNS were explored. The reaction condi-
tions were set at the previously optimized values, and the im-
mobilized catalyst 1a was used. As seen in Table 2, excellent
results were obtained with linear aldehydes (Table 2, entries 1–
5). The corresponding g-nitroaldehyde products were formed
in good yields (between 60 and 90%), the enantioselectivities
were >90%, and the diastereoselectivities were also high.
A branched aldehyde–bearing substituent in the b-position
was also tolerated, but a lower yield was acquired (Table 2,
entry 6). The selectivities obtained with the CF technique com-
pared well with those achieved with the batch procedure, but
the yields are somewhat lower (Table 2). However, taking into
account that the CF reactions took place in 7 min, whereas the
batch reactions required 12–24 h, the CF results are thought-
provoking.[9c] 1,4-Addition of a series of a-branched aldehydes
(2-methylpropanal, 2-methylbutanal, 2-phenylpropanal, phenyl-
acetaldehyde, and diphenylacetaldehyde) to BNS was also at-
tempted, but no conversion was obtained under the utilized
reaction conditions, probably caused by steric hindrance.
Thus, we have developed the first CF method for the asym-
metric organocatalytic conjugate addition of aldehydes to ni-
troolefins. A solid-supported peptide has been utilized as cata-
lyst, which has been synthesized and immobilized in the same
step. Ignoring the peptide cleavage means no work-up, no pu-
rification, and no product loss. The technique is rapid, simple,
and efficient while it lacks most of the drawbacks of the con-
Table 2. Demonstration of the scope and applicability of the CF organo-
catalytic technique, and comparison of the results with the batch data re-
ported by Wennemers et al. utilizing the same catalyst in the homogene-
ous phase.[9c]
Entry R Technique Yield[a] [%] syn/anti[b] ee(syn)[c] [%]
1 Me CF
batch ref.
91
98
11:1
9:1
93
91
2 Et CF
batch ref.
60
93
22:1
25:1
91
95
3 nPr CF
batch ref.
68
94
15:1
15:1
91
92
4 nBu CF
batch ref.
87
quant
14:1
15:1
91
92
5 Bn CF
batch ref.
65
89
36:1
15:1
92
95
6 iPr CF
batch ref.
22
88
20:1
50:1
91
92
[a] Yield of isolated product. [b] Determined by performing 1H NMR spec-
troscopic analysis of the crude material. [c] Determined by using chiral-
phase HPLC analysis.
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ventional batch procedure. After optimization of the reaction
conditions, synthetically useful chiral g-nitroaldehydes have
been obtained in excellent yields and stereoselectivities. The
results are nicely comparable with those of the batch tech-
nique. As a consequence of the beneficial features of the CF
method, the reaction times have been markedly shorter than
with the batch process, whereas the catalyst reusability, the
ease of product isolation and the possibility of facile scale up
enhance the efficiency of the CF technique. Immobilized pepti-
dic organocatalysts are, therefore, useful for broadening the
scope of flow chemical processes.
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III 
z áramlásos technológiákat már régóta alkalmazza az olaj-
ipar, az utóbbi években viszont a szerves szintetikus kémi-
ában is elkezdetek meghonosodni, köszönhetően annak, hogy a
hagyományos szakaszos eljárásokhoz képest számos előnnyel
rendelkeznek, ezek közül a legfontosabbak: a reagensek gyors és
hatékony keveredése, hatékony hőátadás és rövid reakcióidők [1,
2]. A modern áramlásos berendezések nagyon kis anyagmennyi-
ségeket is tudnak kezelni (mikroreaktorok), továbbá a legfonto-
sabb reakcióparaméterek (áramlási sebesség, nyomás és hőmér-
séklet) pontosan szabályozhatók, így az optimális reakciókörül-
mények gyorsan és könnyedén beállíthatók [3]. Nemcsak homo-
gén fázisú reakciók kivitelezhetők folyamatos áramban, az olaj-
iparhoz hasonlóan állóágyas reaktorok is elterjedtek, amelyekben
tetszőleges immobilizált reagensek, katalizátorok helyezhetőek el,
sőt egyes reaktortípusok gáz halmazállapotú reagensek kezelésé-
re is alkalmasak, akár szuperkritikus körülmények között is [4–6].
Mivel a technológiai alapok a nagyiparban gyökereznek, a mé-
retnövelési és automatizálási lehetőségek is adottak, így a labo-
ratóriumi kísérletek köréből kilépve a gyógyszeripar számára is
vonzóvá tehető a technika.
Az organokatalízis olyan újszerű megközelítés a szerves kémi-
ában, amely fématomokat nem tartalmazó szerves molekulákat
alkalmaz katalizátorként. E tudományterület virágzása az ezred-
forduló környékén indult, egy egyszerű aminosav, a prolin mint
organokatalizátor elterjedésével. A prolin a C–C kötések kialakí-
tására szolgáló népszerű Michael-, Mannich- és aldolreakciók ki-
rális katalizátorává vált, jó hozam- és szelektivitásértékek elérése
mellett [7]. Mivel a szintézismódszerek hatékonyságának növelé-
se iránt folyamatosan nőtt az igény, a prolin módosításával szá-
mos aktívabb és/vagy szelektívebb organokatalizátort fejlesztet-
tek ki [8, 9]. Nem nehéz belátni azonban, hogy a kisméretű, pro-
linszerű katalizátorok továbbfejlesztése, módosítása egy adott
szint elérése után korlátozott a funkciós csoportok limitált szá-
ma miatt. Ugyanakkor ha olyan moduláris felépítésű molekulá-
kat alkalmazunk katalizátorként, mint a peptidek, akkor az elő-
ző akadályon könnyedén túllépve, az építőelemek változtatásával
(finomhangolás) kedvező tulajdonságokkal rendelkező katalizá-
torokat állíthatunk elő. A peptidek mellett szóló érv az is, hogy
királis információtartalmuk nem merül ki az aminosavak aszim-
metriájában, hanem másodlagos és harmadlagos szerkezetükből
is jelentős királis indukció adódhat. Az utóbbi években számos
peptid, illetve peptidszerű organokatalizátort fejlesztettek ki, és
megszületett a felismerés, miszerint egyes peptidek a prolin ka-
talitikus tulajdonságait imitálják, sőt túl is mutatnak azon [10]. 
Munkánk során kidolgoztuk az első organokatalitikus áram-
lásos módszert aldehidek nitroolefinekre történő konjugált addí-
ciójához, szilárd hordozós peptidkatalizátor alkalmazásával [6].
Választásunk azért esett a peptidekre, mert szilárd fázisú pep-
tidszintézis alkalmazásával a katalizátor szintézise és immobili-
zációja egy lépésben megvalósítható. Az Fmoc/tBu protokoll sze-
rint történő peptidszintézishez olyan speciális gyantákat keres-
tünk hordozóként, amelyekről a védőcsoport-eltávolítási lépések
során nem hasad le a katalizátor. Végül két hordozóra esett a vá-
lasztásunk: (i) politelinglikol–polisztirol koplimer TentaGel-re és
(ii) 4-metilbenzhidrilamin linkerrel rendelkező térhálósított poli-
sztirol gyantára (MBHA). Ez a kísérleti elrendezés meglehetősen
egyszerű és praktikus, ugyanis megspórolhatók az idő- és ener-
giaigényes peptidtisztítási és feldolgozási lépések, az immobili-
zált katalizátort pedig rozsdamentes acél oszlopokba töltve köz-
vetlenül felhasználhattuk a peptidszintézis után. A folyamatos
áramú reakciókat egy H-Cube® készülék segítségével hajtottuk
végre „no H2” üzemmódban. A katalizátort tartalmazó rozsda-
mentes acél oszlop (katalizátorágy) egy fűthető foglalatba került,
a reagensek folyamatos áramát ezen keresztül egy HPLC pumpa
biztosította. A berendezés egy nyomásszabályzó egységet is tar-
talmazott. A kísérleti elrendezés vázlatát az 1. ábrán szemléltet-
jük [11].
Kiindulásként, a folyamatos áramú módszer finomhangolásá-
hoz irodalmi megfontolások alapján az alábbi peptidkatalizátort
választottuk: H-D-Pro-Pro-Asp-NH2 (Pro = prolin, Asp = aszpara-
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akcióként, a BNS koncentrációját 8 mg  ml–1 konstans értéken
tartva. A továbbiakban az alábbi reakcióparaméterek változtatá-
sának hatását vizsgáltuk: áramlási sebesség, reagensfelesleg, nyo-
más és hőmérséklet. A célunk az volt, hogy a módszert a lehető
leghatékonyabbá tegyük, azaz a minimális reakcióidőt érjünk el
minimális reagensfelesleg alkalmazásával, magas hozam és sze-
lektivitásértékek elérése mellett. Egy áramlásos eljárás esetében
a reakcióidőt a reagensek reaktorban töltött tartózkodási ideje je-
lenti (esetünkben a „reaktor” alatt csak a töltetes oszlopot ért-
jük). Minél nagyobb az áramlási sebesség, annál kisebb a tartóz-
kodási idő és annál nagyobb az eljárás kapacitása, viszont a túl
nagy áramlási sebesség (azaz túl rövid reakcióidő) a konverzió ro-
vására mehet. Ezt jól példázza, hogy 60 bar nyomáson, szobahő-
mérsékleten, 5 ekv aldehidfelesleggel 0,01 ml  perc–1 áramlási se-
besség mellett közel teljes hozamot értünk el, viszont az áram-
lást 0,5 mlperc–1-re növelve a termelés a felére esett vissza (3. áb-
ra). Érdemes ugyanakkor azt is mérlegelni, hogy az előbbi eset-
ben 5 ml reakcióelegyet több mint 8 órába tartott átpumpálni a
reaktoron, viszont 0,5 ml  perc–1 áramláson ugyanez 10 percbe
telt. Ezért kompromisszumként 0,1 ml  perc–1 áramlási sebessé-
get választottunk optimálisnak, amelyen 91%-os termelés adó-
dott. Az áramlási sebesség változtatása nemcsak a termelésre van
hatással, hanem a diasztereomer arányra (dr) is: minél kisebb az
áramlási sebesség, annál alacsonyabb a dr (3. ábra). Ezt azzal
magyarázhatjuk, hogy maga a katalizátor kiválthatja a termék
epimerizációját. Hogy ezt bebizonyítsuk, a termékként kapott
γ-nitroaldehid oldatát újra átpumpáltuk a katalizátorágyon
0,1 ml  perc–1  áramlási sebességgel, és azt tapasztaltuk, hogy ek-
kor a dr 11 : 1-ről 4 :1-re romlik. Ha azonban a peptid N-terminá-
lis D-prolinját először acetilcsoporttal védtük, és csak utána pum-
páltuk át rajta a γ-nitroaldehid terméket, nem változott a dr. Ez
a megfigyelés megerősítette, hogy a lehető legkisebb tartózkodá-
si időt célszerű választani a katalizátorágyon. Az aldehid nagy fe-
leslege a reakciót ugyan a termékképződés irányába mozdíthat-
ja, viszont a túl nagy reagensfelesleg a módszer hatékonyságát
csökkenti. 60 bar nyomáson, szobahőmérsékleten, 0,1 ml  perc–1
áramlás mellett 15 ekv propionaldehid-felesleg közel teljes hoza-
mot eredményezett, azonban az optimális értéket 5 ekv-ben ma-
ximáltuk. Ezután megvizsgáltuk a nyomás növelésének hatását
is (szobahőmérsékleten, 0,1 ml  perc–1 áramlási sebesség mellett).
Azt tapasztaltuk, hogy atmoszférikusról 60 barra növelve a nyo-
mást a termelés 80-ról 91%-ra nő, további emelés azonban ha-
tástalannak bizonyult (4. ábra). Felvetődik a kérdés, hogy a re-
akciót a katalizátor aktivitása mellett a reagensek katalizátor-
hordozó mátrixán belül történő transzportja korlátozhatja-e.
Hogy kijelenthessük: a reakció az általunk megadott körül-
mények között diffúziókontrollált, elvégeztük a Körös–Nowák-
tesztet [13]. Ehhez az amin-végződések acetilezésével az MBHA
gyanta töltöttségét megfeleztük, majd az így kapott 0,32
mmol  g–1 kapacitású gyantán immobilizáltuk a D-Pro-Pro-Asp-
NH2 peptidet (K1b). A tesztreakciót megismételve K1b-vel 78%-
os termelést kaptunk, míg ugyan ilyen körülmények között K1a-
val 91%-ot sikerült elérni. Mivel a termelés csökkenése nem ará-
nyos a katalizátortöltöttség csökkenésével, kijelenthető, hogy a
reakció az általunk szabott feltételek mellett diffúziókontrollált,
és a magas nyomás a reagensek transzportját hivatott elősegíte-
ni a katalizátorhordozó duzzadt mátrixán belül. A hőmérséklet
változtatásának hatásait vizsgálva arra a következtetésre jutot-
tunk, hogy nem érdemes szobahőmérséklet fölé növelni a reak-
tor hőmérsékletét, mert a termelés növekedése mellett draszti-
kus mértékben csökken a sztereoszelektivitás.
ginsav) [12]. E tripeptid prolinmimetikumnak tekinthető, ugyan-
is szekunder amin- és karboxil-funkciót tartalmaz speciális ori-
entációban (2. ábra). A katalitikus aktivitásért az említett funk-
ciós csoportok, a szelektivitásáért pedig elsősorban a peptid má-
sodlagos szerkezete felelős. A peptidet kezdetben 0,64 mmol  g–1
töltöttségű MBHA gyantán immobilizáltuk (K1a). Az oldószer
körültekintő kiválasztása fontos volt, ugyanis figyelembe kellett
vennünk a reagensek oldhatósága mellett a porózus szerkezetű
hordozó duzzadási tulajdonságait is. Mivel alapvetően mind a
kétféle gyanta apoláros oldószerekben duzzad jól, viszont a kiin-
dulási anyagok inkább poláros oldószerekben oldhatók, egy ol-
dószerelegyre, a CHCl3/iPrOH 9 : 1-re esett a választásunk. A re-
akcióparaméterek optimálásához a propionaldehid E-β-nitro-
sztirolra (BNS) történő konjugált addícióját választottuk tesztre-
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2. ábra. Szilárd hordozós peptidkatalizátorok
3. ábra. Az áramlási sebesség finomhangolása 
a propionaldehid BNS-re történő folyamatos áramú konjugált 
addíciója során
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H-D-Pro-Pro-Asp-NH-gyanta
H-D-Pro-(1R,2R)-ACPC-Asp-NH-gyanta
H-D-Pro-(1S,2R)-ACPC-Asp-NH-gyanta H-D-Pro-(1R,2S)-ACPC-Asp-NH-gyanta
H-D-Pro-(1S,2S)-ACPC-Asp-NH-gyanta
H-D-Pro-Pro-Glu-NH-gyanta
Az áramlásos reakció főbb paramétereinek optimálása után a
peptidkatalizátor szerkezeti finomhangolását is elvégeztük. Vizs-
gáltuk a C-terminális aszparginsav cseréjének hatását a vele ho-
mológ glutaminsavra (Glu). A H-D-Pro-Pro-Glu-NH2 peptidszek-
venciát 0,32 és 0,64 mmol  g–1 kapacitású MBHA gyantán is im-
mobilizáltuk (K2a és K2b). A propionaldehid és BNS tesztreak-
cióját az optimális körülményeken megismételve azt tapasztal-
tuk, hogy a glutaminsavat tartalmazó katalizátorok ugyan K1a-
val és K1b-vel összemérhető sztereoszelektivitást nyújtanak, vi-
szont katalitikus aktivitásuk kisebb, ugyanis alacsonyabb terme-
léseket értünk el velük (1. táblázat). Ezután izoszter-helyettesí-
téseket hajtottunk végre a katalizátor középső prolinrészének β-
aminosavakra történő cseréjével, majd vizsgáltuk a peptidkon-
formáció változásának katalitikus aktivitásra gyakorolt hatásait
[14]. Azt tapasztaltuk, hogy (1R,2R)-2-aminociklopentánkarbon-
savra (ACPC) történő csere (K3) gyakorlatilag K1a-val összemér-
hető eredményeket ad, azonban az (1S,2S)- (K4), (1S,2R)- (K5) és
(1R,2S)-ACPC (K6) izomerekkel történő helyettesítés esetén a ka-
talizátor aktivitása és/vagy szelektivitása jelentősen csökken (1.
táblázat). Ezek az eredmények azt bizonyítják, hogy hatékony ka-
talízishez a katalizátor aktív csoportjainak (szek-amin és karbo-
xil) megfelelő orientációja, és ezt biztosító peptidkonformáció
szükséges. A D-Pro-Pro-Asp-NH2 és D-Pro-Pro-Glu-NH2 peptid-
szekvenciákat 0,27 mmol  g–1 töltöttségű TentaGel gyantához
kötve is előállítottuk (K7 és K8). Mivel a TentaGel gyanta duzza-
dási tulajdonságai valamivel kedvezőtlenebbek, sőt a töltöttsége
is alacsonyabb, nem meglepő, hogy az MBHA hordozóhoz ké-
pest alacsonyabb termeléseket sikerült elérnünk (1. táblázat). Az
előállított peptidkatalizátorokat a 2. ábrán szemléltetjük.
Az optimális reakciókörülményeket az alábbiakban foglalhat-
juk össze: 0,1 ml  perc–1 áramlási sebesség, 5 ekv aldehidfeles-
leg, 60 bar nyomás, szobahőmérséklet, K1a katalizátor. Ezeket a
paramétereket alkalmazva a tesztreakció eredményéül (2S,3R)-2-
metil-4-nitro-3-fenilbutanalt 91%-os termelés, 11 : 1 dr és 93% ee
elérésével sikerült előállítanunk. Ezek az eredmények jó egyezést
mutatnak azokkal az irodalmi értékekkel, amelyeket hagyomá-
nyosan lombikban kevertetve hordozómentes H-D-Pro-Pro-Asp-
NH2 peptid katalizátor alkalmazásával értek el (2. táblázat) [12].
Fontos azonban hangsúlyozni, hogy esetünkben a katalizátor-
ágyon töltött tartózkodási idő, ami a reakcióidőnek felel meg,
mindössze 7 perc volt, ezzel szemben a hagyományos szakaszos
eljárás alkalmazásával 24 óra szükséges. A reakcióidő ilyen drasz-
tikus csökkenése az alkalmazott módszer előnyös tulajdonsága-
inak köszönhető: (i) áramlásos kémia, (ii) nagy nyomás és (iii)
magas lokális katalizátorkoncentráció.
Tanulmányoztuk az immobilizált katalizátor újrahasználható-
ságát is. Ezért az optimális körülményeken a tesztreakciót egy-
más után többször végrehajtottuk ugyanazon a katalizátortölte-
ten. Minden egyes reakció során 5 ml kiindulási elegyet pumpál-
tunk át a reaktoron 50 perc alatt. Az első öt reakció után a ter-
melés 80% fölött maradt, és a 10. újrahasználás után is még 70%
körül értékek adódtak (3. táblázat). A kísérletsorozat során az
ee gyakorlatilag nem változott, azonban a dr nőtt. Ez azzal ma-
gyarázható, hogy a D-prolin szek-amin-csoportja a katalizátor ak-
tív részét képezi, ugyanakkor a termék epimerizációját is okoz-
hatja. A katalizátor kimerülésével blokkolódnak ezek a funkciós
csoportok, azaz csökken az aktivitás, viszont epimerizáció sem
történik.
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4. ábra. A nyomásnövelés hatásának vizsgálata a propionaldehid
BNS-re történő folyamatos áramú konjugált addíciója során
Immobilizált katalizátor
Gyanta- Termelés/ dr ee/
töltöttség/ % %
mmol  g–1
K1a: H-D-Pro-Pro-Asp-NH-MBHA 0,64 91 11:1 93
K1b: H-D-Pro-Pro-Asp-NH-MBHA 0,32 78 11:1 92
K2a: H-D-Pro-Pro-Glu-NH-MBHA 0,64 79 12:1 91
K2b: H-D-Pro-Pro-Glu-NH-MBHA 0,32 69 11:1 91
K3: H-D-Pro-(1R,2R)-ACPC-Asp-NH-MBHA 0,64 83 10:1 90
K4: H-D-Pro-(1S,2S)-ACPC-Asp-NH-MBHA 0,64 41 15:1 93
K5: H-D-Pro-(1S,2R)-ACPC-Asp-NH-MBHA 0,64 70 9:1 70
K6: H-D-Pro-(1R,2S)-ACPC-Asp-NH-MBHA 0,64 35 19:1 89
K7: H-D-Pro-Pro-Asp-NH-TentaGel 0,27 81 11:1 92
K8: H-D-Pro-Pro-Glu-NH-TentaGel 0,27 73 12:1 91
1. táblázat. Az immobilizált peptidkatalizátor finomhangolása 
a propionaldehid BNS-re történő folyamatos áramú konjugált 
addíciója során
u
u
u
u
u
R Módszer Reakcióidő Termelés/% dr ee/%
Me áramlás 7 perc 91 11:1 93
batch ref. 24 óra 98 9:1 91
Et áramlás 7 perc 60 22:1 91
batch ref. 12 óra 93 25:1 95
nPr áramlás 7 perc 68 15:1 91
batch ref. 12 óra 94 15:1 92
nBu áramlás 7 perc 87 14:1 91
batch ref. 12 óra 99 15:1 92
Bn áramlás 7 perc 65 36:1 92
batch ref. 12 óra 89 15:1 95
iPr áramlás 7 perc 22 20:1 91
batch ref. 24 óra 88 50:1 92
2. táblázat. A kidolgozott folyamatos áramú módszer
felhasználhatóságának kiterjesztése és az eredmények 
összehasonlítása irodalmi batch referenciával [12]
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tók [12]. Jól látható, hogy az általunk folyamatos áramban elért
sztereoszelektivitások jó egyezésben vannak az irodalmi érté-
kekkel, bár a termelések rendszerint valamivel alacsonyabbak.
Azonban azt is figyelembe kell venni, hogy az általunk kidolgo-
zott módszer nagyon gyors, reakcióideje mindössze 7 perc, vi-
szont a hagyományos eljárás lassú, 12–24 órás kevertetést igé-
nyel.
Munkánkat röviden összefoglalva elmondható, hogy kidolgoz-
tuk az első folyamatos áramú módszert organokatalitikus 1,4-ad-
díciós reakciókhoz. Katalizátorként szilárd hordozóhoz kötött
peptidet alkalmaztunk, amelynek szintézise és immobilizációja
praktikusan egy lépésben történt. A módszer célszerűségét fo-
kozza, hogy a reakcióidőt sikerült jelentősen csökkentenünk a
hagyományos szakaszos eljáráshoz képest, továbbá, hogy az im-
mobilizált katalizátor újrahasználható. 
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A kidolgozott módszer alkalmazhatóságát kiterjesztettük szá-
mos további aldehid és BNS konjugált addíciójára. A reakciókat a
korábban optimalizált körülmények között hajtottuk végre, K1a
alkalmazásával. Elágazást nem tartalmazó aldehidek nagyon jó
reakciópartnernek bizonyultak, ugyanis a megfelelő γ-nitroalde-
hid termékeket magas hozam (60–91%), dr (11 : 1–36 : 1) és ee (91–
93%) elérésével állítottuk elő (2. táblázat). A β-elágazást tartal-
mazó izovaleraldehid esetében alacsonyabb termelést kaptunk,
viszont a sztereoszelektivitás magas volt. A 2. táblázatban saját
eredményeink mellett hagyományos batch referenciák is találha-
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Felhasználás Termelés/% dr ee/%
1. 91 11:1 93
2. 86 12:1 93
3. 84 12:1 94
4. 83 12:1 93
5. 82 13:1 93
6. 76 15:1 93
7. 74 15:1 93
8. 72 16:1 93
9. 67 15:1 94
10. 66 15:1 94
3. táblázat. Az immobilizált organokatalizátor 
újrahasználhatóságának vizsgálata
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Arany(I)tartalmú szupramolekulák 
szintézise és egykristály-röntgendiffrakciós
szerkezetmeghatározása
szupramolekuláris kémia még mindig fiatal területe a ké-
miának, amely a biológiából vett molekuláris önszerveződés
elvének felhasználásával a fizika, az elektronika, a kémiai tech-
nológia, a nanotechnológia számára potenciálisan hasznos anya-
gokat képes létrehozni. A szupramolekuláris kémia a nem kova-
lens kötések kémiája, és defíníció szerint ez a típusú kémia már
a „molekulákon túli” rendszerek kémiája. Éppen ezért nem vélet-
len, hogy a korszerű szupramolekuláris kémia csak a múlt század
nyolcvanas éveiben kezdett el kibontakozni, amikor a modern
szerkezetvizsgálati módszerek is rohamos fejlődésnek indultak
és alkalmazásukkal lehetővé vált a szupramolekulák szerkezet-
meghatározása. Az 1987-ben Donald J. Cram, Jean-Marie Lehn és
Charles J. Pedersen számára odaítélt kémiai Nobel-díj már a szup-
ramolekuláris kémia fontosságának az elismerését jelentette. [1] 
A lumineszcens, katalitikus, redoxaktív és/vagy biológiai szem-
pontból jelentős fémcentrumoknak a szupramolekulákba törté-
nő beépítésével változatos alakzatú és méretű, sokszor szokatlan
tulajdonságú rendszerek állíthatók elő. Az arany(I)tartalmú szup-
ramolekulák vizsgálatának részeként arra kerestük a választ,
hogy az arany(I)ionok és megfelelően megválasztott ligandumok
önszerveződési reakciója milyen egyedi szerkezetű és sajátságú
szupramolekulákat eredményez. A nagyméretű szupramolekulák
A
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A solid-supported peptide-catalyzed continuous-ﬂow (CF) process was developed for asymmetric aldol
reactions. The catalyst was readily synthesized and immobilized by solid-phase peptide synthesis (SPPS)
on a swellable polymer support in one single step. Ignoring the peptide cleavage from the resin means no
work-up, no puriﬁcation, and no product loss. After thorough optimization of the reaction conditions,
synthetically useful b-hydroxyketone products were obtained in high yields and stereoselectivities. It
was found that the heterogeneous catalytic reaction is diffusion-controlled under the present conditions;
thus, elevation of the pressure is necessary to maximize conversion of the ﬂow process. Besides being
simple and efﬁcient, the described method is also rapid and promisingly productive, with short residence
times on the catalyst bed. The immobilized peptidic catalyst is highly recyclable, while further advanta-
geous features are the ease of product isolation and the possibility of facile scale-up, furnishing sustain-
able catalytic methodology.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Asymmetric C–C bond formation has always been a cardinal sub-
ject in organic chemistry. Around the turn of the century, proline
(Pro) was introduced as a promising new catalyst for reactions
involving enamine intermediates [1–3]. In the golden age of asym-
metric catalysis, a hugenumberof Pro-derivedorganocatalystswere
developed that demonstrated enhanced catalytic activity and
selectivity [4–14]. Short peptides and peptide-like molecules (as
Promimetics) proved to be excellent catalysts for asymmetric trans-
formations [15–22]. Small, rigid catalysts offer only a limited num-
ber of sites for structural and functional diversity,whereas synthetic
peptides have the advantage of designable modularity as they are
made up from the same chiral building blocks (amino acid residues)
as enzymes [23,24]. The most reactive peptidic organocatalysts
developed to date for the aldol [25] and Michael [26,27] reactions
were reported by Wennemers et al. These tripeptides contain Pro
and carboxylic acid moieties in a speciﬁc orientation to each other
[28]. It has been shown that both the secondary amine residue and
the carboxyl group are crucial for effective catalysis [29,30], while
immobilization of the peptide on a solid support does not weaken
its effectivity, but ensures excellent ease of use, and catalyst reus-
ability [31,32].ll rights reserved.
p).CF technologies have captured attention in modern synthetic
chemistry as they offer a massive number of advantages over con-
ventional batch procedures, for example, the efﬁcient mixing of
substrates, faster heat and mass transfer, and shorter reaction
times [33–39]. The well-regulated CF reactor concept enables reac-
tions to be performed with an unprecedented level of control. The
most important reaction parameters (such as ﬂow rate, pressure,
and temperature) can be adjusted and monitored quickly and pre-
cisely [35,40–43]. The need for the large-scale use of reagents and
solvents is eliminated, so that the screening of reaction conditions
becomes simple and time- and cost-efﬁcient, which implies even
rapid library synthesis and an opportunity for automatization
[44–47]. Heterogenizing homogeneous catalysts on a solid support
is a trend toward the increase in the efﬁciency of synthetic tech-
niques [48–51]. Through the incorporation of immobilized cata-
lysts and reagents, the scope of ﬂow chemical processes can be
further broadened [52–62]. In consequence of these beneﬁts, the
conversion of laboratory-based ﬂow chemistry experiments to
the subsequent production scale is straightforward [63,64].
A literature search reveals the thought-provoking ﬁnding that
aldol reactions in standard batch mode involving the use of
peptides or other Pro mimetics as catalysts usually demand many
hours or even days if high yields and high stereoselectivities are to
be attained (Table S1, see Supporting information). In the last few
years, several CF approaches have also been described for organo-
catalytic aldol reactions; but in most cases, these have a number of
180 S.B. Ötvös et al. / Journal of Catalysis 295 (2012) 179–185drawbacks such as (i) long process times [65], (ii) difﬁculties of
product isolation [66], and (iii) lower conversions [67] that limit
their practical applicability yet. It must be noted here that, around
the ﬁnal stage of the preparation of this manuscript, Pericas et al.
reported a promising CF method for aldol reactions with an immo-
bilized proline derivative as organocatalyst [68].
With the aim of creating a more sustainable and industrially
reliable catalytic procedure for stereoselective aldol reactions, we
have developed a simple and efﬁcient CF method in which a
solid-supported peptide is utilized as chiral organocatalyst. The de-
scribed technique permits outstanding catalyst reusability, ease of
product isolation, and the opportunity of facile scale-up. Reaction
condition optimization led to high yields, stereoselectivities, and
productivities. Short residence times were utilized on the catalyst
bed, this being the fastest CF technique to date to the best of our
knowledge.2. Experimental
2.1. General information
The materials and reagents used were of the highest commer-
cially available grade andwere appliedwithout any further puriﬁca-
tion steps. Flash column chromatography was performed on Merck
silica gel 60, particle size 63–200 lm, and analytical thin-layer
chromatography (TLC) onMerck silica gel 60 F254 plates. Compounds
were visualized by means of UV or KMnO4. 1H NMR and 13C NMR
spectra were recorded on a Bruker Avance DRX 400 spectrometer,
in CDCl3 as solvent, with TMS as internal standard, at 400.1 and
100.6 MHz, respectively.MSanalysiswas carriedoutwithanAgilent
1100 LC/MSD Trap. HPLC analyzes were performed on an analytical
HPLC with a diode array detector from JASCO. An H-Cube system
was utilized as CF reactor.2.2. Synthesis of catalysts
The peptidic catalysts were synthetized manually by a
solid-phase technique, utilizing 9H-ﬂuoren-9-ylmethoxycarbonyl/
tert-butyl (Fmoc/tBu) chemistry on two solid supports: polyethyl-
ene glycol (PEG)–polystyrene (PS) copolymer without any linker
(TentaGel, with a loading of 0.27 mmol g1), and PS resin with a 4-
methylbenzhydrylamine linker (PS-MBHA, with a loading of
0.64 mmol g1) (Fig. 1).WhenTentaGel resinwasutilized, thewhole
peptide synthesis procedure was carried out in DMF; for PS-MBHA,
DMF/CH2Cl2 1:1was used as solvent. Before any synthetic steps, theFig. 1. Solid supports utilized in this study for catalyst immobilization: (a)
TentaGel, (b) PS-MBHA.resin was swollen by agitation for 1 h in the applied solvent. In the
case of PS-MBHA, further treatment with 5% N,N-diisopropylethyl-
amine (DIEA) solution was necessary to liberate the amino function
from the HCl salt form. DIEA (6 eq) was added to a solution of Fmoc-
protected amino acid (3 eq) and 1-[bis-(dimethylamino)meth-
yliumyl]-1H-1,2,3-triazolo[4,5-b]pyridine-3-oxide (HATU, 3 eq).
The activated amino acid was then added to the amino-functional-
ized resin, and the mixture was agitated for 3 h. After coupling, the
resin was washed (CH2Cl2 3, MeOH 2, CH2Cl2 3), and the amino
acid incorporation was checked bymeans of the Kaiser or isatin test
[69,70]. Fmoc deprotection was carried out in a solution of 2% 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) and2%piperidinewith agita-
tion for 2  15 min. After ﬁltration, the resin was washed, and the
coupling and deprotection steps were repeated. Finally, the tBu
side-chain protecting group was removed from the aspartic acid
(Asp) residue in a mixture of triﬂuoroacetic acid (TFA) and H2O
(9:1 v/v) at room temperature (RT) for 3 h (Scheme 1). After removal
of TFA in vacuo, the resinwaswashed thoroughly (CH2Cl2 6, MeOH
5, CH2Cl2 6) and was then kept at RT for 6 h to dry. The immobi-
lized catalyst was utilized as TFA salts after the SPPS.2.3. Analysis of catalysts
The structure of the TentaGel-immobilized catalysts was
checked by means of suspension-phase 13C NMR measurements.
In the case of PS-MBHA-immobilized catalysts, the swelling prop-
erties of the resin made suspension-phase NMR unfeasible. MS
and RP-HPLC investigations were therefore carried out after cleav-
age from the resin in a mixture of thioanisole, 1,2-ethanedithiol
(EDT), TFA, and triﬂuoromethanesulfonic acid (TFMSA) (2:1:20:2
v/v/v/v) for 0.5 h at 10 C and then at RT for 1.5 h. The peptide
was next precipitated by the addition of cold Et2O, collected by ﬁl-
tration and dissolved in TFA. After reduction of the TFA volume to
1 mL by evaporation, the peptide was precipitated with Et2O, col-
lected by ﬁltration, dissolved in 10% AcOH and lyophilized. The de-
tailed analytical data are presented in Supporting information.
2.4. CF methodology
Flow experiments were performed in a dedicated high-pressure
CF reactor with a ﬁxed catalyst bed (H-Cube, operated in ‘‘no H2’’
mode). For the experiments 300 mg of the solid-supported peptide
was incorporated into a replaceable stainless steel cartridge with
internal dimensions of 70  4 mm. The ﬁlled cartridge was placed
into a stainless steel block, which contains a Peltier heating system
that can be heated to 100 C. A back pressure valve was built in to
ensure constant pressures up to 100 bar. The reaction mixture was
pumped through the cartridge by means of an HPLC pump (Knauer
WellChrom HPLC-pump K-120) at ﬂow rates of 0.01–1.0 mL min1.
This experimental setup allowed the systematical adjustment of
the most important reaction parameters such as catalyst type,
pressure, temperature, and ﬂow rate in order to determine the
optimal conditions. A brief outline of the CF catalytic system is pre-
sented in Scheme 2 [71].
2.5. General aspects of the preparation of aldol products in CF
For the CF method development, 20 mg (0.13 mmol, 1 eq)
p-nitrobenzaldehyde (pNBA) and 0.9 mg (0.013 mmol, 0.1 eq)
imidazole were dissolved in 5 mL acetone. The solution was
homogenized by sonication for 3 min and was then pumped
through the CF reactor under the appropriate conditions. The com-
pletion of the reaction was checked by TLC with a mixture of n-
hexane/EtOAc as eluent. The crude aldol products were evaporated
and then, if necessary, puriﬁed by column chromatography with a
Scheme 1. Synthesis of the heterogeneous catalyst H-Pro-Pro-Asp-NH-resin.
Scheme 2. A brief outline of the CF organocatalytic procedure.
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characterized by NMR spectroscopy and chiral NP-HPLC. The
detailed analytical data can be found in Supporting information.
Between two reactions in the CF reactor, the catalyst bed was
washed for 10 min with acetone at 1 mL min1.2.6. Measurement of the residence time on the catalyst bed
The residence time on the catalyst bed was determined by
pumping an acetone solution of ink through the system and
measuring the time that elapsed between the ﬁrst contact of the
182 S.B. Ötvös et al. / Journal of Catalysis 295 (2012) 179–185dye with the resin and the moment when a blue color appeared at
the column output.Fig. 3. Fine-tuning of the concentration of pNBA in the CF test reaction.3. Results and discussion
3.1. Catalyst synthesis and immobilization
Employing a peptide as catalyst was the best possible choice as
the catalyst synthesis and the immobilization can easily be
combined in SPPS, therebyeliminating theneed for further synthetic
steps, and it offers thehighest structural diversity. After the coupling
steps, the deprotection of the carboxyl side chain was carried with-
out cleavage of the peptide, as non-TFA-labile resins were used as
support for the SPPS, which served further on as catalyst carrier
(Fig. 1 and Scheme1). This experimental setup is simple and reason-
ably economical, as there is no need for the time-consumingpeptide
work-up and puriﬁcation steps. After thoroughwashing of the resin,
the heterogenized organocatalyst was ready to use in CF. Currently,
the most effective peptidic organocatalyst for aldol reactions is the
tripeptide H-Pro-Pro-Asp-NH2 [25], and we therefore chose this
catalyst initially for CF method development.
3.2. Optimization of the reaction conditions
For optimization of the initial reaction conditions, the aldol reac-
tion between pNBA and acetone was chosen as test reaction, with
imidazole as base to prevent the formation of elimination side prod-
uct. Acetone served not only as reagent, but also as solvent. As con-
cerns the catalyst accessibility, appropriate swelling of the solid
support is a crucial factor. In polar solvents, TentaGel resin swells
better than PS-MBHA [72]; hence, the H-Pro-Pro-Asp-NH-resin cat-
alyst was initially synthetized on TentaGel (catalyst 1) (Fig. 2). For
rapid ﬁne-tuning of the aldehyde concentration in the reactionmix-
ture, an initially high ﬂow rate of 0.5 mL min1, RT and atmospheric
pressurewere applied. This quick screening indicated that the lower
the amount of aldehyde in the reactionmixture, the higher the con-
version (Fig. 3). A concentration of 4 mg mL1 seemed to be a good
compromise between conversion and productivity.
There are a number of examples in the literature where eleva-
tion of the pressure in organocatalytic procedures led to increasedFig. 2. Heterogeneous peptidic catalysts.conversion and selectivity [73–76]. Hence, we also investigated the
pressure dependence of the aldol reaction. Even at atmospheric
pressure (caldehyde = 4 mg mL1; ﬂow rate = 0.5 mL min1; RT), a
conversion of >70% and an ee of 80% could be achieved, but in-
crease in the pressure resulted in still higher conversions up to
an optimal 60 bar (Fig. 4). Further elevation to 100 bar was not
beneﬁcial, and the conversion remains steady at around 80%. (It
is noteworthy that ee was not dependent on the pressure.) This
phenomenon raises the question of whether the conversion is
dependent on the catalyst activity itself or is inﬂuenced by the
transport phenomena of the reactants in the matrix of the polymer.
To probe the diffusion dependence, the Koros–Nowak test was per-
formed [77,78]. When the catalyst loading in the cartridge was
halved by simply using a mixture of 150 mg blank TentaGel resin
and 150 mg catalyst 1, the conversion of the same reaction de-
creased from 81% to 52%. The fall in the conversion is not propor-
tional to the loading decrease. Consequently, the reaction is
diffusion-controlled, and the effect of the elevated pressure is
equivalent to an increase in the surface area of the catalyst.
To improve the conversion further, we tried elevating the tem-
perature. It emerged that heating led to higher conversions, but
also dramatically lowered ee. For example, at 80 C, 60 bar and a
ﬂow rate of 0.5 mL min1, the conversion was nearly quantitative,Fig. 4. Investigation of the pressure dependence of the test aldol reaction in CF.
Fig. 5. Investigation of the temperature dependence of the test aldol reaction in CF.
Fig. 6. Fine-tuning of the ﬂow rate in the test CF reaction.
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temperature.
In further parameter screening, the aim was to make the
procedure efﬁcient whilemaintaining high conversion and selectiv-
ity. Under the previously optimized reaction conditions, the ﬂow
rate was also ﬁne-tuned for optimization of the residence time on
the catalyst bed; the longer the residence time, the higher the
conversion. When the ﬂow rate was reduced to the optimal
0.1 mL min1, the residence timewas long enough to achieve quan-
titative conversion and 80% ee. Even at 1 mL min1, the conversion
was still nearly 60% (Fig. 6). It is worth mentioning that the ee was
not dependent on the ﬂow rate.
For additional optimization, the peptidic catalyst too was
ﬁne-tuned. As a solid support of the H-Pro-Pro-Asp-NH-resin, PS-
MBHA (catalyst 2) was tested under the previously optimized con-
ditions. Its poorer swelling properties in acetone resulted in lower
conversion and ee than with catalyst 1 (Table 1, entry 4). H-D-Pro-
Pro-Asp-NH2 is an effective catalyst for the 1,4-addition of alde-
hydes to nitrooleﬁns [26]. We were interested in its efﬁciency in al-
dol reactions and tested the effect of replacement of the N-terminal
L-Pro by D-Pro. H-D-Pro-Pro-Asp-NH-resin was synthetized on Ten-
taGel (catalyst 3) and also on PS-MBHA (catalyst 4) as solid sup-
port, but in both cases, the conversion and ee were dramatically
less than with catalyst 1 (Table 1, entries 5 and 6). The structures
of the utilized catalysts are depicted in Fig. 2.
3.3. Results of the test reaction and comparison with the batch data
Under the overall optimized reaction conditions, with catalyst
1, the corresponding b-hydroxyketone product of the test reaction
was obtained in a yield of >99% with 80% ee (Table 1, entry 2).When the reaction was performed at 4 C instead of RT, ee in-
creased to 85%, while the isolated yield was still around 90% (Table
1, entry 3). It is noteworthy that no self-aldol or H2O-eliminated
side product was observed at all. At the optimal ﬂow rate of
0.1 mL min1, the residence time on the catalyst bed was only
6 min, and it took 50 min to pump through a 5-mL aliquot of the
reaction mixture, leading to around 27.5 mg crude product. When
the same solid-supported catalyst was used for the aldol reaction
between pNBA and acetone in a simple ﬂask, a reaction time of
6 h was needed for completion (Table 1, entry 1), and a somewhat
lower yield and ee were achieved than in CF [32]. When other Pro-
derived organocatalysts were employed in batch, the reaction
times were even longer (Table S1, entries 1–14). It must be noted
here that literature batch reactions were usually carried out in a
larger volume than in our small-scale test experiments, but scaling
up in CF is straightforward through extension of the reactor size.
On collection of the solution of the crude product material, no
work-up or puriﬁcation steps were needed, which further
enhances the efﬁcacy of the described method. These promising
results are due to the beneﬁcial features of the utilized technique:
the application of CF, the swellable polymer-supported peptidic
catalyst, and the high local catalyst concentration in the catalyst
bed and the high pressure.3.4. Testing of the catalyst reusability
The efﬁcacy of a reaction mediated by a solid-supported cata-
lyst may be characterized by the degree of reusability of the cata-
lyst. Accordingly, the test aldol reaction between pNBA and
acetone was repeated under the optimized reaction conditions,
the same portion of catalyst 1 loaded in the cartridge being recy-
cled. It was found that after the 20th consecutive experiment,
the conversion was still quantitative and ee was 80%, just as in
the ﬁrst reaction (Table 2). In each run, a 5-mL aliquot of the reac-
tion mixture was pumped through the system in 50 min, leading to
around 27.5 mg crude product without further puriﬁcation. When
all of the test reactions involved in the catalyst recycling study
were taken into account, the ﬁnding was that, after nearly 17 h
of persistent use under optimal ﬂow conditions, the immobilized
peptidic catalyst was still as active as initially. The described CF
technique is therefore prominently robust. In order to determine
the turnover number (TON) of the immobilized catalyst, the exper-
iment was run further after the recycling study, utilizing the same
Table 3
Investigation of the scope and applicability of the CF organocatalytic procedure under
the overall optimized reaction conditions.
Ar Ar
OOHO
SH
acetone
0.1 mL min-1; 60 bar, RT
0.1 eq imidazole
catalyst 1
4 mg mL-1
Entry Ara Productivityb Conv. (%)c Yield (%)d ee (%)e
1 p-NO2C6H4 1.96 Quant. >99 80
2 o-NO2C6H4 1.96 Quant. >99 79
3 p-NCC6H4 2.26 Quant. >99 74
4 o-ClC6H4 2.11 Quant. >99 79
5 m-ClC6H4 1.50 78 71 (5)f 76
6 p-ClC6H4 1.48 80 70 (7)f 78
7 p-BrC6H4 1.09 76 68 (6)f 80
8 p-FC6H4 2.05 Quant. 86 (13)f 79
9 o-MeOC6H4 0.81 39 37 76
10 C6H5 1.65 76 59 (13)f 70
11 2-Naphthyl 0.57 37 30 (5)f 75
12 1-Naphthyl 0.51 35 27 (4)f 71
a A 5-mL aliquot of the solution of the starting material was pumped through in
50 min.
b In mmol of pure isolated product (mmol1resin h
1).
c Determined by 1H NMR spectroscopic analysis of the crude material.
Table 1
Fine-tuning of the catalyst for the aldol reaction between pNBA and acetone under the optimized ﬂow conditions, and comparison of the CF results with a batch reference from
the literature.
OOH
O
O2N
S
H
O2N
acetone
0.1 mL min-1; 60 bar
immobilized catalyst
0.1 eq imidazole
4 mg mL-1
Entry Process Catalyst T (C) Time (min)a Conv. (%)b Yield (%)c ee (%)d
1e Batch 1 RT 360 n.d. 94 78
2 CF 1 RT 6 Quant. >99 80
3 CF 1 4 6 90 89 85
4 CF 2 RT 6 71 68 62
5 CF 3 RT 6 29 27 –26f
6 CF 4 RT 6 19 16 –18f
a Reaction time of the batch experiment, residence time of the CF reactions.
b Determined by 1H NMR spectroscopic analysis of the crude material.
c Yield of isolated product.
d Determined by chiral-phase HPLC analysis.
e Batch reference from the literature [32].
f Absolute conﬁguration of the resulting b-hydroxyketone inverted to R.
Table 2
Testing of the reusability of catalyst 1 in CF under optimal conditions.
OOH
O
O2N
S
H
O2N
acetone
0.1 mL min-1; 60 bar , RT
0.1 eq imidazole
catalyst 1
4 mg mL-1
Entry Cycle Conv. (%)a Yield (%)b ee (%)c
1 1–5 98-quant. 97–>99 79–80
2 6–10 Quant. 97–>99 78–81
3 11–15 Quant. >99 79–80
4 16–20 99-quant. 98–>99 79–80
a Determined by 1H NMR spectroscopic analysis of the crude material.
b Yield of isolated product.
c Determined by chiral-phase HPLC analysis.
184 S.B. Ötvös et al. / Journal of Catalysis 295 (2012) 179–185portion of resin and the optimized CF conditions, with continuous
pumping-through of a 4 mg mL1 solution of pNBA and 0.1 eq
imidazole in acetone [79]. The CF conditions resulted in a TON of
710 [80], whereas the TON calculated from the batch data was
472 [32].d Yield of isolated product.
e Determined by chiral-phase HPLC analysis.
f Yield of the corresponding dehydration product.3.5. Investigation of the scope and applicability of the method
In order to verify the scope and applicability of the described CF
method, a number of further aldol reactions between various aro-
matic aldehydes and acetone were carried out under the optimized
conditions with catalyst 1. The data in Table 3 (entries 1–8) dem-
onstrate that, for aldehydes with an electron-withdrawing group
on the aromatic ring, good or excellent yields (68–>99%) and high
ee (75–80%) were obtained. When the conversion was quantitative,
no further work-up or puriﬁcation steps were needed (Table 3, en-
tries 1–4). The yield increased with the electron-withdrawing
capability of the substituting residue and was dependent on the
position of the electron-withdrawing group: in the aldol reaction
between o-chlorobenzaldehyde and acetone, the yield was >99%,
but for m- and p-chlorobenzaldehyde, it was lower. Aldehydes
bearing an electron-donating substituent on the aromatic ring or
no substituent at all proved to be weaker reaction partners in the
aldol reaction with acetone. Lower yields (27–59%), but still highee (70–76%), were obtained. No side reaction of self-aldol product
formation occurred, but in several cases, H2O elimination from
the resulting b-hydroxyketone was observed. These yield and ee
values are competitive with those of the standard batch procedures
(for comparison, a number of batch references are listed in
Table S1), and the productivities were excellent in almost all cases
(Table 3).4. Conclusions
We have developed a heterogeneous catalytic CF method for
asymmetric aldol reactions utilizing a solid-supported peptide as
organocatalyst. The peptide was synthetized by SPPS and immobi-
lized in the same step. The lack of peptide cleavage has the results
S.B. Ötvös et al. / Journal of Catalysis 295 (2012) 179–185 185that no work-up and no puriﬁcation are necessary, and there is no
product loss. After optimization of the reaction conditions and the
peptidic catalyst, b-hydroxyketone products were obtained in high
yields and stereoselectivities comparable with literature batch
results. The residence time on the catalyst bed was as low as
6 min and, due to further beneﬁcial features of the technique,
promisingly high productivities were achieved. The peptidic
catalyst is highly recyclable, so that the procedure is exceedingly
robust, while the ease of product isolation and the possibility of
facile scale-up further enhance the efﬁcacy of the described
method. Heterogeneous catalysis is therefore a useful tool for
broadening the scope of ﬂow chemistry.
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Alkyne–Azide Cycloadditions with Copper Powder in a High-Pressure
Continuous-Flow Reactor: High-Temperature Conditions versus the Role of
Additives
Sndor B. tvçs, Istvn M. Mndity, Lrnd Kiss, and Ferenc Flçp*[a]
Introduction
The Huisgen 1,3-dipolar cycloaddition reaction of organic
azides with acetylenes is a simple route to useful 1,2,3-tria-
zoles.[1] Following thermal induction, this reaction results in
an approximate 1:1 mixture of 1,4- and 1,5-disubstituted tri-
azole isomers.[2] Owing to the pioneering work of Sharpless
and co-workers[3] and Meldal and co-workers[4] on copper
catalysis, the Huisgen reaction has captured enormous inter-
est in the field of synthetic chemistry. In contrast with the
thermal route, the CuI-catalyzed azide–alkyne cycloaddition
(CuAAC) reaction is regioselective, thereby exclusively
giving the 1,4-regioisomer within a short reaction time
(Scheme 1). The selective formation of 1,5-disubstituted
1,2,3-triazoles through ruthenium catalysis has also been de-
scribed,[5] but the broad applicability, reliability, and efficien-
cy of CuAAC has led to it becoming the standard of the
“click chemistry” concept. Applications of CuAAC can in-
creasingly be found in many areas of modern chemistry,
such as polymer and materials sciences,[6] supramolecular
chemistry,[7] bioconjugation,[8] and combinatorial chemistry.[9]
The CuAAC reaction is also significant from the viewpoint
of drug discovery,[10] because 1,2,3-triazoles possess a wide
range of biological properties, such as antiviral (1),[11] anti-
bacterial (2),[12] antifungal (3),[13] and anticancer activities (4 ;
Scheme 2).[14] The 1,2,3-triazole moiety is extensively used in
medicinal chemistry as a pharmacophore to modify known
bioactive molecules and to potentiate their biological activi-
ties. For example, the 1,2,3-triazole analogues of antiviral
agent zanamivir (5)[15] and the well-known bioactive carba-
nucleoside neplanocin A (6) exhibit notable antiviral activity
(Scheme 2).[16]
Flow-chemistry techniques are currently enjoying an up-
surge in interest because they offer great advantages over
traditional batch-based synthetic procedures.[17] The well-
regulated continuous-flow (CF) reactor concept allows the
efficient mixing of substrates and faster heat and mass trans-
fer,[18] so that reactions can be performed with an unprece-
dented level of control within short reaction times.[19] Be-
Abstract: A safe and efficient flow-
chemistry-based procedure is presented
for 1,3-dipolar cycloaddition reactions
between organic azides and acetylenes.
This simple and inexpensive technique
eliminates the need for costly special
apparatus and utilizes Cu powder as
a plausible CuI source. To maximize
the reaction rates, high-pressure/high-
temperature conditions are utilized; al-
ternatively, the harsh reaction condi-
tions can be moderated at room tem-
perature by the joint application of
basic and acidic additives. A compari-
son of the performance of these two
approaches in a series of model reac-
tions has resulted in the formation of
useful 1,4-disubstituted 1,2,3-triazoles
in excellent yields. The risks that are
associated with the handling of azides
are lowered, thanks to the benefits of
flow processing, and gram-scale pro-
duction has been safely implemented.
The synthetic capability of this continu-
ous-flow technique is demonstrated by
the efficient syntheses of some highly
functionalized derivatives of the anti-
fungal cispentacin.
Keywords: alkynes · azides · click
chemistry · continuous-flow reac-
tors · copper
[a] S. B. tvçs, Dr. I. M. Mndity, Dr. L. Kiss, Prof. Dr. F. Flçp
Institute of Pharmaceutical Chemistry
University of Szeged
H-6720 Szeged, Eçtvçs u. 6 (Hungary)
Fax: (+36)62-545-705
E-mail : fulop@pharm.u-szeged.hu
Supporting information for this article is available on the WWW
under http://dx.doi.org/10.1002/asia.201201125.
Scheme 1. 1,3-Dipolar cycloaddition reactions between organic azides
and acetylenes, which result in disubstituted triazoles.
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cause the need for the large-scale use of reagents and sol-
vents is eliminated, the screening of the reaction conditions
becomes simple, time- and cost-efficient, and safe.[20] These
benefits facilitate rapid library synthesis and afford an op-
portunity for automatization and excellent transferability
between laboratory-based investigations and subsequent
production scales.[21]
A number of CF strategies for CuAAC reactions have
been reported. The most popular sources of CuI for CF
methods are heterogeneous approaches that employ copper-
in-charcoal (Cu/C),[22] immobilized CuI species,[23] or copper
flow-reactor technology without extraneous CuI salts,[24] etc.
In contrast, Hessel and co-workers recently reported an effi-
cient homogeneous approach for CF CuAAC reactions, by
using [Cu ACHTUNGTRENNUNG(phen) ACHTUNGTRENNUNG(PPh3)2]NO3 as a catalyst.
[25]
To improve the practical applicability of CF CuAAC pro-
cedures, we set out to develop a simple and inexpensive
technique that could eliminate the need for costly apparatus
or special catalyst types, whilst at the same time being safe
and efficient. Thus, we used Cu powder as the cheapest
available source of CuI and exploited the merits of flow
processing by increasing the reaction rates with high-pres-
sure/high-temperature conditions; we were subsequently
able to moderate these harsh reaction conditions through
the use of both basic and acidic additives at room tempera-
ture. The results that were obtained by using these two
methods were compared for a series of model CuAAC reac-
tions. The risks that are associated with the handling of ex-
plosive azides were minimized as a consequence of the ben-
eficial features of CF technology. We also applied this
method to the synthesis of highly functionalized derivatives
of the antifungal cispentacin, (1R,2S)-2-aminocyclopentane-
carboxylic acid, which is an interesting precursor for new tri-
azole carbanucleosides. Scale-up experiments were also per-
formed, thus achieving gram-scale syntheses.
Results and Discussion
Method
The CF experiments were performed in a dedicated high-
pressure/high-temperature reactor (H-Cube, operated in “no
H2” mode) that consisted of a replaceable stainless steel car-
tridge (internal dimensions: 70 mm4 mm) as a catalyst
bed, a Peltier heating system to heat the cartridge up to
100 8C, and a pressure-control unit to ensure constant pres-
sures of up to 100 bar (Figure 1).[26] The reaction mixture
was pumped through the cartridge by using a HPLC pump
(Knauer WellChrom HPLC-pump K-120). The experimental
setup allowed the safe application of high-pressure/high-
temperature conditions for unstable reactants, such as
azides, without the potential hazard of an explosion, because
only limited amounts of the reactants were exposed to the
zone of harsh reaction conditions and, even then, only for
a safely controllable, short amount of time. Fine-tuning of
the most important reaction parameters, such as pressure,
temperature, and flow rate, is simple and efficient, thus
making the whole screening process promisingly rapid.
Cu powder was utilized as a simple and cheap source of
CuI. When exposed to air, Cu metal undergoes constant oxi-
dation, with the formation of non-self-protecting layers of
different Cu oxides, such as Cu2O.
[27] Thus, Cu powder can
be regarded as a “supported” CuI catalyst. Accordingly, if
the oxide layers are removed from the Cu surface, the cata-
lytic activity decreases significantly.[22b] For the flow experi-
ments, Cu powder (900 mg) with an average particle size of
about 200 mm was incorporated into the catalyst cartridge.
Optimization of the Reaction Conditions
To achieve the maximum conversion within the shortest pos-
sible process time, the most important reaction conditions
(pressure, temperature, flow rate, and additives) were sys-
tematically fine-tuned. For the optimization studies, the 1,3-
dipolar cycloaddition reaction between benzyl azide and
phenylacetylene was chosen as a test reaction (Scheme 3).
Figure 1. Experimental setup for the CF CuAAC procedure.
Scheme 2. Some examples of bioactive 1,2,3-triazoles.
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On the basis of literature data, CH2Cl2 was used as the sol-
vent.[28] To achieve maximum productivity, we planned to
apply the highest possible azide concentration and 0.085m
was found to be the most appropriate: Higher concentra-
tions led to the precipitation of the triazole product in the
CF reactor. In small-scale test experiments, aliquots
(2.5 mL) of a reaction mixture that contained 1 equivalent
of benzyl azide and 1.5 equivalents of phenylacetylene were
pumped through the system in each run.
First, we set out to maximize the rate of the test reaction
under high-pressure/high-temperature conditions. Thus, the
pressure was increased from atmospheric pressure to
100 bar, whilst the temperature and flow rate were kept con-
stant at room temperature and 0.5 mLmin1, respectively.
At atmospheric pressure, a conversion of only 20% could
be achieved and the pressure had to be increased to
>80 bar to obtain higher conversion (Figure 2). At 100 bar,
a conversion of 34% was achieved, which was taken as the
optimal value. Elevation of the pressure not only increased
the rate of triazole production, in accordance with Le Cha-
telier’s principle, but also allowed the use of higher tempera-
tures without the solvent boiling over. In this way, the
system could be heated to well above the boiling point of
CH2Cl2, whilst the pressure and flow rate were maintained
at 100 bar and 0.5 mLmin1, respectively. Figure 3 shows
that the conversion started to increase sharply at about
40 8C; at 50 8C, the conversion exceeded 90% and, at 100 8C,
practically quantitative conversion was obtained.
The fine-tuning of the flow rate is related to the optimiza-
tion of the residence time on the catalyst bed. Longer resi-
dence times lead to higher conversions, but also involve
longer process times. Because quantitative conversion was
obtained under the previously optimized conditions
(100 bar, 100 8C) at a flow rate of 0.5 mLmin1, it was un-
necessary to decrease the flow rate. However, when we at-
tempted to decrease the residence time on the catalyst bed
by increasing the flow rate, we found that the conversion de-
creased dramatically. For example, at a flow rate of
1 mLmin1, the conversion was only 31% and, when the
flow rate was increased to as high as 3 mLmin1, the conver-
sion fell sharply to about 10% (Figure 4).
It is well-known that the application of amines as basic
additives can boost the reactivity of the CuAAC reaction
considerably.[29] The amine serves as a ligand to liberate the
catalytically active CuI species from its matrix by coordinat-
ing to it and accelerating the formation of a distinct Cu
alkyne complex (Scheme 4).[3,28, 30] It was recently demon-
strated that catalytic amounts of certain acids could further
improve the rate of the reaction through acceleration of the
conversion of intermediates that contained CCu bonds by
protonation (Scheme 4).[28,31] With the aim of moderating
the harsh reaction conditions, we set out to check the effects
of both basic and acidic additives on the rate of the test
CuAAC reaction at room temperature. On the basis of liter-
ature data, N,N-diisopropylethylamine (DIEA) and HOAc
were chosen as the basic and acidic additives, respective-
ly.[28,31] With no additives, at 100 bar, room temperature, and
Scheme 3. 1,3-Dipolar cycloaddition reaction between benzyl azide and
phenylacetylene as a test reaction for optimization of the CF reaction
conditions.
Figure 2. Investigation of the pressure dependence of the test reaction be-
tween benzyl azide and phenylacetylene under CF: ~ room temperature,
flow rate: 0.5 mLmin1, no additives; & room temperature, flow rate:
0.5 mLmin1, DIEA (0.04 equiv)+HOAc (0.04 equiv).
Figure 3. Investigation of the temperature dependence of the test reac-
tion at 100 bar between benzyl azide and phenylacetylene in CF (flow
rate: 0.5 mLmin1) without any additives.
Figure 4. Fine-tuning of the flow rate in the test reaction between benzyl
azide and phenylacetylene under high-pressure/high-temperature and
high-pressure/RT conditions with additives in CF: ~ 100 bar, 100 8C, no
additives; & 100 bar, room temperature, DIEA (0.04 equiv)+HOAc
(0.04 equiv).
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a flow rate of 0.5 mLmin1, a conversion of 34% could be
achieved (Table 1, entry 1). Upon the addition of 0.1 equiva-
lents of HOAc, with maintenance of the same pressure, tem-
perature, and flow rate, the conversion improved to 56%
(Table 1, entry 2) and, when 0.1 equivalents of DIEA were
used, the conversion rose further to 96% (Table 1, entry 3).
The best result was obtained with both additives together:
With DIEA (0.1 equiv)+HOAc (0.1 equiv), the reaction
proceeded quantitatively (Table 1, entry 4). Next, we exam-
ined the effect of the amount of DIEA+HOAc on the reac-
tion rate. The addition of 0.04 equivalents of each additive
was sufficient to obtain quantitative conversion (Table 1, en-
tries 5 and 6); however, lower amounts gave lower conver-
sions (Table 1, entries 7 and 8). The pressure dependence of
the reaction with the use of additives was also investigated.
We found that lowering the pressure from 100 bar to atmos-
pheric pressure led to a moderate decrease in conversion
(Figure 2). Consequently, elevated pressure is needed to
obtain good conversions. When the flow rate was increased,
to decrease the residence time on the catalyst bed, at
100 bar and room temperature, with DIEA (0.04 equi-
v)+HOAc (0.04 equiv), we found that the drop in the con-
version was not as steep as under the high-pressure/high-
temperature conditions (Figure 4). This result means that
the joint use of basic and acidic additives can successfully
relive the harsh reaction conditions and appreciably enhance
the efficiency of the flow process.
As a result of this screening process, we selected two dis-
tinct parameter sets as our optimal conditions: 1) 100 bar,
100 8C, flow rate: 0.5 mLmin1, without any additives (con-
ditions CFA) and 2) 100 bar, room temperature, flow rate:
0.5 mLmin1, with DIEA (0.04 equiv)+HOAc (0.04 equiv)
(conditions CF B). Both sets of conditions afforded quanti-
tative conversion in the test CuAAC reaction between
benzyl azide and phenylacetylene and selectively gave the
1,4-disubstituted 1,2,3-triazole isomer (7) as the product.
These small-scale test experiments afforded about 50 mg of
triazole 7 in each run, without the need for further purifica-
tion after evaporation. At the optimal flow rate of
0.5 mLmin1, the residence time on the catalyst bed was as
low as 1.5 min and a process time of only 5 min was needed
to pump through the 2.5 mL aliquot of the reaction mixture.
Scale-Up Experiments
One of the most appealing advantages of flow processing is
its inherent scalability, which means that, in CF production,
the volume is given as a function of time and flow rate,
whereas, in standard flask-based (batch) processes, the
output depends on the batch size.[21b,d,e] The batch scale-up
of processes that involve unstable reactants, such as azides,
can be dangerous, because the accumulation of high concen-
trations of these materials can give rise to an explosive
hazard, whereas, in CF processes, this risk is minimized be-
cause the residence time in the active zone of the reactor is
nicely controllable and the procedure remains simple and
safe, even upon scale-up.
To probe the preparative abilities of our above-described
CF methods, the CuAAC reaction between benzyl azide
and phenylacetylene was scaled-up under both conditions
CFA and CF B. A reaction mixture of the azide (1 equiv,
cazide=0.085m), the alkyne (1.5 equiv), and DIEA (0.04 equi-
v)+HOAc (0.04 equiv, only under conditions CF B) in
CH2Cl2 was continuously pumped through the system. In
both experiments, 75 mL of the reaction mixture was
pumped through in 150 min, thus leading to the formation
of about 1.5 g of triazole 7, which was equivalent to a yield
of 99%. This result meant that, altogether, almost 3 g of the
triazole product could be isolated (after evaporation) within
5 h, without the need for any further work-up or purification
steps, in a simple and safe manner.
Investigation of the Scope and Applicability of these CF
Methods
To determine the scope of these CF procedures, a series of
model reactions were performed, some of which afforded
possible precursors of biologically useful compounds. These
reactions were performed under both sets of optimal condi-
tions (CFA and CF B) and the efficacies of these methods
were then compared. In all cases, when terminal alkynes
were used, their corresponding 1,4-disubstituted 1,2,3-tria-
zole isomers were formed selectively.
Scheme 4. Catalytic cycle of the CuAAC reaction, jointly promoted by
an acid and a base.[3,28, 30, 31]
Table 1. Effect of the DIEA/HOAc ratio on the reaction between benzyl
azide and phenylacetylene in a CF reactor.[a]
Entry DIEA [equiv] HOAc [equiv] Conversion[b] [%]
1 0 0 34
2 0 0.1 56
3 0.1 0 96
4 0.1 0.1 quantitative
5 0.08 0.08 quantitative
6 0.04 0.04 quantitative
7 0.02 0.02 63
8 0.01 0.01 40
[a] 100 bar, room temperature, flow rate: 0.5 mLmin1. [b] Determined
by 1H NMR spectroscopy of the crude material.
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Outstanding results were obtained in the reactions be-
tween phenylacetylene and various azides. As shown in
Table 2, both aromatic and aliphatic azides were found to be
excellent substrates for the CF CuAAC reaction. In the case
of aromatic azides, we found that both electron-withdrawing
(Table 2, entries 2–7) and electron-donating groups (Table 2,
entries 8–10) on the phenyl rings were nicely tolerated and
the yields were not significantly affected by the position of
the substituent(s). a-Azido ketones are known to be less re-
active than simple azides in CuAAC reactions, but their cy-
cloaddition reactions with different alkynes can lead to a di-
verse range of compounds of pharmaceutical importance.[32]
Thus, the reaction of 2-azidoacetophenone with phenylace-
tylene was also studied (Table 2, entry 13) and we found
that both CF methods afforded triazole 19 in excellent
yields. Interestingly, the use of additives (conditions CF B)
gave slightly better results in terms of the azide scope and,
in certain cases, somewhat higher yields were afforded than
with method CFA (Table 2, entries 2, 5, 7–9, and 11–13).
As shown in Table 3, a series of alkynes were also tested
as reaction partners of benzyl azide. We found that, besides
phenylacetylene, non-aromatic alkynes, such as pent-1-yne
and ethyl propiolate, performed well in the CF CuAAC re-
action (Table 3, entries 1 and 2). A non-terminal alkyne, di-
ethyl acetylenedicarboxylate, was also successfully utilized
as a dipolarophile, thus giving a high yield of 1,4,5-trisubsti-
tuted triazole 24 (Table 3, entry 3), which is known to be
a potent antitubercular agent.[33] Ferrocene-substituted bio-
molecules are of increasing interest in medicinal chemis-
try:[34] The labeling of biomolecules with ferrocene has been
extensively used for electrochemical detection or for immu-
noassays[35] and the incorporation of ferrocene into amino
acids or peptides has received considerable attention in the
investigation of the secondary structures of different pep-
tides.[36] Thus, the scope of this method was further broad-
ened by the reaction between benzyl azide and ethynyl fer-
rocene. The corresponding ferrocenyl triazole model com-
pound (25) was obtained in excellent yield (99%) with both
CF methods (Table 3, entry 4). In general, conditions CFA
and CF B performed equally well in tests of the alkyne
scope.
Notably, when the conversion was quantitative and any
excess alkyne could be volatilized on evaporation (phenyla-
cetylene, pent-1-yne, and ethyl propiolate), no further work-
up or purification step was needed.
Batch and CF Syntheses of Highly Functionalized
Cispentacin Derivatives
Cispentacin is a naturally occurring carbocyclic b-amino
acid that possesses strong antifungal properties.[37] Several
other related alicyclic b-amino acid derivatives (e.g., icofun-
gipen, oryzoxymycin, etc.) have also been reported to be an-
tibacterial agents.[38] Carbocyclic and heterocyclic b-amino
acids are key elements of a series of bioactive products with
antitumoral, antibacterial, or antiviral activities.[39]
Table 2. Model reactions between phenylacetylene and various azides
under optimized conditions in a CF reactor.
Entry Azide Product Yield [%][a]
CFA[b] CF B[c]
1 99 99
2 98 99
3 99 99
4 99 99
5 93 99
6 99 99
7 94 99
8 83 99
9 72 94
10 99 99
11 94 99
12 77 98
13 96 99
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We investigated the application of our CF CuAAC proce-
dures (CFA and CF B) for the synthesis of potentially bio-
active 1,2,3-triazole-modified cispentacin derivatives, in
comparison with the results that were obtained by using
standard batch techniques. In all cases, the 1,4-disubstituted
triazole isomers were formed selectively. To prepare tria-
zole-modified cispentacins, either under batch conditions or
by using CF methods, the previously synthetized azido-sub-
stituted cispentacins (26 and 27) were used as reaction part-
ners of phenylacetylene or ethynyl ferrocene.[40] Compounds
26 and 27 were racemates; the structures in Table 4 show
their relative stereochemistry. In contrast to the reactions
with ethyl propiolate or diethyl acetylenedicarboxylate,[41]
the batch reactions of phenylacetylene with azido esters 26
or 27 under thermal conditions did not result in the desired
triazole derivatives (28 and 29, respectively). Thus, the use
of a CuI catalyst was necessary. In the presence of CuI in
MeCN at reflux for 12 h, the reactions afforded triazole-sub-
stituted cispentacin derivatives 28 and 29 in only moderate
yields (69% and 73%, respectively; Table 4, entries 1 and
2). For both triazoles, method CFA resulted in yields that
were comparable with those of the batch processes, but,
under conditions CF B, the yields were significantly higher
(99% in both cases) and both triazoles 28 and 29 could be
obtained in their pure form without the need for any further
work-up steps after evaporation (Table 4, entries 1 and 2).
We measured and compared the copper content in unpuri-
fied triazoles 28 and 29 that were synthetized by using both
methods (CFA and CF B). The analytical data in Table 5,
entries 1–4, showed that the level of copper contamination
in the samples that were obtained without any additives
(method CFA) were lower than those when DIEA+HOAc
were jointly applied (method CF B).
Next, azido-substituted cispentacin derivatives 26 and 27
were subjected to dipolar cycloaddition with ethynyl ferro-
cene in batch processes in the presence of CuI at reflux in
MeCN. Surprisingly, no transformations were detected
under these conditions. On changing the catalyst from CuI
to CuSO4/ascorbic acid, the reaction furnished ferrocenyl tri-
azole derivatives 30 and 31 in moderate yields (51% and
69%, respectively) within 14 h (Table 4, entries 3 and 4). In
contrast, under conditions CFA or CF B, triazoles 30 and 31
were obtained in excellent yields (99%) in both cases
(Table 4, entries 3 and 4). Because the excess ethynyl ferro-
cene was not volatilized on evaporation, purification of the
crude product by column chromatography on silica gel was
required after both CF reactions. In the cases of triazoles 30
and 31, their copper content was determined after purifica-
tion. As shown in Table 5, entries 5–8, the levels of copper
impurities in both methods decreased considerably after
flash column chromatography.
Thus, method CF B was found to be more efficient for the
synthesis of triazole-modified cispentacin derivatives. How-
ever, a direct comparison with the batch results is difficult,
because the local copper concentration in the flow tech-
nique is much higher than that in a simple flask reaction
and the batch reactions were performed in larger volumes
than the CF experiments. Nonetheless, the short process
times, the excellent yields and efficacy, the ease of product
isolation, and the opportunity for the simple and safe scale-
up of the reaction demonstrate the outstanding synthetic ca-
pabilities of this CF method. This CF method may also be
useful for the synthesis of products that are derived from
large biomolecules (such as peptides, dendrimers, and
sugars),[42] although its applicability to hydrophilic structures
is limited, owing to the non-polar reaction medium that is
used. The presence of trace amounts of copper in the isolat-
ed reaction products must be acknowledged as another po-
tential drawback. However, it should be emphasized that
Table 2. (Continued)
Entry Azide Product Yield [%][a]
CFA[b] CF B[c]
14 99 99
15 99 99
[a] Yield of isolated product. [b] Conditions CFA : 100 bar, 100 8C, flow
rate: 0.5 mLmin1, without any additives. [c] Conditions CF B : 100 bar,
room temperature, flow rate: 0.5 mLmin1, with DIEA (0.04 equi-
v)+HOAc (0.04 equiv).
Table 3. Model reactions between benzyl azide and various alkynes
under optimized conditions in a CF reactor.
Entry Acetylene Product Yield [%][a]
CFA[b] CF B[c]
1 94 91
2 99 99
3 84 82
4 99 99
[a] Yield of isolated product. [b] Conditions CFA : 100 bar, 100 8C, flow
rate: 0.5 mLmin1, without any additives. [c] Conditions CF B : 100 bar,
room temperature, flow rate: 0.5 mLmin1, with DIEA (0.04 equi-
v)+HOAc (0.04 equiv).
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copper is a biogenic substance, unlike many other heavy
metals, and simple chromatographic purification can de-
crease its content substantially, as shown in Table 5. The
copper content in our triazole products compare well with
other literature results of CF[22b] or batch processes.[43]
Conclusions
A simple and inexpensive CF
method was implemented for
the 1,3-dipolar cycloaddition of
organic azides and acetylenes,
which utilized Cu powder as
the cheapest available CuI
source. The need for costly ap-
paratus and special catalyst spe-
cies is eliminated and the high-
pressure/high-temperature con-
ditions were successfully mod-
erated through the joint use of
basic and acidic additives to
maximize the reaction rates.
The benefits of flow processing
meant that the risks that were
associated with the handling of
dangerous azides were signifi-
cantly reduced and gram-scale
syntheses were successfully ach-
ieved in a safe and simple
manner. This CF technique has
a wide scope for azides and al-
kynes and selectively results in
synthetically useful 1,4-disubsti-
tuted 1,2,3-triazole compounds
in excellent yields within short
process times, some of which
have notable biological activity.
The utilization of additives in
flow processes not only im-
proved the safety but also effi-
cacy of these reactions and typically afforded higher yields
than under the high-temperature conditions. Some highly
functionalized derivatives of the antifungal cispentacin were
also effectively synthetized with this CF methodology and
also with conventional batch procedures, thus demonstrating
the outstanding synthetic capabilities of flow processing.
The cispentacin derivatives are interesting precursors for
new triazole carbanucleosides with possible biological activi-
ties.
Experimental Section
General Information
The reagents and materials were of the highest commercially available
purity and were used without any further purification steps. Flash column
chromatography was performed on Merck silica gel 60 (particle size: 63–
200 mm) and analytical thin-layer chromatography (TLC) was performed
on Merck silica gel 60 F254 plates. Compounds were visualized by UV ir-
radiation or by staining with KMnO4.
1H NMR, 13C HSQC, and
13C HMBC NMR spectra were recorded on a Bruker Avance DRX 400
spectrometer in CDCl3 with TMS as an internal standard (
1H: 400.1, 13C:
100.6 MHz). Microanalysis was performed on a Perkin–Elmer 2400 ele-
mental analyzer. A H-Cube system was used as a CF reactor.
Table 4. Synthesis of highly functionalized cispentacin derivatives in a CF reactor and under standard batch condi-
tions.
Entry Azide Acetylene Product Yield [%][a]
CFA[b] CF B[c] Batch
1 62 99 69[d]
2 42 99 73[d]
3 99 99 51[e]
4 99 99 69[e]
[a] Yield of isolated product. [b] Conditions CFA : 100 bar, 100 8C, flow rate: 0.5 mLmin1, without any additives.
[c] Conditions CF B : 100 bar, room temperature, flow rate: 0.5 mLmin1, with DIEA (0.04 equiv)+HOAc
(0.04 equiv). [d] To a solution of azido ester 26 or 27 (1 equiv) in MeCN were added CuI (1 equiv) and alkyne
(1.1 equiv) and the mixture was stirred under reflux for 12 h. [e] To a solution of azido ester 26 or 27 (1 equiv) in
EtOH/water (12:1) were added CuSO4 (1 equiv), ascorbic acid (1 equiv), and alkyne (1.1 equiv) and the mixture
was stirred at room temperature for 14 h.
Table 5. Copper content in the triazole-modified cispentacins that were
obtained by using various CF methods.
Entry Triazole product Method Copper content [mgg1][a]
1 28 CFA 14.8ACHTUNGTRENNUNG(0.8)[b]
2 28 CF B 70.1ACHTUNGTRENNUNG(1.4)[b]
3 29 CFA 12.1ACHTUNGTRENNUNG(0.7)[b]
4 29 CF B 66.2ACHTUNGTRENNUNG(1.5)[b]
5 30 CFA 4.4ACHTUNGTRENNUNG(0.3)[c]
6 30 CF B 7.1ACHTUNGTRENNUNG(0.6)[c]
7 31 CFA 5.2ACHTUNGTRENNUNG(0.5)[c]
8 31 CF B 7.3ACHTUNGTRENNUNG(0.7)[c]
[a] Determined by ICP-MS. [b] Without chromatographic purification.
[c] After purification by column chromatography on silica gel.
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Determination of the Copper Content of the Triazole Products
Copper concentrations were determined by inductively coupled plasma
mass spectrometry on an Agilent 7700x-type instrument that was
equipped with a collision cell. Determination of the copper content was
performed on the 63Cu isotope by using He as a collision gas. The stan-
dard solutions for external calibration were prepared from a stock solu-
tion (Certipur, Merck), by dilution with doubly deionized water (Milli-
pore MillQ, Merck). All glassware and plastic utensils that were used
during the determination were pre-cleaned by alternately soaking in solu-
tions of trace-quality nitric acid and hydrochloric acid (Suprapur,
Merck), followed by rinsing with copious amounts of doubly deionized
water.
Preparation of Benzylic and Aliphatic Azides
NaN3 (25 mmol, 1.5 equiv) was added to a stirring solution of the corre-
sponding bromide (17 mmol, 1 equiv) in DMSO (25 mL) and the result-
ing mixture was stirred at 60 8C for 4 h. Then, brine and Et2O were
added to the solution and the organic layer was washed thoroughly with
brine. Next, the combined organic layers were dried over Na2SO4 and the
solvent was removed under reduced pressure. The corresponding azides
were obtained in a purity of >99% and were used in subsequent reac-
tions without further work-up.[44]
Preparation of Phenyl Azide
Aniline (10 mmol, 1 equiv) was suspended in 17% hydrochloric acid
(60 mL) at RT and EtOH (5 mL) was added. The mixture was cooled to
0 8C and NaNO2 (15 mmol, 1.5 equiv) was added in small portions. After
stirring at 0 8C for 30 min, NaN3 (15 mmol, 1.5 equiv) was slowly added
and the mixture was stirred for an additional 2 h at RT. The reaction mix-
ture was extracted with Et2O and the combined organic layers were
washed with a saturated solution of NaHCO3 and with brine.
[44] After
drying over Na2SO4, the solvent was evaporated and phenyl azide was
obtained in a purity of 98%. The product was used in subsequent reac-
tions without further work-up.[44]
General Procedure for the CF Reactions
For the CF reactions, the azide (0.21 mmol, 1 equiv) and the alkyne
(0.32 mmol, 1.5 equiv), as well as DIEA (0.0084 mmol, 0.04 equiv) and
HOAc (0.0084 mmol, 0.04 equiv) in method CF B, were dissolved in
CH2Cl2 (2.5 mL). The solution was homogenized by sonication for 1 min
and then pumped through the CF reactor under the appropriate condi-
tions. The crude product was checked by TLC (n-hexane/EtOAc) and the
solvent was removed under reduced pressure. If necessary, the products
were purified by column chromatography on silica gel (n-hexane/
EtOAc). The triazole products were characterized by elemental analysis
and NMR spectroscopy. For detailed analytical data, see the Supporting
Information. Between two reactions in the CF reactor, the catalyst bed
was washed for 5 min with CH2Cl2 at a rate of 1 mLmin
1.
General Procedure for the CuI-Catalyzed Batch Reaction
CuI (1.95 mmol, 1 equiv) and alkyne (2.15 mmol, 1.1 equiv) were added
to a solution of azido ester 26 or 27 (1.95 mmol, 1 equiv) in MeCN and
the mixture was stirred under reflux for 12 h. The solvent was then re-
moved under vacuum and the residue was purified by column chromatog-
raphy on silica gel (n-hexane/EtOAc, 2:1).
General Procedure for the CuSO4/Ascorbic-Acid-Catalyzed Batch
Reaction
CuSO4 (1.95 mmol, 1 equiv), ascorbic acid (1.95 mmol, 1 equiv), and
alkyne (2.15 mmol, 1.1 equiv) were added to a solution of azido ester 26
or 27 (1.95 mmol, 1 equiv) in EtOH (6 mL) and water (0.5 mL) and the
mixture was stirred at RT for 14 h. The solvent was removed under
vacuum and the residue was purified by column chromatography on
silica gel (n-hexane/EtOAc, 1:1).
Measurement of the Residence Time on the Catalyst Bed
A solution of a blue ink in CH2Cl2 was pumped through the system and
the time that elapsed between the first contact of the ink with the cata-
lyst bed and the moment when the blue color appeared at the column
output was measured to determine the residence time.
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Abstract
The preparation of novel multi-substituted 1,2,3-triazole-modified β-aminocyclohexanecarboxylic acid derivatives in a simple and
efficient continuous-flow procedure is reported. The 1,3-dipolar cycloaddition reactions were performed with copper powder as a
readily accessible Cu(I) source. Initially, high reaction rates were achieved under high-pressure/high-temperature conditions. Subse-
quently, the reaction temperature was lowered to room temperature by the joint use of both basic and acidic additives to improve
the safety of the synthesis, as azides were to be handled as unstable reactants. Scale-up experiments were also performed, which led
to the achievement of gram-scale production in a safe and straightforward way. The obtained 1,2,3-triazole-substituted β-aminocy-
clohexanecarboxylates can be regarded as interesting precursors for drugs with possible biological effects.
Introduction
In recent years, triazole-containing compounds have become
potential targets for drug discovery [1,2]. A large number of
1,2,3-triazoles exhibit various biological effects [3], e.g.,
antiviral (1), antibacterial (2), antifungal (3) and anticancer (4)
activities [4-7] (Figure 1). The 1,2,3-triazole skeleton is
frequently used as a pharmacophore for the modification of
known pharmaceuticals. Triazole analogues of several bioac-
tive compounds have recently been reported. Examples are
those of the well-known highly functionalized antiviral cyclic
amino acid derivatives oseltamivir and zanamivir (5 and 6 in
Figure 1) [8,9]. The 1,2,3-triazole moiety is a constituent part of
many modified nucleosides or carbanucleosides with antiviral,
anti-HIV or cytostatic activities [10-12]. However, the scope of
triazole chemistry is not confined to drug discovery. There are
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an increasing number of applications in numerous other areas of
modern chemical sciences, such as bioconjugation [13], supra-
molecular chemistry, [14] and polymer sciences [15].
Figure 1: Examples of 1,2,3-triazoles with various biological activities.
Probably the most useful and powerful procedure for the syn-
thesis of 1,2,3-triazoles is the Huisgen 1,3-dipolar cycloaddi-
tion of organic azides with acetylenes [16]. The classical
Huisgen reaction, thermally induced, gives an approximate 1:1
mixture of 1,4- and 1,5-disubstituted 1,2,3-triazole isomers
(Scheme 1) [17]. However, when Cu(I) catalysis is applied, the
reaction becomes regioselective, exclusively yielding the 1,4-
regioisomer within a relatively short reaction time [18-20].
Recently, Cu(I)-catalyzed azide–alkyne cycloaddition (CuAAC)
has become the basis of the so-called click chemistry concept
due to its wide applicability and efficiency.
Over the past twenty years, alicyclic β-amino acids have
attracted great interest among synthetic chemists, thanks to their
massive pharmacological potential [21,22]. For example,
cispentacin ((1R,2S)-2-aminocyclopentanecarboxylic acid, 7) is
a widely investigated naturally occurring carbocyclic β-amino
acid with strong antifungal properties against Candida species
(Figure 2) [23]. Its synthetic 4-methylene derivative
icofungipen (8), also an antifungal agent, is now proceeding
Scheme 1: 1,3-Dipolar azide–alkyne cycloadditions.
through clinical development for the oral treatment of yeast
infections (Figure 2) [24]. Certain multi-substituted cyclo-
hexane amino acid derivatives, such as oryzoxymycin (9) and
tilidine (10), are also well-known bioactive agents with anti-
cancer, antibacterial, antiviral or analgesic effects (Figure 2)
[25,26]. The alicyclic β-amino acids are key intermediates for
the synthesis of a series of pharmaceutically relevant products
[27], such as amino esters, amino alcohols, azides and hetero-
cycles. Moreover, they are frequently used as building blocks
for the synthesis of new peptides and foldamers with possible
biological effects [28].
Figure 2: Selected bioactive alicyclic β-amino acids.
Modern continuous-flow (CF) technologies offer many advan-
tages over classical batch-based procedures [29-32], including
efficient mixing quality [33], excellent heat and mass transfer
[34], shorter reaction times [35-37], reduced reagent consump-
tion [38-40], improved safety [41,42], and operational
simplicity [43]. Furthermore, CF methodologies provide oppor-
tunities for a simple and rapid scale-up [44,45] and automation
[46,47] of chemical processes. They also tend to be environ-
mentally benign technologies [48]. In consequence of these
benefits, flow chemistry-based techniques have exerted a
significant impact on modern synthetic chemistry, ranging from
laboratory-based experiments to industrial-scale production.
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Here, we describe a safe and efficient CF synthesis of a series
of novel 1,2,3-triazole-modified β-aminocyclohexanecar-
boxylic acid derivatives as potential biologically active com-
pounds. Gram-scale production is also reported, which predicts
a possible usefulness for the pharmaceutical industry.
Results and Discussion
Several approaches are to be found in the literature for the
Cu(I)-catalysed flow synthesis of triazoles. Heterogeneous
Cu(I) sources are most popular, such as copper-in-charcoal
(Cu/C) [49,50], solid supported Cu(I) species [51-54], and
heated copper wirings [55-58], but a homogeneous technique
has also recently emerged [59]. The main driving forces behind
these CF methodologies are the safety aspects associated with
the handling of azides and the inherent scalability of flow
processing. Moreover, when organic azides are formed in situ,
operational safety can be further improved [55,57]. We envi-
sioned that it would be simplest to make use of copper powder
as a catalytic source [60]. Similarly to cases when heated rings
of copper wire are employed, a copper surface acts as a source
of active copper species. Copper is constantly oxidized when
exposed to air, and non-self-protecting layers of different
oxides, including Cu2O, are formed on its surface [61], which
can promote CuAAC. Thus, we utilized copper powder in a
stainless steel column, which served as a catalyst bed later on.
The catalyst bed was placed into a stainless steel block with a
Peltier heating system, which could heat the column up to
100 °C. A backpressure regulator was also integrated to ensure
pressures up to 100 bar. The mixture of the reactants was
pumped through the system continuously by means of an HPLC
pump. This experimental setup is practical and cheap, as it does
not require costly catalysts or special apparatus. At the same
time this setup is safe, even with unstable reactants such as
azides (Figure 3).
To maximize the CF triazole synthesis reaction rates, it
appeared easiest to use high-temperature conditions initially.
The application of elevated pressure in CuAAC is also benefi-
cial, as it can promote the product formation in accordance with
Le Chatelier’s principle [60] and also prevents the solvent from
boiling over when high temperature is used. Thus, 100 °C and
100 bar were selected as conditions A for the CF synthesis.
However, when azides are reacted, it is important to minimize
the explosion hazard. Accordingly, we attempted to improve the
rates of the reaction in the presence of additives, without the use
of high temperature [60]. Amines are known to accelerate
CuAAC, in particular by coordinating to catalytically active
Cu(I) species and promoting their liberation from the copper
matrix [62,63]. It was recently shown that the use of certain
acids as additives is also beneficial, as this can further accel-
erate the formation of the triazole product [64-66] and also
Figure 3: Experimental setup for the CF reactions.
prevents the accumulation of unwanted byproducts, such as
diacetylenes, bistriazoles, etc. [67]. At the same time, byproduct
formation is catalysed by a base, and the joint utilization of a
basic and an acidic additive is therefore favourable. This buffer
system gives rise to a high reactivity in CuAAC, even at room
temperature (rt), but without byproduct formation [60,67]. This
system thus greatly improves the safety relative to the high-
temperature conditions. The literature data led us to select N,N-
diisopropylethylamine (DIEA) as a base and HOAc as an acid
[67], which were used jointly as additives, each in
0.04 equivalents, at 100 bar and rt as conditions B [60].
As starting materials for the CF CuAAC reactions, azido-substi-
tuted β-aminocyclohexanecarboxylates 11–14 were prepared
previously by a diastereoselective epoxidation of the corres-
ponding 2-aminocyclohexenecarboxylates, followed by a
regioselective oxirane ring opening with NaN3 [68]. Three
different alkynes (phenylacetylene, diethyl acetylenedicarboxy-
late and ethynyl ferrocene) were employed as dipolarophiles to
yield a library of novel 1,2,3-triazole-modified cyclic β-amino
acid derivatives. Compounds 11–14 were racemates, the struc-
tures in Table 1 show their relative stereochemistry. The CF
syntheses were carried out under both conditions A and B in
order to obtain a clear comparison between the performances of
the two approaches. CH2Cl2 was used as a solvent, and the
starting azides were used in a concentration of 0.085 M. A
higher concentration of the starting azides led to the precipita-
tion of the triazole product and a blockage in the CF reactor.
Aliquots of 2.5 mL of a reaction mixture containing 1 equiva-
lent of the azide and 1.5 equivalents of the acetylene were
pumped through the reactor in each run with a a flow rate of
0.5 mL min–1. At this flow rate the residence time on the cata-
lyst bed was as low as 1.5 min and it took only 5 min of process
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Table 1: CF synthesis of 1,2,3-triazole-substituted alicyclic β-amino acid derivatives.
Entry Azidea (1 equivalent) Acetylene (1.5 equivalents) Product Yieldb (%)
Ac Bd
1
11
15
61 96
2
12
16
47 97
3
13 17
33 76(98)e
4
14
18
53 89(98)e
5
11
19
98 97
6
12
20
97 98
7
13 21
97 96
time to pump the 2.5 mL aliquots through the system. This
resulted in around 100 mg of crude product, depending on the
conversion and the molecular masses of the reactants.
In the Cu(I)-catalysed reactions between phenylacetylene and
the azido-substituted β-amino acid derivatives 11–14, 1,4-disub-
stituted 1,2,3-triazole isomers (15–18) were regioselectively
formed. The high-pressure/high-temperature conditions A led to
only medium yields (Table 1, entries 1–4), but under conditions
B the yields of triazoles 15 and 16 were excellent, and those of
triazoles 17 and 18 were high (76% and 89%, respectively;
Table 1, entries 1–4). When the CF reactions of azides 13 and
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Table 1: CF synthesis of 1,2,3-triazole-substituted alicyclic β-amino acid derivatives. (continued)
8
14
22
97 98
9
11
23
95 97
10
12
24
91 98
11
13
25
96 93
12
14
26
75 97
acazide = 0.085 M. bYield of isolated product. cConditions A: CH2Cl2 as solvent, 100 bar, 100 °C, flow rate 0.5 mL min–1, without any additives.
dConditions B: CH2Cl2 as solvent, 100 bar, rt, flow rate 0.5 mL min–1, with 0.04 equivalents of DIEA + 0.04 equivalents of HOAc. eAchieved under the
following conditions: CH2Cl2 as solvent, 100 bar, 100 °C, flow rate 0.5 mL min–1, with 0.04 equivalents of DIEA + 0.04 equivalents of HOAc.
14 with phenylacetylene were repeated under high-pressure/
high-temperature conditions with the simultaneous use of addi-
tives (100 bar, 100 °C, 0.04 equivalents each of DIEA and
HOAc; further conditions were not modified), triazoles 17 and
18 were obtained in very high yields (98% in both cases;
Table 1, entries 3 and 4).
1,4,5-Trisubstituted 1,2,3-triazoles are of notable importance in
drug discovery. For example, several 1,2,3-triazole-4,5-dicar-
boxylates display significant antituberculotic activity in vitro
[69]. Thus, a nonterminal alkyne, diethyl acetylenedicarboxy-
late, was subjected to CF CuAAC with the azido-functionalized
β-amino acid derivatives 11–14 as reaction partners. 1,4,5-
Trisubstituted 1,2,3-triazole dicarboxylates 19–22 were
obtained in excellent yields (>96%) under both conditions A
and B (Table 1, entries 5–8). In this set of CF syntheses, no
significant difference was observed between the performances
of the two methods.
Ferrocene-triazole conjugates play a crucial role in the labelling
and detection of various systems, such as biomolecules, poly-
mers, nanomaterials and supramolecular assemblies [70]. They
also have potential applications in medicinal chemistry and drug
discovery as biosensing probes, in immunoassays and in
host–guest chemistry [71]. Ferrocene-substituted amino acids
have been of significant importance in the investigation of the
secondary structures of different peptides and foldamers [72].
Thus, conjugates of the azido-functionalized β-amino acid
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Scheme 2: Gramm-scale CF synthesis of triazole 22 under conditions B.
derivatives 11–14 were prepared with ethynylferrocene as a
dipolarophile. Both conditions A and B afforded ferrocenyltria-
zoles 23–25 in excellent yields (>91%; Table 1, entries 9–11).
However, in the case of ferrocenyltriazole 26 the high-pressure/
high-temperature conditions A led to a yield of only 75%,
whereas the use of additives at rt (conditions B) proved more
efficient, with a yield of 97% (Table 1, entry 12). Triazoles
23–26 were obtained selectively as 1,4-disubstituted regioiso-
mers.
To understand the differences between the results obtained with
the three different dipholarophiles, it must be taken into account
that the carboxylate groups of diethyl acetylenedicarboxylate
and the aromatic system of the ferrocenyl group as ligands can
probably coordinate copper from its matrix. Therefore, the
concentration of the catalytically active Cu(I) species is
increased as compared to the reactions with phenylacetylene
[73-75]. Accordingly, the yields were usually higher in the reac-
tions with diethyl acetylenedicarboxylate and ethynylferrocene
than with phenylacetylene (Table 1, entries 5–12 versus entries
1–4). These differences can mainly be observed between the
results obtained under conditions A. This is because the base, as
an additive, evolves the same effect and improves the reactivity
through the CuAAC, thus in the case of conditions B (the use of
additives) the influence of the alkyne is practically masked.
The presence of trace amounts of copper in the chromatographi-
cally purified triazole products was determined by means of
inductively coupled plasma mass spectrometry (ICP–MS). The
analytical data in Table 2 show that the contents of copper
impurities in the products were appropriately low, i.e., amounts
of 3.9–9.1 µg g–1 were detected. It should be noted that the
samples obtained with the joint use of DIEA + HOAc (condi-
tions B) contained more copper than those obtained under
conditions A (high-temperature/high-pressure without addi-
tives). The levels of copper contamination detected in our tria-
zole products compare well with literature results relating to CF
[50] and conventional batch experiments [76].
In conventional batch-based chemistry, the scale-up of chem-
ical reactions can be a challenge because the output depends on
Table 2: Copper contents in the triazole products after column
chromatographic purification on silica gel.
Entry Product Copper content (µg g–1)a
Ab Bc
1 15 4.6 (±0.5) 8.4 (±0.6)
2 16 4.2 (±0.3) 7.7 (±0.6)
3 17 3.9 (±0.5) 8.0 (±0.4)
4 18 4.7 (±0.6) 8.2 (±0.7)
5 19 5.2 (±0.4) 7.9 (±0.4)
6 20 5.1 (±0.3) 7.5 (±0.6)
7 21 4.8 (±0.6) 7.7 (±0.7)
8 22 5.3 (±0.3) 8.2 (±0.6)
9 23 6.1 (±0.5) 8.6 (±0.5)
10 24 4.8 (±0.4) 7.7 (±0.8)
11 25 5.4 (±0.3) 9.1 (±0.4)
12 26 4.9 (±0.6) 7.8 (±0.7)
aDetermined by ICP–MS. bConditions A: CH2Cl2 as solvent, 100 bar,
100 °C, flow rate 0.5 mL min–1, without any additives. cConditions B:
CH2Cl2 as solvent, 100 bar, rt, flow rate 0.5 mL min–1, with
0.04 equivalents of DIEA + 0.04 equivalents of HOAc.
the batch size. The situation becomes even more complicated
when unstable reactants such as azides are handled on a large
scale. However, the scalability of CF procedures is a straight-
forward function of time and the flow rate, and the risks asso-
ciated with the accumulation of hazardous species are mini-
mized, because the solution of the reactants is eluting continu-
ously from the active zone of the reactor [33,34,44,45,60]. The
CF CuAAC between azide 14 and diethyl acetylenedicarboxy-
late was scaled up in a simple, safe and efficient manner to
achieve gram-scale production (Scheme 2). Methods A and B
proved equally efficient in the small-scale CF syntheses of tria-
zole 22 (Table 1, entry 8). However, we performed the large-
scale experiment at 100 bar and rt in the presence of the addi-
tives (conditions B) so as to ensure maximum safety through-
out the procedure. A CH2Cl2 solution of the reaction mixture
containing 1 equivalent of the azide (cazide = 0.085 M),
1.5 equivalents of the acetylene and 0.04 equivalents of each
additive was pumped continuously through the system at a flow
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rate of 0.5 mL min–1. During the whole scale-up procedure, the
same portion of copper powder was used in the catalyst bed.
The solution of the crude product was collected for 100 min,
and after purification 2.06 g of triazole 22 was obtained, which
is equivalent to a yield of 96%.
Conclusion
Twelve highly functionalized 1,2,3-triazole-substituted
β-aminocyclohexanecarboxylic acid racemates were success-
fully prepared in CF mode as a small library of novel com-
pounds with possible biological effects. The CF syntheses were
first performed under high-pressure/high-temperature condi-
tions with copper powder as a readily accessible Cu(I) source.
Subsequently, to moderate the harsh reaction conditions, the
reaction temperature could be lowered to rt in the presence of
additives. The joint use of a base and an acid dramatically im-
proved the reactivity in the CuAAC, while it completely elimi-
nated unwanted byproduct formation. These conditions ensured
enhanced safety and typically higher yields than those attained
under the harsh reaction conditions. Simple, efficient and safe
gram-scale production was also implemented in a short
processing time, which can be important for potential industrial
applications.
Experimental
General Information
The reagents and materials were of the highest commercially
available purity grade and were used without any further purifi-
cation. Flash column chromatography was performed on Merck
silica gel 60, particle sizes ranged from 63 to 200 μm, and
analytical thin-layer chromatography (TLC) on Merck silica gel
60 F254 plates. Compounds were visualized with UV light or
KMnO4. 1H and 13C NMR spectra were recorded on a Bruker
Avance DRX 500 spectrometer, in CDCl3 as a solvent, with
TMS as internal standard, and at 500.1 and 125.0 MHz, respect-
ively. Microanalyses were performed on a Perkin-Elmer 2400
elemental analyser.
Determination of the copper contents of the
triazole products
Copper concentrations were determined by ICP–MS by using
an Agilent 7700x instrument equipped with a collision cell. The
determination was carried out on the isotope 63Cu, with He as
collision gas. The standard solutions for external calibration
were prepared from a stock solution (Certipur, Merck) by dilu-
tion with doubly deionized water (Millipore MillQ, Merck). All
glassware and plastic utensils used during the determination
were precleaned by soaking in solutions of trace-metal-grade
nitric acid and hydrochloric acid (Suprapur, Merck), followed
by rinsing with copious amounts of doubly deionized water.
General procedure for the CF reactions
An H-Cube® system was used as a CF reactor in the “no H2”
mode. For the CF reactions, the catalyst bed (internal dimen-
sions: 70 mm × 4 mm) was filled with ~900 mg of copper
powder with an average particle size of 200 µm. 70 mg
(0.21 mmol, 1 equivalent) of the corresponding azide and
0.32 mmol (1.5 equivalents) of the alkyne, and (only in method
B) 1.5 µL (0.0084 mmol, 0.04 equivalents) of DIEA and 0.5 µL
(0.0084 mmol, 0.04 equivalents) of HOAc were dissolved in
2.5 mL of CH2Cl2. The solution was homogenized by sonica-
tion, and then pumped through the CF reactor under the appro-
priate conditions. Between two reactions in the CF reactor, the
catalyst bed was washed at rt for 5 min with CH2Cl2 at a flow
rate of 1 mL min–1. The crude product was checked by TLC
with a mixture of n-hexane/EtOAc as an eluent, and the solvent
was next evaporated off under vacuum. Column chromato-
graphic purification was carried out on silica gel with a mixture
of n-hexane/EtOAc as an eluent. The 1,2,3-triazole-modified
compounds were characterized by elemental analysis and NMR
experiments. For detailed analytical data see Supporting Infor-
mation File 1.
Measurement of the residence time on the
catalyst bed
To determine the residence time, a CH2Cl2 solution of a blue
ink was pumped through the catalyst bed. The time that elapsed
between the first contact of the ink with the bed and the moment
when the blue colour appeared at the column outlet was
measured.
Supporting Information
Supporting Information File 1
Detailed analytical data of the prepared compounds and a
collection of NMR spectra.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-9-172-S1.pdf]
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